drug,drug_cui,synonyms,variations,additional_umls_atoms,drug_type,source_type,id,hit_drug,hit_type,evidence,evidence_source,category,subcategory,regex
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC3569575_20201005_0.5,,,In vitro Intestinal Mucosal Epithelial Responses to Wild-Type Salmonella Typhi and Attenuated Typhoid Vaccines,title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC3569575_20201005_0.5,,,intestinal mucosal barrier|epithelial permeability|mucosal immunity|typhoid vaccines|cytokines,author_keywords,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC3569575_20201005_0.5,ty21a typhoid vaccine,drug_name,"Humans|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Salmonella typhi|Vaccines, Attenuated|Caco-2 Cells|Typhoid Fever|Polysaccharides, Bacterial|Intestinal Mucosa|Antibodies, Bacterial|Salmonella enterica",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC3569575_20201005_0.5,ty21a typhoid vaccine,drug_name,"We have evaluated in vitro the effects of wild-type S. Typhi, the licensed Ty21a typhoid vaccine and the leading strains CVD 908-htrA and CVD 909 vaccine candidates on intestinal barrier function and immune response.",abstract,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC3751609_20201005_0.5,,,Genome Sequence of Salmonella enterica Serovar Typhi Oral Vaccine Strain Ty21a,title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC3751609_20201005_0.5,ty21a typhoid vaccine,drug_name,"Salmonella typhi|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Typhoid Fever|Polysaccharides, Bacterial|Vaccines, Attenuated|Antibodies, Bacterial|Base Sequence",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC3155226_20201005_0.5,ty21a typhoid vaccine,drug_name,"Rats|Male|Animals|Dextran Sulfate|Rats, Wistar|Colitis|Inflammatory Bowel Diseases|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Colon|Polysaccharides, Bacterial|Inflammation|Salmonella|Disease Models, Animal|Gastrointestinal Microbiome|Salmonella typhi|Peroxidase",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC5776093_20201005_0.5,,,Salmonella Typhi Bactericidal Antibodies Reduce Disease Severity but Do Not Protect against Typhoid Fever in a Controlled Human Infection Model,title,Antibodies,None,antibod
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC5776093_20201005_0.5,ty21a typhoid vaccine,drug_name,"Adult|Humans|Typhoid Fever|Salmonella typhi|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Antibodies, Bacterial|Salmonella paratyphi A|Polysaccharides, Bacterial|Vaccines, Attenuated|Cross Reactions|Salmonella enterica|Lipopolysaccharides|Vaccination",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID1457647_20201005_0.5,ty21a typhoid vaccine,drug_name,Effects of antimalarial chemoprophylactic agents on the viability of the Ty21a typhoid vaccine strain.,title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID1457647_20201005_0.5,,,Chloroquine|Mefloquine|Microbial Sensitivity Tests|Salmonella typhi|Typhoid-Paratyphoid Vaccines,mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID11179942_20201005_0.5,ty21a typhoid vaccine,drug_name,"Compliance to live oral Ty21a typhoid vaccine, and its effect on viability.",title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID11179942_20201005_0.5,,,"Administration, Oral|Adult|Aged|Drug Storage|Female|Humans|Immunization Schedule|Male|Middle Aged|Patient Compliance|Patient Education as Topic|Polysaccharides, Bacterial|Surveys and Questionnaires|Travel|Typhoid Fever|Typhoid-Paratyphoid Vaccines",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID11179942_20201005_0.5,ty21a typhoid vaccine,drug_name,"BACKGROUND Concerns have been expressed that in travelers the efficacy of the live oral Ty21a typhoid vaccine Vivotif could be lower than reported, maybe due to a lack of compliance.",abstract,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC3634757_20201005_0.5,,,"Administration, Oral|Bacteria|Biodiversity|Feces|Gastrointestinal Tract|Humans|Immunity, Cellular|Immunity, Humoral|Microbiota|Phylogeny|Polysaccharides, Bacterial|RNA, Ribosomal, 16S|Salmonella typhi|Typhoid Fever|Typhoid-Paratyphoid Vaccines|Vaccination",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC3634757_20201005_0.5,ty21a typhoid vaccine,drug_name,The fecal microbiota composition and temporal dynamics were characterized using bacterial 16S rRNA pyrosequencing from individuals who were either immunized with the Ty21a typhoid vaccine (n = 13) or served as unvaccinated controls (n = 4).,abstract,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID8854008_20201005_0.5,,,Reasons for instability of bacterial vaccines.,title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID8854008_20201005_0.5,,,"Amino Acid Sequence|Bacterial Vaccines|Chemical Phenomena|Chemistry, Physical|Delayed-Action Preparations|Drug Stability|Drug Storage|Freeze Drying|Genetic Vectors|Molecular Sequence Data|Temperature|Toxoids|Vaccines, Attenuated|Vaccines, Conjugate|Vaccines, Inactivated|Vaccines, Synthetic",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID8854008_20201005_0.5,ty21a typhoid vaccine,drug_name,Live attenuated vaccines such as BCG and Ty21a typhoid vaccines lose potency through loss of viability when exposed to adverse conditions.,abstract,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID1976928_20201005_0.5,ty21a typhoid vaccine,drug_name,Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial.,title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID1976928_20201005_0.5,,,"Administration, Oral|Adolescent|Age Factors|Bacterial Vaccines|Capsules|Child|Child, Preschool|Chile|Double-Blind Method|Follow-Up Studies|Humans|Immunization Schedule|Incidence|Methylcellulose|Salmonella typhi|Solutions|Travel|Typhoid Fever|Vaccination|Vaccines, Attenuated",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID9772310_20201005_0.5,,,"Patient compliance in the use of Vivotif Berna(R) vaccine, typhoid vaccine, live oral Ty21a.",title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID9772310_20201005_0.5,,,"Administration, Oral|Adult|Drug Storage|Humans|Patient Compliance|Patient Education as Topic|Polysaccharides, Bacterial|Surveys and Questionnaires|Travel|Typhoid Fever|Typhoid-Paratyphoid Vaccines|Vaccines, Attenuated",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID9772310_20201005_0.5,ty21a typhoid vaccine,drug_name,These include the Salmonella typhi Ty21a typhoid vaccine (Vivotif Berna(R) Vaccine) and Vibrio cholerae CVD103-HgR cholera vaccine (Mutacol Berna(R) Vaccine).,abstract,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID26140240_20210211_0.5,,,Local Salmonella immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor.,title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID26140240_20210211_0.5,ty21a typhoid vaccine,drug_name,"Female|Humans|Mice|Animals|Urinary Bladder Neoplasms|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Administration, Intravesical|BCG Vaccine|Typhoid Fever|CD8-Positive T-Lymphocytes|Immunization|Cancer Vaccines|Polysaccharides, Bacterial|Urinary Bladder|Uterine Cervical Neoplasms|Neoplasm Recurrence, Local|Antigens, Neoplasm|Vaccines, Combined|Salmonella",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID30951606_20210311_0.5,,,"Adolescent|Adult|Aged|CD4-Positive T-Lymphocytes|CD8-Positive T-Lymphocytes|Child|Female|Humans|Male|Middle Aged|Polysaccharides, Bacterial|Salmonella typhi|Typhoid-Paratyphoid Vaccines|Vaccination|Young Adult",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID30951606_20210311_0.5,ty21a typhoid vaccine,drug_name,"The oral live attenuated Ty21a typhoid vaccine protects against this severe disease by eliciting robust, multifunctional cell-mediated immunity (CMI), shown to be associated with protection in wild-type S. Typhi challenge studies.",abstract,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID15908381_20201005_0.5,,,"Adult|Antigens, Bacterial|CD8-Positive T-Lymphocytes|Cell Line|Cytotoxicity, Immunologic|Flow Cytometry|Genes, T-Cell Receptor beta|Humans|Immunization|Immunologic Memory|Interferon-gamma|Polysaccharides, Bacterial|Salmonella typhi|Typhoid-Paratyphoid Vaccines",mesh_terms,"Cellular Immunotherapy, Other Therapies","T-cell Receptor-engineered T-cells, Vaccines","T.cell Receptor, Vaccine"
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID15908381_20201005_0.5,ty21a typhoid vaccine,drug_name,"To this end, we determined the TCR beta chain (Vbeta) usage of CD8(+) T cells from three volunteers orally immunized with Ty21a typhoid vaccine by flow cytometry using a panel of monoclonal antibodies.",abstract,"Antibodies, Cellular Immunotherapy, Other Therapies","None, Monoclonal Antibodies, T-cell Receptor-engineered T-cells, Vaccines","antibod, Monoclonal Antibod, TCR, Vaccine"
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID2105702_20201005_0.5,,,"Administration, Oral|Adult|Female|Humans|Incidence|Injections|Male|Nepal|Paratyphoid Fever|Salmonella paratyphi A|Salmonella typhi|Travel|Typhoid Fever|Typhoid-Paratyphoid Vaccines",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID2105702_20201005_0.5,ty21a typhoid vaccine,drug_name,"Among 22 vaccinated foreigners, S typhi was isolated from 35%, compared with 65% with S paratyphi A. Nine percent of tourists had received the oral Ty21A typhoid vaccine.",abstract,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID24383914_20201005_0.5,,,Cross-reactive immune response induced by the Vi capsular polysaccharide typhoid vaccine against Salmonella Paratyphi strains.,title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID24383914_20201005_0.5,,,"Adult|Antibodies, Bacterial|Cross Reactions|Female|Humans|Male|Middle Aged|O Antigens|Paratyphoid Fever|Polysaccharides, Bacterial|Salmonella paratyphi A|Salmonella paratyphi B|Salmonella paratyphi C|Typhoid-Paratyphoid Vaccines|Vaccination|Young Adult",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID24383914_20201005_0.5,ty21a typhoid vaccine,drug_name,"No section There are no vaccines in clinical use against paratyphoid fever, caused by Salmonella Paratyphi A and B or, rarely, C. Oral Salmonella Typhi Ty21a typhoid vaccine elicits a significant cross-reactive immune response against S. Paratyphi A and B, and some reports suggest cross-protective efficacy against the disease.",abstract,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID31629569_20210211_0.5,ty21a typhoid vaccine,drug_name,Differential functional patterns of memory CD4+ and CD8+ T-cells from volunteers immunized with Ty21a typhoid vaccine observed using a recombinant Escherichia coli system expressing S. Typhi proteins.,title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID31629569_20210211_0.5,,,Human|Recombinant E. coli|Salmonella|T-cells|Vaccine,author_keywords,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID31629569_20210211_0.5,,,"Adult|CD4-Positive T-Lymphocytes|CD8-Positive T-Lymphocytes|Escherichia coli|Humans|Middle Aged|Polysaccharides, Bacterial|Salmonella typhi|Typhoid Fever|Typhoid-Paratyphoid Vaccines|Vaccination|Vaccines, Attenuated|Young Adult",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID24426167_20201005_0.5,,,Caenorhabditis elegans|Innate immune response|Pre-exposed host|RNAi|Salmonella enterica serovar Typhi,author_keywords,Gene Therapy,RNAi Therapeutics,RNAi
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID24426167_20201005_0.5,ty21a typhoid vaccine,drug_name,"Animals|Humans|Salmonella typhi|Caenorhabditis elegans|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Typhoid Fever|Salmonella paratyphi A|Polysaccharides, Bacterial|Vaccines, Attenuated|Antibodies, Bacterial|Salmonella typhimurium|Cross Reactions|Immunoglobulin G",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID12165550_20201005_0.5,ty21a typhoid vaccine,drug_name,Characterization of CD8(+) effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine.,title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID12165550_20201005_0.5,,,"Adult|Antigens, Bacterial|CD8-Positive T-Lymphocytes|Cytotoxicity, Immunologic|Humans|Immunization|In Vitro Techniques|Interferon-gamma|Lymphocyte Activation|Phytohemagglutinins|Salmonella typhi|T-Lymphocyte Subsets|T-Lymphocytes, Cytotoxic|Typhoid Fever|Typhoid-Paratyphoid Vaccines|Vaccines, Attenuated",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID12165550_20201005_0.5,ty21a typhoid vaccine,drug_name,"Despite years of research, the identity of the protective immunological mechanisms elicited by immunization with the Ty21a typhoid vaccine remains elusive.",abstract,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID12165550_20201005_0.5,ty21a typhoid vaccine,drug_name,The present study was designed to characterize effector T cell responses in volunteers immunized with S. typhi strain Ty21a typhoid vaccine.,abstract,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC5626924_20201005_0.5,ty21a typhoid vaccine,drug_name,Systemic and Terminal Ileum Mucosal Immunity Elicited by Oral Immunization With the Ty21a Typhoid Vaccine in Humans,title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC5626924_20201005_0.5,ty21a typhoid vaccine,drug_name,"Adult|Humans|Ty21a typhoid vaccine|Immunity, Mucosal|Typhoid-Paratyphoid Vaccines|Polysaccharides, Bacterial|Salmonella typhi|Typhoid Fever|Immunization|Vaccination|CD8-Positive T-Lymphocytes|Interferon-gamma|Flow Cytometry|Immunity, Cellular|Ileum",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID6174449_20210611_0.5,ty21a typhoid vaccine,drug_name,Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain.,title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID6174449_20210611_0.5,,,"Animals|Antibodies, Bacterial|Antigens, Bacterial|Epitopes|Galactose|Immunization|Mice|Plasmids|Salmonella typhi|Shigella sonnei|Vaccines",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID28197393_20210211_0.5,,,Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer.,title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID28197393_20210211_0.5,,,BCG|Ty21a vaccine|immunotherapy|non-muscle invasive bladder cancer,author_keywords,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID28197393_20210211_0.5,ty21a typhoid vaccine,drug_name,"Humans|Mice|Animals|Urinary Bladder Neoplasms|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Leukocytes, Mononuclear|Neoplasm Recurrence, Local|Administration, Intravesical|BCG Vaccine|Cystectomy|Immunotherapy|Adjuvants, Immunologic|Mycobacterium bovis|Polysaccharides, Bacterial|Disease Progression|Treatment Outcome|Treatment Failure",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC5046385_20201005_0.5,,,Development of an Acid-Resistant Salmonella Typhi Ty21a Attenuated Vector For Improved Oral Vaccine Delivery,title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC5046385_20201005_0.5,ty21a typhoid vaccine,drug_name,"Humans|Salmonella typhi|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Typhoid Fever|Polysaccharides, Bacterial|Vaccines, Attenuated|Drug Delivery Systems|Plasmids|Dysentery, Bacillary|Anthrax|Immunization|Antibodies, Bacterial|Salmonella enterica|Vaccination|Gene Transfer Techniques",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC5643418_20201005_0.5,,,Induction of Cell Cycle and NK Cell Responses by Live-Attenuated Oral Vaccines against Typhoid Fever,title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC5643418_20201005_0.5,,,typhoid|typhoid vaccines|functional genomics|vaccine immunity|Ty21a|NK cell|cell cycle regulation,author_keywords,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC5643418_20201005_0.5,ty21a typhoid vaccine,drug_name,"Humans|Typhoid Fever|Leukocytes, Mononuclear|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Salmonella typhi|Vaccines, Attenuated|Polysaccharides, Bacterial|Antibodies, Bacterial|Killer Cells, Natural|Vaccination|Salmonella enterica",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC5627300_20201005_0.5,ty21a typhoid vaccine,drug_name,"Humans|Female|Mice|Animals|Rabbits|Inhalation anthrax|Anthrax|Bacillus anthracis|Biothrax|Anthrax Vaccines|Salmonella typhi|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Respiratory Tract Infections|Immunization|Vaccination|anthrax toxin|Polysaccharides, Bacterial|Bacterial Toxins|Spores, Bacterial|Exotoxins|Antibodies, Bacterial|Administration, Intranasal|Typhoid Fever|Enzyme-Linked Immunosorbent Assay",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC4607552_20201005_0.5,,,"Immunization with Ty21a live oral typhoid vaccine elicits cross-reactive multifunctional CD8+ T cell responses against Salmonella enterica serovar Typhi, S. Paratyphi A and S. Paratyphi B in humans",title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC4607552_20201005_0.5,,,"Adult|CD8-Positive T-Lymphocytes|Cross Reactions|Female|Flow Cytometry|Humans|Male|Middle Aged|Paratyphoid Fever|Polysaccharides, Bacterial|Salmonella paratyphi A|Salmonella paratyphi B|Salmonella typhi|Typhoid Fever|Typhoid-Paratyphoid Vaccines|Young Adult",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC4607552_20201005_0.5,ty21a typhoid vaccine,drug_name,No section Previously we have extensively characterized Salmonella enterica serovar Typhi (S. Typhi)-specific cell-mediated immune responses (CMI) in volunteers orally immunized with the licensed Ty21a typhoid vaccine.,abstract,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC5600385_20201005_0.5,,,"Adult|Antigen Presentation|Antigens, Bacterial|Bacterial Proteins|Escherichia coli|Female|Flow Cytometry|Humans|Male|Middle Aged|Polysaccharides, Bacterial|Recombinant Proteins|Salmonella typhi|T-Lymphocytes|Typhoid-Paratyphoid Vaccines|Volunteers|Young Adult",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC5600385_20201005_0.5,ty21a typhoid vaccine,drug_name,"Here, cells from individuals immunized with Ty21a typhoid vaccine were collected before and after immunization and used as effectors.",abstract,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID26443352_20201005_0.5,,,"Vaccines against Infections Caused by Salmonella, Shigella, and Pathogenic Escherichia coli.",title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID26443352_20201005_0.5,ty21a typhoid vaccine,drug_name,"Humans|Escherichia coli|Shigella|Salmonella|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Typhoid Fever|Escherichia coli Infections|Vaccines, Attenuated|Dysentery, Bacillary|Salmonella typhi|Salmonella Infections|Bacterial Vaccines|Cholera Vaccines|Polysaccharides, Bacterial|Vaccines, Inactivated",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID27655911_20201005_0.5,,,Stable expression of Shigella dysenteriae serotype 1 O-antigen genes integrated into the chromosome of live Salmonella oral vaccine vector Ty21a.,title,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID27655911_20201005_0.5,,,Combination oral vaccine|Ty21a vector expressing Shigella dysenteriae 1 O-antigen|shigellosis-enteric fever combination vaccine|stable expression of inserted antigenic genes|λ red-mediated recombineering,author_keywords,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID27655911_20201005_0.5,ty21a typhoid vaccine,drug_name,"Mice|Animals|O Antigens|Shigella dysenteriae|Serogroup|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Shigella Vaccines|Salmonella typhi|Vaccines, Attenuated|Polysaccharides, Bacterial|Typhoid Fever|Salmonella Vaccines|Dysentery, Bacillary|Shigella sonnei|Salmonella|Antibodies, Bacterial|Chromosomes",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC8053564_20210511_0.5,,,Aging|Oral vaccine|Terminal ileum LPMC|Tissue resident memory T cells|Ty21a|Vaccine-induced responses,author_keywords,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMC8053564_20210511_0.5,ty21a typhoid vaccine,drug_name,"Aged|Humans|Adult|Middle Aged|Young Adult|Male|Ty21a typhoid vaccine|Typhoid-Paratyphoid Vaccines|Immunologic Memory|Polysaccharides, Bacterial|Immunization|Vaccination|Salmonella typhi|CD8-Positive T-Lymphocytes|CD4-Positive T-Lymphocytes|T-Lymphocyte Subsets|Ileum|Vaccines|Immunity, Mucosal|IL17A protein, human|Interleukin-17|Mucous Membrane",mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID7726905_20201005_0.5,,,Antimalarials|Cost of Illness|Cost-Benefit Analysis|Drug Costs|Hepatitis A|Hepatitis A Vaccines|Hepatovirus|Hospital Costs|Humans|Incidence|Malaria|Malaria Vaccines|Patient Acceptance of Health Care|Retrospective Studies|Travel|Typhoid Fever|United Kingdom|Viral Hepatitis Vaccines,mesh_terms,Other Therapies,Vaccines,Vaccine
Ty21a typhoid vaccine,C0147265,,ty-21a typhoid vaccine|ty 21a typhoid vaccine,,inn,PubMed,PMID7726905_20201005_0.5,ty 21a typhoid vaccine,drug_name_variant,"Similarly, low incidence of typhoid (0.02%) and its high cost gave whole cell killed, polysaccharide Vi, and oral Ty 21a typhoid vaccines cost-benefit ratios of 18.1, 18.0, and 22.0 respectively.",abstract,Other Therapies,Vaccines,Vaccine
paroxetine hemihydrate,Z0000023363,,,paroxetine hydrochloride hemihydrate,inn,PubMed,PMID22607046_20201005_0.5,paroxetine hydrochloride hemihydrate,drug_umls_atom,"Development and comparative evaluation of in vitro, in vivo properties of novel controlled release compositions of paroxetine hydrochloride hemihydrate as against Geomatrix™ platform technology.",title,Gene Therapy,In Vivo,In Vivo
paroxetine hemihydrate,Z0000023363,,,paroxetine hydrochloride hemihydrate,inn,PubMed,PMID22607046_20201005_0.5,paroxetine hydrochloride hemihydrate,drug_umls_atom,"No section The objective of this study is to develop, in vitro and in vivo evaluation of novel approaches for controlled release of paroxetine hydrochloride hemihydrate (PHH) in comparison to patented formulation PAXIL CR(®) tablets of GlaxoSmithKline (GeomatrixTM technology).",abstract,Gene Therapy,In Vivo,In Vivo
infracyanine,Z0000013997,,,,inn,PubMed,PMID16988623_20201005_0.5,,,"Aged|Angiography|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Choroidal Neovascularization|Female|Fluorescein Angiography|Follow-Up Studies|Humans|Indocyanine Green|Injections|Macular Degeneration|Ranibizumab|Time Factors|Tomography, Optical Coherence|Vitreous Body",mesh_terms,Antibodies,None,antibod
infracyanine,Z0000013997,,,,inn,PubMed,PMID9801048_20201005_0.5,,,"Aged|Blood Pressure|Coloring Agents|Drug Administration Routes|Drug Therapy, Combination|Female|Fluorescein Angiography|Fundus Oculi|Glucocorticoids|Head-Down Tilt|Histamine Antagonists|Humans|Hypotension|Indocyanine Green|Macular Degeneration|Retinal Detachment|Shock|Vasoconstrictor Agents",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
infracyanine,Z0000013997,,,,inn,PubMed,PMID19823863_20201005_0.5,infracyanine,drug_name,"To compare possible toxicities of the two vital stains membrane blue and infracyanine green in vivo, we conducted a prospective, randomized, clinical trial.",abstract,Gene Therapy,In Vivo,In Vivo
Urochloa mutica,C0331513,,,para grass pollen,trade_name,PubMed,PMID29549697_20201005_0.5,,,"Adolescent|Adult|Allergens|Antibody Specificity|Antigens, Plant|Child|Chromatography, Liquid|Cross Reactions|Enzyme-Linked Immunosorbent Assay|Female|Humans|Immunoglobulin E|Male|Middle Aged|Poaceae|Pollen|Rhinitis, Allergic|Tandem Mass Spectrometry|Thailand|Tropical Climate|Young Adult",mesh_terms,Antibodies,None,antibod
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMC7886030_20210311_0.5,,,Flortaucipir (tau) PET in LGI1 antibody encephalitis,title,Antibodies,None,antibod
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMC7866464_20210211_0.5,,,In vivo tau pathology is associated with synaptic loss and altered synaptic function,title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID33527648_20210611_0.5,,,"Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease.",title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMC7892378_20210311_0.5,,,In vivo PET imaging of neuroinflammation in familial frontotemporal dementia,title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32762790_20210511_0.5,,,Association Between Visual Memory and In Vivo Amyloid and Tau Pathology in Preclinical Autosomal Dominant Alzheimer's Disease.,title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID33497190_20210411_0.5,,,"Radiosynthesis, In Vitro and In Vivo Evaluation of [18F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies.",title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMC7144772_20201005_0.5,,,In vivo network models identify sex differences in the spread of tau pathology across the brain,title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID33594726_20210311_0.5,,,Significant effects of cholinesterase inhibitors on tau pathology in the Alzheimer's disease continuum: An in vivo positron emission tomography study.,title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID27802224_20201005_0.5,,,"In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease.",title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID27171905_20210111_0.5,t807,drug_name_variant,"With these radioligands, we identified two distinct binding sites for small molecules, one site with high affinity for THK-523 and the other with high affinity for T807.",abstract,Small molecules,None,Small molecule
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMC4249716_20201005_0.5,t807,drug_name_variant,"New positron emission tomography (PET) ligands (e.g., [  F] T807) that identify brain tauopathy have been successfully deployed for the in vitro and in vivo detection of presumptive tauopathy in the brains of subjects with clinically probable CTE.",abstract,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID23411393_20201005_0.5,t807,drug_name_variant,In vivo studies in mice demonstrated that [(18)F]T807 was able to cross the blood-brain barrier and washed out quickly.,abstract,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID23411393_20201005_0.5,t807,drug_name_variant," CONCLUSIONS [(18)F]T807 demonstrates high affinity and selectivity to PHF-tau as well as favorable in vivo properties, making this a promising candidate as an imaging agent for AD.",abstract,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID27765859_20201005_0.5,,,Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology.,title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32251785_20210611_0.5,,,Alzheimer Disease|Animals|Biomimetics|Curcumin|Mice|Mitochondria|Nanoparticles|Neurons,mesh_terms,Nanoparticles,None,Nanoparticle
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32251785_20210611_0.5,t807,drug_name_variant,"Herein, we devised and tested a strategy for functional antioxidant delivery to neuronal mitochondria by loading antioxidants into red blood cell (RBC) membrane-camouflaged human serum albumin nanoparticles bearing T807 and triphenylphosphine (TPP) molecules attached to the RBC membrane surface (T807/TPP-RBC-NPs).",abstract,Nanoparticles,None,Nanoparticle
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32251785_20210611_0.5,t807,drug_name_variant,"With the advantage of the suitable physicochemical properties of the nanoparticles and the unique biological functions of the RBC membrane, the T807/TPP-RBC-NPs are stabilized and promote sustained drug release, providing improved biocompatibility and long-term circulation.",abstract,Nanoparticles,None,Nanoparticle
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32251785_20210611_0.5,t807,drug_name_variant,"After encapsulating curcumin (CUR) as the model antioxidant, the research data demonstrated that CUR-loaded T807/TPP-RBC-NPs can relieve AD symptoms by mitigating mitochondrial oxidative stress and suppressing neuronal death both in vitro and in vivo.",abstract,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32251785_20210611_0.5,t807,drug_name_variant,"Herein, we designed a red blood cell (RBC) membrane-coated human serum albumin nanoparticle dual-modified with T807 and TPP (T807/TPP-RBC-NPs) to accomplish these objectives.",abstract,Nanoparticles,None,Nanoparticle
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID25239654_20201005_0.5,t807,drug_name_variant,"Recently, several tau PET tracers including T807, THK-5117, and PBB3 have been developed and succeeded in imaging neurofibrillary pathology in vivo.",abstract,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID27334944_20201005_0.5,t807,drug_name_variant,"Tau positron emission tomography radiolabelled probes such as T807, THK-5117, and PBB3 can image the pathology of the disease in vivo.",abstract,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID26344059_20201005_0.5,t807,drug_name_variant,"OBJECTIVE To examine region- and substrate-specific autoradiographic and in vitro binding patterns of positron emission tomography tracer [F-18]-AV-1451 (previously known as T807), tailored to allow in vivo detection of paired helical filament-tau-containing lesions, and to determine whether there is off-target binding to other amyloid/non-amyloid proteins.",abstract,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID28697559_20201214_0.5,t807,drug_name_variant," METHODS We measured depressive symptoms using the Geriatric Depression Scale (GDS), and in vivo cerebral tau using T807 PET in 111 CN older adults.",abstract,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMC6486902_20201005_0.5,,,Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging,title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID26299160_20201005_0.5,t807,drug_name_variant,"Selective PET ligands including [18F]THK5117, [18F]THK5351, [18F]AV1451 (T807) and [11C]PBB3 now provide in vivo imaging information about the timing and distribution of tau in the early phases of neurodegenerative diseases.",abstract,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32614677_20210211_0.5,t807,drug_name_variant,T807-modified human serum albumin biomimetic nanoparticles for targeted drug delivery across the blood-brain barrier.,title,Nanoparticles,None,Nanoparticle
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32614677_20210211_0.5,t807,drug_name_variant,Blood-brain barrier|T807|biomimetic nanoparticles|drug delivery|human serum albumin,author_keywords,Nanoparticles,None,Nanoparticle
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32614677_20210211_0.5,,,"Humans|Blood-Brain Barrier|Biomimetics|Serum Albumin, Human|Nanoparticles|Drug Delivery Systems|Biological Transport|Drug Carriers|Brain|Serum Albumin|Microscopy, Electron, Transmission|Endothelial Cells",mesh_terms,Nanoparticles,None,Nanoparticle
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32614677_20210211_0.5,t807,drug_name_variant,No section Novel biocompatible Human Serum Albumin (HSA) nanoparticles composed of membrane of erythrocytes (ETm)-coated and DSPE-PEG3400-T807 segments have been designed for sustained drug delivery across the blood-brain barrier (BBB).,abstract,Nanoparticles,None,Nanoparticle
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32614677_20210211_0.5,t807,drug_name_variant,"The chemical, physical and biocompatible properties of the T807/ETm-HSA nanoparticles have been characterised by hydrogen nuclear magnetic resonance, matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry, transmission electron microscopy, dynamic light scattering and confocal laser scanning microscopy techniques.",abstract,Nanoparticles,None,Nanoparticle
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32614677_20210211_0.5,t807,drug_name_variant,The unique targeting properties of the nanoparticles after fabrication with the brain-targeted ligand T807 was demonstrated by their attaching to brain cells as well as their enhanced transport ability to cross the BBB.,abstract,Nanoparticles,None,Nanoparticle
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32614677_20210211_0.5,t807,drug_name_variant,"In a further demonstration of their ability to target brain cells, in vivo living imaging revealed that T807/ETm-HSA nanoparticles accumulated in the mice brain after intravenous injection.",abstract,"Nanoparticles, Gene Therapy","None, In Vivo","Nanoparticle, In Vivo"
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32614677_20210211_0.5,t807,drug_name_variant,The surface modification of ETm/HSA nanoparticles with the brain-targeted T807 demonstrated in this work represents a highly novel and effective strategy to provide efficient brain targeting and shows promise for the future in using modified ETm-coated HSA nanoparticles to penetrate the brain.,abstract,Nanoparticles,None,Nanoparticle
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMC7222444_20201005_0.5,,,Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer’s disease,title,Nanoparticles,None,Nanoparticle
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMC7222444_20201005_0.5,,,"Alzheimer Disease|Animals|Apoptosis|Biomimetic Materials|Blood-Brain Barrier|Cell Line|Curcumin|Disease Models, Animal|Drug Carriers|Hippocampus|Humans|Maze Learning|Mice|Nanoparticles|Neurons|Protective Agents|tau Proteins",mesh_terms,Nanoparticles,None,Nanoparticle
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMC7222444_20201005_0.5,t807,drug_name_variant,"When CUR was encapsulated, our data also demonstrated that CUR-loaded T807/RPCNP NPs can relieve AD symptoms by reducing p-tau levels and suppressing neuronal-like cells death both in vitro and in vivo.",abstract,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID22119002_20201005_0.5,,,Antagonism of NMDA receptors by butanesulfonyl-homospermine guanidine and neuroprotective effects in in vitro and in vivo.,title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID31287716_20210611_0.5,,,Emerging advances of in vivo detection of chronic traumatic encephalopathy and traumatic brain injury.,title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMC6486902_20201005_0.5,,,Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging,title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMC7545921_20210111_0.5,,,"Humans|Male|Middle Aged|Aged|aducanumab|Apolipoprotein E4|Tomography, X-Ray Computed|Antibodies, Monoclonal, Humanized|Amyloid beta-Peptides|Alzheimer Disease|Amyloidogenic Proteins|tau Proteins|Amyloid|Positron-Emission Tomography|Magnetic Resonance Imaging|Brain|Amyloidosis|Patients",mesh_terms,Antibodies,None,antibod
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID31476153_20201214_0.5,flortaucipir,drug_umls_atom,Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging.,title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID31476153_20201214_0.5,flortaucipir,drug_umls_atom,"By translating the neuropathologic algorithm to flortaucipir PET scans, patterns of tau pathology consistent with autopsy findings, and with a similar prevalence, were identified in vivo.",abstract,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32350558_20210611_0.5,,,Temporal trajectories of in vivo tau and amyloid-β accumulation in Alzheimer's disease.,title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMC6961761_20201005_0.5,flortaucipir,drug_umls_atom,"The PSP-SL variant showed greater volume loss and flortaucipir uptake in supplementary motor area and motor cortex compared to all other variants, but showed less involvement of subthalamic nucleus and midbrain.",abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID31279635_20201005_0.5,flortaucipir,drug_umls_atom,"No section Progressive supranuclear palsy is characterized primarily by 4R tau inclusions, atrophy in the brainstem and basal ganglia, and neurodegeneration along the dentatorubrothalamic tract, which are measurable in vivo using flortaucipir PET, T1-weighted MRI, and MRI with diffusion tensor imaging (DTI).",abstract,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID29751288_20201214_0.5,,,"Aged|Aged, 80 and over|Alzheimer Disease|Amyloid beta-Peptides|Aniline Compounds|Cerebral Cortex|Female|Fluorine Radioisotopes|Humans|Magnetic Resonance Imaging|Male|Middle Aged|Neuroimaging|Positron-Emission Tomography|Radiopharmaceuticals|Stilbenes|tau Proteins",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32338734_20210311_0.5,flortaucipir,drug_umls_atom,Supplemental autopsy [18F]flortaucipir images and pathological samples were also collected from 16 historically collected cases.,abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID31484787_20210111_0.5,,,In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury.,title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMC7567681_20210111_0.5,flortaucipir,drug_umls_atom,Purpose In vivo Alzheimer's disease (AD) biomarkers for tau pathology are cerebrospinal fluid (CSF) phosphorylated tau (p-tau) and [ F]flortaucipir positron emission tomography (PET).,abstract,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID33547556_20210611_0.5,flortaucipir,drug_umls_atom, CONCLUSIONS Current literature provides partial evidence for clinical utility of [18F]flortaucipir PET.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID32285577_20210211_0.5,,,"Interaction effect of Alzheimer's disease pathology and education, occupation, and socioeconomic status as a proxy for cognitive reserve on cognitive performance: in vivo positron emission tomography study.",title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID29127552_20201214_0.5,flortaucipir,drug_umls_atom,MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding.,title,Gene Therapy,In Vivo,In Vivo
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID29127552_20201214_0.5,flortaucipir,drug_umls_atom,"Utilizing another tau-tracer, flortaucipir ([18F]AV-1451), we previously reported that non-demented Parkinson's disease patients show off-target binding in subcortical structures, but no appreciable cortical uptake.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID29538658_20201005_0.5,flortaucipir,drug_umls_atom,We evaluated the utility of 18F-FDG-PET to differentiate flortaucipir tau PET negative from flortaucipir positive amnestic mild cognitive impairment and dementia and used an autopsy confirmed cohort to test the hypothesis that hippocampal sclerosis might account for the observed pattern.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMID33461093_20210611_0.5,,,"Aged, 80 and over|Alzheimer Disease|Autoantibodies|Autoantigens|Autoimmune Diseases|Encephalitis|Female|Humans|Intracellular Signaling Peptides and Proteins|Neuroimaging|Positron-Emission Tomography|Recurrence",mesh_terms,Antibodies,None,antibod
"7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole",C3885550,tauvid|t-807|ly-3191748,"t 807|t807|ly3191748|ly 3191748|fluoropyridin 3-yl)-5h-pyrido(4,3-b)indole|fluoropyridin3-yl)-5h-pyrido(4,3-b)indole",flortaucipir (18f)|flortaucipir f 18|flortaucipir f|flortaucipir|[18f] flortaucipir|flortaucipir f18,inn,PubMed,PMC6096533_20201005_0.5,flortaucipir,drug_umls_atom," Results Different classes of tau tracers such as flortaucipir, THK5317, and PBB3 have been developed and utilized in previous clinical studies.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID22790056_20201005_0.5,levoleucovorin,drug_name,"Aged|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Carcinoma, Neuroendocrine|Colorectal Neoplasms|Combined Modality Therapy|Female|Fluorouracil|Humans|Levoleucovorin|Tomography, X-Ray Computed",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC7672899_20210111_0.5,levoleucovorin,drug_name,"Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Clinical Trials, Phase II as Topic|Colorectal Neoplasms|Female|Fluorouracil|Follow-Up Studies|Humans|Irinotecan|Levoleucovorin|Male|Middle Aged|Multicenter Studies as Topic|Oxaliplatin|Prognosis|Prospective Studies|Receptors, Vascular Endothelial Growth Factor|Recombinant Fusion Proteins|Survival Rate|Young Adult",mesh_terms,Peptide or Protein Therapeutics,Fusion proteins,Fusion Protein
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC4438152_20201005_0.5,levoleucovorin,drug_name,"PRC|Humans|Female|Fluorouracil|Cetuximab|Hepatectomy|irinotecan|Leucovorin|Infusions, Intra-Arterial|Antineoplastic Combined Chemotherapy Protocols|Neoplasm Recurrence, Local|Levoleucovorin|Camptothecin|Liver Neoplasms|oxaliplatin|Organoplatinum Compounds|Sigmoid Neoplasms|panitumumab|Antibodies, Monoclonal|Combined Modality Therapy|Adenocarcinoma|Lymphatic System",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC7477301_20201005_0.5,levoleucovorin,drug_name,"Child|Humans|Autism Spectrum Disorder|Double-Blind Method|FOLR1 protein, human|Folate Receptor 1|Folic Acid|Leucovorin|Metabolic Clearance Rate|Reduced Folate Carrier Protein|Levoleucovorin|Autoantibodies|Inactivation, Metabolic|Calcium, Dietary",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID20354823_20201005_0.5,levoleucovorin,drug_name,"Adult|Aged|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Colorectal Neoplasms|Drugs, Generic|Female|Fluorouracil|Humans|Levoleucovorin|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC5762360_20201005_0.5,levoleucovorin,drug_name,"PRC|Humans|Leucovorin|Fluorouracil|panitumumab|docetaxel|Cisplatin|Stomach Neoplasms|Antibodies, Monoclonal|Taxoids|Esophagogastric Junction|Levoleucovorin|Neutropenia|pegfilgrastim|Granulocyte Colony-Stimulating Factor|Exanthema|Anorexia|Diarrhea|Asthenia|Disease Progression",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC3814899_20201005_0.5,,,"Adult|Aged|Aged, 80 and over|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Asian Continental Ancestry Group|Bevacizumab|Colorectal Neoplasms|DNA-Binding Proteins|Disease-Free Survival|Drug Administration Schedule|Endonucleases|Female|Fluorouracil|Follow-Up Studies|Genotype|Glutathione S-Transferase pi|Humans|Infusions, Intravenous|Japan|Kaplan-Meier Estimate|Leucovorin|Male|Middle Aged|Neoplasm Recurrence, Local|Organoplatinum Compounds|Polymorphism, Single Nucleotide|Prospective Studies|Real-Time Polymerase Chain Reaction|Xeroderma Pigmentosum Group D Protein",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC3814899_20201005_0.5,levofolinate calcium,drug_umls_atom," Methods Bevacizumab (5 mg/kg) was administered intravenously, and then oxaliplatin (85 mg/m ) and levofolinate calcium (200 mg/m ) were infused intravenously over 2 h. Subsequently, a bolus dose of 5-fluorouracil (400 mg/m ) was injected, followed by infusion of 5-fluorouracil (2400 mg/m ) for 46 h. This regimen was repeated every 2 weeks until 24 cycles unless there was disease progression, unacceptable toxicity or patient refusal.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID24206590_20201005_0.5,,,Anticancer drugs|Anticancéreux|Anticorps monoclonaux|Dose banding|Monoclonal antibodies|Stabilis(®)|Stability|Stabilité,author_keywords,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID24206590_20201005_0.5,,,"Antibodies, Monoclonal|Antineoplastic Agents|Chemotherapy, Adjuvant|Drug Stability|Humans|Medical Oncology|Pharmacists|Pharmacy Service, Hospital|Societies, Pharmaceutical",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID19151582_20201005_0.5,,,"Aged|Angiotensin Receptor Antagonists|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antihypertensive Agents|Antineoplastic Agents|Bevacizumab|Blood Pressure|Female|Humans|Hypertension|Immunotherapy|Liver Neoplasms|Receptors, Angiotensin|Sigmoid Neoplasms",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID14579760_20201005_0.5,,,"Antibodies, Monoclonal|Antineoplastic Agents|Antineoplastic Agents, Phytogenic|Camptothecin|Colorectal Neoplasms|Fluorouracil|Humans|Irinotecan|Liver Neoplasms",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID24390266_20201005_0.5,,,"Adenocarcinoma|Antibodies, Monoclonal, Humanized|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Cetuximab|Colonic Neoplasms|Fatal Outcome|Female|Fluorouracil|Humans|Leucovorin|Middle Aged|Skin Neoplasms",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID17212159_20201005_0.5,,,[Utility of arterial infusion chemotherapy and radiation therapy for the pelvic local recurrence of rectal cancer].,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID27141384_20210211_0.5,,,CTLs|Colon cancer|GOLFIG chemo-immunotherapy|epitope peptides|peptide vaccine|thymidylate synthase,author_keywords,Other Therapies,Vaccines,Vaccine
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID27141384_20210211_0.5,,,"Humans|Male|Adult|Middle Aged|Female|Thymidylate Synthase|Cancer Vaccines|Epitopes|tetraphenylporphine sulfonate|Vaccines, Subunit|Interleukin-2|Fluorouracil|Immunotherapy|Colonic Neoplasms|gemcitabine|Deoxycytidine|Leucovorin|Oxaliplatin|Colorectal Neoplasms|sargramostim|Granulocyte-Macrophage Colony-Stimulating Factor|Organoplatinum Compounds|Antineoplastic Combined Chemotherapy Protocols|Rectal Neoplasms|Vaccination",mesh_terms,Other Therapies,Vaccines,Vaccine
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC3771374_20201005_0.5,,,"Adult|Aged|Angiogenesis Inhibitors|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Colorectal Neoplasms|Disease-Free Survival|Female|Fluorouracil|Humans|Leucovorin|Liver Neoplasms|Lung Neoplasms|Lymphatic Metastasis|Male|Middle Aged|Organoplatinum Compounds|Peritoneal Neoplasms|Treatment Outcome",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC3771374_20201005_0.5,levofolinate,drug_umls_atom,"Methods Previously untreated patients were assigned to mFOLFOX7 (oxaliplatin 85 mg/m , levofolinate [l -LV] 200 mg/m , 5-fluorouracil [5-FU] 2400 mg/m ) + bevacizumab (5 mg/kg) administered every 2 weeks for 8 cycles, maintenance without oxaliplatin for 8 cycles, and reintroduction of mFOLFOX7 + bevacizumab for 8 cycles or until disease progression.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID21804330_20201005_0.5,,,"Adult|Aged|Aged, 80 and over|Angiogenesis Inhibitors|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Asian Continental Ancestry Group|Bevacizumab|Blood Pressure|Camptothecin|Colorectal Neoplasms|Disease-Free Survival|Female|Fluorouracil|Forecasting|Humans|Hypertension|Leucovorin|Male|Middle Aged|Molecular Targeted Therapy|Organoplatinum Compounds|Retrospective Studies|Treatment Outcome|Vascular Endothelial Growth Factor A",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID14524579_20201005_0.5,,,"Aged|Female|Folic Acid|Homocysteine|Humans|Leucovorin|Linear Models|Male|Middle Aged|Prospective Studies|Renal Dialysis|Statistics, Nonparametric|Vitamin B 6",mesh_terms,Other Therapies,Vitamin and Mineral Supplement,Vitamin
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID14524579_20201005_0.5,levofolinate,drug_umls_atom,"Patients matched for age, sex and time on HD were assigned to 1 of 2 groups: Those in group A continued to receive their previous supplements while in group B, FA was substituted by calcium levofolinate 5 mg given orally every 48 hours.",abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID14524579_20201005_0.5,levofolinate,drug_umls_atom, CONCLUSIONS After 6 months of calcium-levofolinate supplementation tHcy levels did not decrease and were similar to those in patients given the same dose of FA.,abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC5951897_20201005_0.5,,,"Adult|Aged|Antibodies, Monoclonal|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Colorectal Neoplasms|Female|Fluorouracil|Humans|Irinotecan|Leucovorin|Male|Maximum Tolerated Dose|Middle Aged|Organoplatinum Compounds|Oxaliplatin|Panitumumab|Treatment Outcome|ras Proteins",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID22790056_20201005_0.5,,,"Aged|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Carcinoma, Neuroendocrine|Colorectal Neoplasms|Combined Modality Therapy|Female|Fluorouracil|Humans|Levoleucovorin|Tomography, X-Ray Computed",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC3814899_20201005_0.5,,,"Adult|Aged|Aged, 80 and over|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Asian Continental Ancestry Group|Bevacizumab|Colorectal Neoplasms|DNA-Binding Proteins|Disease-Free Survival|Drug Administration Schedule|Endonucleases|Female|Fluorouracil|Follow-Up Studies|Genotype|Glutathione S-Transferase pi|Humans|Infusions, Intravenous|Japan|Kaplan-Meier Estimate|Leucovorin|Male|Middle Aged|Neoplasm Recurrence, Local|Organoplatinum Compounds|Polymorphism, Single Nucleotide|Prospective Studies|Real-Time Polymerase Chain Reaction|Xeroderma Pigmentosum Group D Protein",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC3814899_20201005_0.5,levofolinate,drug_umls_atom," Methods Bevacizumab (5 mg/kg) was administered intravenously, and then oxaliplatin (85 mg/m ) and levofolinate calcium (200 mg/m ) were infused intravenously over 2 h. Subsequently, a bolus dose of 5-fluorouracil (400 mg/m ) was injected, followed by infusion of 5-fluorouracil (2400 mg/m ) for 46 h. This regimen was repeated every 2 weeks until 24 cycles unless there was disease progression, unacceptable toxicity or patient refusal.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC7841196_20210311_0.5,,,"Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo",title,Gene Therapy,In Vivo,In Vivo
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID24206590_20201005_0.5,,,Anticancer drugs|Anticancéreux|Anticorps monoclonaux|Dose banding|Monoclonal antibodies|Stabilis(®)|Stability|Stabilité,author_keywords,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID24206590_20201005_0.5,,,"Antibodies, Monoclonal|Antineoplastic Agents|Chemotherapy, Adjuvant|Drug Stability|Humans|Medical Oncology|Pharmacists|Pharmacy Service, Hospital|Societies, Pharmaceutical",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC7672899_20210111_0.5,,,"Adult|Aged|Aged, 80 and over|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Clinical Trials, Phase II as Topic|Colorectal Neoplasms|Female|Fluorouracil|Follow-Up Studies|Humans|Irinotecan|Levoleucovorin|Male|Middle Aged|Multicenter Studies as Topic|Oxaliplatin|Prognosis|Prospective Studies|Receptors, Vascular Endothelial Growth Factor|Recombinant Fusion Proteins|Survival Rate|Young Adult",mesh_terms,Peptide or Protein Therapeutics,Fusion proteins,Fusion Protein
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID19583675_20201005_0.5,,,"Chromatography, High Pressure Liquid|Drug Packaging|Drug Stability|Drug Storage|Freezing|Glucose|Hydrogen-Ion Concentration|Leucovorin|Microwaves|Pharmaceutical Vehicles|Polyenes|Regression Analysis|Solutions|Temperature|Time Factors|Vitamin B Complex",mesh_terms,Other Therapies,Vitamin and Mineral Supplement,Vitamin
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID19151582_20201005_0.5,,,"Aged|Angiotensin Receptor Antagonists|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antihypertensive Agents|Antineoplastic Agents|Bevacizumab|Blood Pressure|Female|Humans|Hypertension|Immunotherapy|Liver Neoplasms|Receptors, Angiotensin|Sigmoid Neoplasms",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID26124348_20201005_0.5,,,"Aged|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Asian Continental Ancestry Group|Camptothecin|Colorectal Neoplasms|Disease Progression|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID26124348_20201005_0.5,levofolinate,drug_umls_atom,"BACKGROUND This phase Ib study evaluated the pharmacokinetic profile and safety of ramucirumab, a recombinant human IgG1 neutralizing monoclonal antibody specific for vascular endothelial growth factor receptor 2, in combination with irinotecan, levofolinate and 5-fluorouracil (FOLFIRI) in Japanese patients with metastatic colorectal carcinoma (mCRC).",abstract,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC3717157_20210411_0.5,,,"Administration, Intravenous|Aged|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Asian Continental Ancestry Group|Camptothecin|Colorectal Neoplasms|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Neoplasm Metastasis|Receptors, Vascular Endothelial Growth Factor|Recombinant Fusion Proteins|Vascular Endothelial Growth Factor A",mesh_terms,Peptide or Protein Therapeutics,Fusion proteins,Fusion Protein
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID20354823_20201005_0.5,,,"Adult|Aged|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antineoplastic Combined Chemotherapy Protocols|Bevacizumab|Colorectal Neoplasms|Drugs, Generic|Female|Fluorouracil|Humans|Levoleucovorin|Male|Middle Aged|Organoplatinum Compounds|Oxaliplatin",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID17630037_20201005_0.5,levofolinate,drug_umls_atom,"Strategy A (control group) was single-agent fluorouracil (given with levofolinate over 48 h every 2 weeks) until failure, then single-agent irinotecan.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID14579760_20201005_0.5,,,"Antibodies, Monoclonal|Antineoplastic Agents|Antineoplastic Agents, Phytogenic|Camptothecin|Colorectal Neoplasms|Fluorouracil|Humans|Irinotecan|Liver Neoplasms",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID24390266_20201005_0.5,,,"Adenocarcinoma|Antibodies, Monoclonal, Humanized|Antineoplastic Agents|Antineoplastic Combined Chemotherapy Protocols|Camptothecin|Cetuximab|Colonic Neoplasms|Fatal Outcome|Female|Fluorouracil|Humans|Leucovorin|Middle Aged|Skin Neoplasms",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID26171179_20201005_0.5,,,"Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach.",title,Other Therapies,Vitamin and Mineral Supplement,Vitamin
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID26171179_20201005_0.5,,,"Humans|Male|Adult|Middle Aged|Female|Epoetin Alfa|Biosimilar Pharmaceuticals|Iron|Vitamin B 12|Retrospective Studies|Erythropoietin|Hematinics|Anemia|Folic Acid|Anemia, Refractory|Hemoglobins|Renal Dialysis|Renal Insufficiency, Chronic|Recombinant Proteins|Liposomes|Treatment Outcome|Europe",mesh_terms,"Nanoparticles, Other Therapies","Liposomes, Vitamin and Mineral Supplement","Liposome, Vitamin"
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID26171179_20201005_0.5,levofolinate,drug_umls_atom,"In addition, they received liposomal iron (Sideral®), calcium levofolinate and vitamin B12.",abstract,Other Therapies,Vitamin and Mineral Supplement,Vitamin
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC5922357_20201005_0.5,,,"Middle Aged|Aged|Adult|Male|Humans|Female|Bevacizumab|FOLFOXIRI protocol|Prospective Studies|Antineoplastic Combined Chemotherapy Protocols|Leucovorin|Camptothecin|Organoplatinum Compounds|Fluorouracil|Disease-Free Survival|Colorectal Neoplasms|Antibodies, Monoclonal, Humanized|Kaplan-Meier Estimate|Colonic Neoplasms|Treatment Outcome|Neutropenia|Mutation|Japan",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID17212159_20201005_0.5,,,[Utility of arterial infusion chemotherapy and radiation therapy for the pelvic local recurrence of rectal cancer].,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC7841196_20210311_0.5,,,"Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo",title,Gene Therapy,In Vivo,In Vivo
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID11135086_20201005_0.5,l-folinic acid,drug_umls_atom," CONCLUSIONS Relative to high-dose FA, high-dose oral L-folinic acid-based supplementation does not afford improved tHcy-lowering efficacy in hemodialysis patients.",abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID18083404_20201005_0.5,,,"Adjuvants, Immunologic|Adult|Aged|Aged, 80 and over|Antimetabolites, Antineoplastic|Colorectal Neoplasms|Combined Modality Therapy|Female|Fluorouracil|Humans|Leucovorin|Levamisole|Male|Middle Aged|Neoplasm Recurrence, Local|Vitamin B Complex",mesh_terms,Other Therapies,Vitamin and Mineral Supplement,Vitamin
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC4438152_20201005_0.5,,,"PRC|Humans|Female|Fluorouracil|Cetuximab|Hepatectomy|irinotecan|Leucovorin|Infusions, Intra-Arterial|Antineoplastic Combined Chemotherapy Protocols|Neoplasm Recurrence, Local|Levoleucovorin|Camptothecin|Liver Neoplasms|oxaliplatin|Organoplatinum Compounds|Sigmoid Neoplasms|panitumumab|Antibodies, Monoclonal|Combined Modality Therapy|Adenocarcinoma|Lymphatic System",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC5762360_20201005_0.5,,,"PRC|Humans|Leucovorin|Fluorouracil|panitumumab|docetaxel|Cisplatin|Stomach Neoplasms|Antibodies, Monoclonal|Taxoids|Esophagogastric Junction|Levoleucovorin|Neutropenia|pegfilgrastim|Granulocyte Colony-Stimulating Factor|Exanthema|Anorexia|Diarrhea|Asthenia|Disease Progression",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC3488188_20201005_0.5,,,"Adult|Aged|Aged, 80 and over|Antibodies, Monoclonal|Antineoplastic Combined Chemotherapy Protocols|Colonic Neoplasms|Combined Modality Therapy|Female|Fluorouracil|Humans|Male|Middle Aged|Neoadjuvant Therapy|Neoplasm Staging|Organoplatinum Compounds|Oxaliplatin|Panitumumab|Preoperative Period|Rectal Neoplasms",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID20472346_20201214_0.5,,,Adenocarcinoma|Adult|Aged|Antineoplastic Combined Chemotherapy Protocols|Combined Modality Therapy|Diarrhea|Female|Fluorouracil|Humans|Leucovorin|Male|Middle Aged|Neoplasm Proteins|Neoplasm Staging|Neutropenia|Organoplatinum Compounds|Oxaliplatin|Postoperative Complications|Preoperative Care|Prognosis|Quinazolines|Radiotherapy Dosage|Rectal Neoplasms|Remission Induction|Thiophenes|Thymidylate Synthase|Treatment Outcome|Vitamin B Complex,mesh_terms,Other Therapies,Vitamin and Mineral Supplement,Vitamin
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID26367522_20201005_0.5,,,"Adult|Dietary Supplements|Female|Folic Acid|Health Knowledge, Attitudes, Practice|Humans|Italy|Neural Tube Defects|Preconception Care|Pregnancy|Pregnant Women|Prenatal Care|Prospective Studies|Vitamins",mesh_terms,Other Therapies,Vitamin and Mineral Supplement,"Vitamin, Supplement"
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID26367522_20201005_0.5,levofolinic acid,drug_umls_atom,Seven hundred thirty-three (31.8%) women consumed multivitamins containing 413 (17.9%) consumed products containing FA only and 17 (0.7%) 15 mg of levofolinic acid.,abstract,Other Therapies,Vitamin and Mineral Supplement,Vitamin
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID31394027_20201005_0.5,,,Toxoplasma gondii-induced brachial plexus neuropathy after allogeneic hematopoietic stem cell transplantation.,title,Other Therapies,Stem cell therapy,Stem.Cell
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID31394027_20201005_0.5,,, Toxoplasma gondii |allogeneic hematopoietic stem cell transplantation|brachial plexus neuropathy,author_keywords,Other Therapies,Stem cell therapy,Stem.Cell
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID31394027_20201005_0.5,,,"Aged|Brachial Plexus|Brachial Plexus Neuropathies|Female|Hematopoietic Stem Cell Transplantation|Humans|Magnetic Resonance Imaging|Toxoplasma|Toxoplasmosis|Transplantation, Homologous",mesh_terms,Other Therapies,Stem cell therapy,Stem.Cell
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID19712610_20201005_0.5,,,Antineoplastic Agents|Drug Utilization|Humans|Longitudinal Studies|Neoplasms,mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID22576349_20201005_0.5,,,"Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antineoplastic Agents|Camptothecin|Case-Control Studies|Cell Line, Tumor|Cetuximab|Colorectal Neoplasms|Dendritic Cells|Deoxycytidine|Drug Administration Schedule|ErbB Receptors|Female|Fluorouracil|Humans|Immunomodulation|Immunotherapy|Interleukin-2|Irinotecan|Killer Cells, Natural|Male|Middle Aged|Recombinant Proteins|T-Lymphocyte Subsets",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID25291957_20201005_0.5,,,"Administration, Oral|Adolescent|Adult|Dietary Supplements|Drug Administration Schedule|Erythrocytes|Female|Homocysteine|Humans|Leucovorin|Male|Sex Factors|Time Factors|Vitamin B Complex|Young Adult",mesh_terms,Other Therapies,Vitamin and Mineral Supplement,"Vitamin, Supplement"
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID14524579_20201005_0.5,,,"Aged|Female|Folic Acid|Homocysteine|Humans|Leucovorin|Linear Models|Male|Middle Aged|Prospective Studies|Renal Dialysis|Statistics, Nonparametric|Vitamin B 6",mesh_terms,Other Therapies,Vitamin and Mineral Supplement,Vitamin
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID14524579_20201005_0.5,levofolinic acid,drug_umls_atom,"We decided to perform a study to evaluate the therapeutic effectiveness of oral levofolinic acid, the pharmacologically active form of folinic acid in our population of HD patients already on treatment with oral FA and vitamin B6.",abstract,Other Therapies,Vitamin and Mineral Supplement,Vitamin
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID20399639_20201005_0.5,,,Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).,title,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID20399639_20201005_0.5,,,"Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antibody-Dependent Cell Cytotoxicity|Antineoplastic Agents|Blotting, Western|Camptothecin|Cell Line, Tumor|Cetuximab|Colonic Neoplasms|Deoxycytidine|Drug Synergism|ErbB Receptors|Fluorouracil|Genes, ras|Humans|Irinotecan|Killer Cells, Lymphokine-Activated|Mutation|Panitumumab|Up-Regulation",mesh_terms,Antibodies,None,antibod
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID19583675_20201005_0.5,,,"Chromatography, High Pressure Liquid|Drug Packaging|Drug Stability|Drug Storage|Freezing|Glucose|Hydrogen-Ion Concentration|Leucovorin|Microwaves|Pharmaceutical Vehicles|Polyenes|Regression Analysis|Solutions|Temperature|Time Factors|Vitamin B Complex",mesh_terms,Other Therapies,Vitamin and Mineral Supplement,Vitamin
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMC7841196_20210311_0.5,,,"Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo",title,Gene Therapy,In Vivo,In Vivo
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID26171179_20201005_0.5,,,"Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach.",title,Other Therapies,Vitamin and Mineral Supplement,Vitamin
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID26171179_20201005_0.5,,,"Humans|Male|Adult|Middle Aged|Female|Epoetin Alfa|Biosimilar Pharmaceuticals|Iron|Vitamin B 12|Retrospective Studies|Erythropoietin|Hematinics|Anemia|Folic Acid|Anemia, Refractory|Hemoglobins|Renal Dialysis|Renal Insufficiency, Chronic|Recombinant Proteins|Liposomes|Treatment Outcome|Europe",mesh_terms,"Nanoparticles, Other Therapies","Liposomes, Vitamin and Mineral Supplement","Liposome, Vitamin"
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID26171179_20201005_0.5,calcium levofolinate,drug_umls_atom,"In addition, they received liposomal iron (Sideral®), calcium levofolinate and vitamin B12.",abstract,Other Therapies,Vitamin and Mineral Supplement,Vitamin
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID14524579_20201005_0.5,,,"Aged|Female|Folic Acid|Homocysteine|Humans|Leucovorin|Linear Models|Male|Middle Aged|Prospective Studies|Renal Dialysis|Statistics, Nonparametric|Vitamin B 6",mesh_terms,Other Therapies,Vitamin and Mineral Supplement,Vitamin
levoleucovorin,C2721771,"cl-307,782|fusilev|khapzory|lederfolin","cl 307,782|cl307,782",levofolene 4 mg 30 cpr|levofolinate calcium|levofolinate pentahydrate|calcium levofolinate pentahydrate|levofolinate calcium (l-lv)|levofolinate|calcium levofolinate_irstirccs|levofolinate de calcium (acide l folinique)|levo- leucovorin|disodium levofolinate|l-folinic acid|levofolinate de|levo-folinic acid|levofolinate_irstirccs|l-isomer of leucovorin|l-isomer leucovorin|levofolinate de calcium|calcio levofolinate|levofolene|levofolinate de (acide l folinique)|levofolinic acid|acido levo-folinico (l-leucovorin)|calcium levofolinate,inn,PubMed,PMID14524579_20201005_0.5,calcium levofolinate,drug_umls_atom,"Patients matched for age, sex and time on HD were assigned to 1 of 2 groups: Those in group A continued to receive their previous supplements while in group B, FA was substituted by calcium levofolinate 5 mg given orally every 48 hours.",abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
leukotrap,Z0000082417,,,,trade_name,PubMed,PMID16078926_20201005_0.5,,,In vitro and in vivo evaluation of leukoreduced platelets stored for 7 days in CLX containers.,title,Gene Therapy,In Vivo,In Vivo
leukotrap,Z0000082417,,,,trade_name,PubMed,PMID1284694_20201005_0.5,leukotrap,drug_name,The determination of lymphocyte subpopulations by flow cytometry after filtration with the Leukotrap system showed a more effective adsorption of B cells than of T and natural killer cells.,abstract,Cellular Immunotherapy,Natural Killer Cells,Natural Killer Cell
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID11686825_20201005_0.5,,,"Adult|Analysis of Variance|Anti-Infective Agents, Local|Chlorhexidine|Confidence Intervals|Cross-Over Studies|Dental Calculus|Dental Plaque|Dose-Response Relationship, Drug|Drug Interactions|Female|Follow-Up Studies|Gingivitis|Humans|Male|Middle Aged|Mouthwashes|Oils, Volatile|Pigmentation Disorders|Placebos|Povidone|Single-Blind Method|Statistics as Topic|Statistics, Nonparametric|Tongue Diseases|Tooth Discoloration|Treatment Outcome",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID16367850_20201005_0.5,,,A method to study sustained antimicrobial activity of rinse and dentifrice components on biofilm viability in vivo.,title,Gene Therapy,In Vivo,In Vivo
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID11940138_20201005_0.5,chlorhexidine rinse,drug_umls_atom,Anti-plaque effect of tempered 0.2% chlorhexidine rinse: an in vivo study.,title,Gene Therapy,In Vivo,In Vivo
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMC4080614_20201005_0.5,,,"Adult|Male|Humans|Middle Aged|Female|Cross-Sectional Studies|Intensive Care Units|Pneumonia, Ventilator-Associated|Respiration, Artificial|Oral Hygiene|Chlorhexidine|Critical Care|Intubation|Clinical Competence|Hospitalization|Iran",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID21226852_20201005_0.5,,,"Animals|Anti-Infective Agents, Local|Biofilms|Cattle|Chlorhexidine|Colony Count, Microbial|Drug Combinations|Mouthwashes|Oils, Volatile|Tooth Discoloration",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID8613561_20201005_0.5,,,"Anti-Infective Agents, Local|Bacterial Adhesion|Chlorhexidine|Cross-Over Studies|Dental Plaque|Dental Plaque Index|Dental Prophylaxis|Humans|Male|Mouthwashes|Oils, Volatile|Oral Hygiene|Phenols|Polyethylene Glycols|Polymethacrylic Acids|Single-Blind Method|Surface-Active Agents|Water",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID12060421_20201005_0.5,,,"Adult|Analysis of Variance|Anti-Infective Agents, Local|Bacteria|Biguanides|Chlorhexidine|Colony Count, Microbial|Cross-Over Studies|Dental Plaque|Double-Blind Method|Drug Combinations|Female|Humans|Male|Mouth Mucosa|Mouthwashes|Normal Distribution|Oils, Volatile|Placebos|Reproducibility of Results|Salicylates|Statistics as Topic|Terpenes|Tooth",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID12931087_20201005_0.5,,,"Adult|Anti-Infective Agents, Local|Antifungal Agents|Candida albicans|Candidiasis, Oral|Cause of Death|Chemoprevention|Chlorhexidine|Female|Gingivitis, Necrotizing Ulcerative|Hematopoietic Stem Cell Transplantation|Humans|Length of Stay|Male|Middle Aged|Mouth|Mouthwashes|Nystatin|Stomatitis|Transplantation, Autologous|Transplantation, Homologous|Treatment Outcome",mesh_terms,Other Therapies,Stem cell therapy,Stem.Cell
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID1447382_20201005_0.5,,,"Adult|Alkaloids|Astringents|Benzophenanthridines|Chamomile|Chlorhexidine|Chlorides|Dental Plaque|Double-Blind Method|Eugenol|Female|Flavonoids|Humans|Isoquinolines|Krameriaceae|Male|Mouthwashes|Oils, Volatile|Plants, Medicinal|Resins, Plant|Sodium Dodecyl Sulfate|Tannins|Terpenes|Thymol|Triclosan|Zinc|Zinc Compounds",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID7593704_20201005_0.5,,,An approach to efficacy screening of mouthrinses: studies on a group of French products (II). Inhibition of salivary bacteria and plaque in vivo.,title,Gene Therapy,In Vivo,In Vivo
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID7738271_20201005_0.5,,,Dietary staining in vitro by mouthrinses as a comparative measure of antiseptic activity and predictor of staining in vivo.,title,Gene Therapy,In Vivo,In Vivo
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID7738271_20201005_0.5,,,"Analysis of Variance|Anti-Infective Agents, Local|Cetylpyridinium|Chlorhexidine|Drug Combinations|Drug Synergism|Food Coloring Agents|Hexetidine|Materials Testing|Methylmethacrylate|Methylmethacrylates|Models, Structural|Mouthwashes|Oils, Volatile|Phenols|Salicylates|Saliva|Spectrophotometry|Tea|Terpenes|Tooth Discoloration|Triclosan|Zinc Compounds",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID15752094_20201005_0.5,chlorhexidine rinse,drug_umls_atom,"In our preliminary trials of the use of a chlorhexidine rinse followed by strain K12 lozenges, the majority (8/13) of subjects with confirmed halitosis maintained reduced breath levels of volatile sulphur compounds for at least 2 weeks.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID2127318_20201005_0.5,,,Further in vivo studies on the plaque-inhibiting effect of chlorhexidine and its binding mechanisms.,title,Gene Therapy,In Vivo,In Vivo
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID25443306_20201005_0.5,,,Prophylactic oral health procedures to prevent hospital-acquired and ventilator-associated pneumonia: a systematic review.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID25443306_20201005_0.5,,,Aspiration pneumonia|Dentistry|Hospital-acquired pneumonia|Oral health|Oral prophylaxis|Ventilator-associated pneumonia,author_keywords,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID25443306_20201005_0.5,,,"Cross Infection|Humans|Oral Health|Pneumonia, Ventilator-Associated",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID25443306_20201005_0.5,chlorhexidine rinse,drug_umls_atom," CONCLUSIONS Current evidence suggests that chlorhexidine rinses, gels and swabs may be effective oral disinfectants in patients at high risk for hospital-acquired and ventilator-associated pneumonia.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID16451383_20201005_0.5,chlorhexidine rinse,drug_umls_atom, CONCLUSIONS Based on extensive literature for the correlation of this test in vitro with chlorhexidine anti-plaque activity and propensity to stain in vivo these ADS rinses will have the same anti-plaque efficacy and potential to cause stain as established chlorhexidine rinse products.,abstract,Gene Therapy,In Vivo,In Vivo
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID9344275_20201005_0.5,chlorhexidine rinse,drug_umls_atom,Other preventive agents such as chlorhexidine rinses and xylitol gum supplement the program as risk factors increase or when health and disability limit the ability to effectively perform oral hygiene procedures.,abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMC3200021_20201005_0.5,,,Chlorhexidine|halitosis|organoleptic|spectrophotometry|volatile sulfur compounds (VSCs),author_keywords,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMC3200021_20201005_0.5,,,"Middle Aged|Adult|Male|Humans|Female|Mouthwashes|Halitosis|Chlorhexidine|Anti-Infective Agents, Local|Sulfhydryl Compounds|Oils, Volatile|Spectrophotometry",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID14600693_20201005_0.5,chlorhexidine rinse,drug_umls_atom,OBJECTIVE The purpose of this study was to establish whether addition of a 2% chlorhexidine rinse to a conventional treatment protocol enhances the rate of the successful disinfection of the root canal system in vivo.,abstract,Gene Therapy,In Vivo,In Vivo
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID44385_20201005_0.5,,,Effect of chlorhexidine on acidogenicity of dental plaque in vivo.,title,Gene Therapy,In Vivo,In Vivo
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID8583018_20201005_0.5,,,Comparative staining in vitro and plaque inhibitory properties in vivo of 0.12% and 0.2% chlorhexidine mouthrinses.,title,Gene Therapy,In Vivo,In Vivo
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID7823270_20201005_0.5,,,"Adult|Cetylpyridinium|Chlorhexidine|Dental Plaque|Dental Plaque Index|Double-Blind Method|Female|Gingiva|Humans|Male|Mouthwashes|Oils, Volatile|Oral Hygiene|Placebos|Polymers|Triclosan",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID22874549_20201005_0.5,,,An evidence-based oral care protocol to decrease ventilator-associated pneumonia.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID22874549_20201005_0.5,,,"Chlorhexidine|Cross Infection|Humans|Infection Control|Intensive Care Units|Nursing Audit|Oral Hygiene|Pneumonia, Ventilator-Associated|Respiration, Artificial",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID22874549_20201005_0.5,chlorhexidine rinse,drug_umls_atom,No section The purpose of this study was to examine the impact of 0.12% chlorhexidine rinses and an oral care protocol on ventilator-associated pneumonia rates.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID10682411_20201005_0.5,chlorhexidine rinse,drug_umls_atom,Until the 5th day of washout a clear-cut carryover effect of the chlorhexidine rinse on the gingival index was observed.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID1860286_20201005_0.5,,,Taurolin as an oral rinse. II. Effects on in vitro and in vivo plaque regrowth.,title,Gene Therapy,In Vivo,In Vivo
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID1860286_20201005_0.5,chlorhexidine rinse,drug_umls_atom,"The findings showed that the Taurolin reduced in vitro bacterial surface growth and in vivo plaque regrowth compared to saline, but was not as effective as a chlorhexidine rinse.",abstract,Gene Therapy,In Vivo,In Vivo
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID24155621_20201005_0.5,,,"Humans|Male|Middle Aged|Female|Mouthwashes|Gingivitis|Chlorhexidine|Anti-Infective Agents, Local|Double-Blind Method|Listerine|Terpenes|Salicylates|Periodontal Index|Oral Hygiene|Oils, Volatile|Drug Combinations|Analysis of Variance|Plaque, Amyloid|Plaque, Atherosclerotic",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID9667160_20201005_0.5,,,"Chlorhexidine, fluoride varnish, and xylitol chewing gum: underutilized preventive therapies?",title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID11350523_20201005_0.5,chlorhexidine rinse,drug_umls_atom,The aim of these studies in vivo was to determine whether PVP affected plaque and dietary staining by a low concentration chlorhexidine rinse.,abstract,Gene Therapy,In Vivo,In Vivo
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID8195448_20201005_0.5,,,Comparison of 2 chlorhexidine mouthwashes on plaque regrowth in vivo and dietary staining in vitro.,title,Gene Therapy,In Vivo,In Vivo
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID10783565_20201005_0.5,chlorhexidine rinse,drug_umls_atom,Until the 5th day of washout a clear-cut carry over of the chlorhexidine rinse on mutans streptococci as well as on the gingival index was evident.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID20074477_20201005_0.5,,,"Adenocarcinoma|Alveolar Bone Loss|Amoxicillin-Potassium Clavulanate Combination|Angiogenesis Inhibitors|Anti-Bacterial Agents|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Bevacizumab|Bone Neoplasms|Chlorhexidine|Humans|Jaw Diseases|Lung Neoplasms|Male|Middle Aged|Mouthwashes|Osteonecrosis|Pain|Tooth Extraction|Treatment Outcome",mesh_terms,Antibodies,None,antibod
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID24106323_20201005_0.5,chlorhexidine gluconate oral rinse,drug_umls_atom,Effect of oral hygiene and 0.12% chlorhexidine gluconate oral rinse in preventing ventilator-associated pneumonia after cardiovascular surgery.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID24106323_20201005_0.5,,,cardiovascular surgery|chlorhexidine|prevention|ventilator-associated pneumonia,author_keywords,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID24106323_20201005_0.5,,,"Anti-Infective Agents, Local|Cardiovascular Surgical Procedures|Chlorhexidine|Female|Historically Controlled Study|Humans|Incidence|Length of Stay|Male|Middle Aged|Mouthwashes|Pneumonia, Ventilator-Associated|Postoperative Complications|Toothbrushing",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID20194614_20201005_0.5,,,"Adult|Critical Illness|Cross-Sectional Studies|Guideline Adherence|Health Care Surveys|Humans|Intensive Care Units|Internet|Intubation, Intratracheal|Mouth|Oral Hygiene|Pneumonia, Ventilator-Associated|Practice Guidelines as Topic|Respiration, Artificial|United States",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID26443484_20201005_0.5,chlorhexidine oral rinse,drug_umls_atom,Reduced occurrence of ventilator-associated pneumonia after cardiac surgery using preoperative 0.2% chlorhexidine oral rinse: results from a single-centre single-blinded randomized trial.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID26443484_20201005_0.5,,,Cardiac surgery|Chlorhexidine|Prophylaxis|Ventilator-associated pneumonia,author_keywords,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID26443484_20201005_0.5,,,"Adolescent|Adult|Aged|Chlorhexidine|Disinfectants|Female|Humans|Incidence|Male|Middle Aged|Mouthwashes|Pneumonia, Ventilator-Associated|Prospective Studies|Single-Blind Method|Thoracic Surgery|Treatment Outcome|Young Adult",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMC6252557_20201005_0.5,,,"1267. Nonventilator Hospital Acquired Pneumonia (NV-HAP) Prevention Initiative in Colombia, Bogotá",title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMC6252557_20201005_0.5,,,"Middle Aged|Adult|Male|Humans|Female|Healthcare-Associated Pneumonia|Colombia|Pneumonia, Ventilator-Associated|Cross Infection|Patient Care Bundles|Intensive Care Units|Ventilators, Mechanical|Hospitals, University|Decontamination|Drive",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID12931087_20201005_0.5,,,"Adult|Anti-Infective Agents, Local|Antifungal Agents|Candida albicans|Candidiasis, Oral|Cause of Death|Chemoprevention|Chlorhexidine|Female|Gingivitis, Necrotizing Ulcerative|Hematopoietic Stem Cell Transplantation|Humans|Length of Stay|Male|Middle Aged|Mouth|Mouthwashes|Nystatin|Stomatitis|Transplantation, Autologous|Transplantation, Homologous|Treatment Outcome",mesh_terms,Other Therapies,Stem cell therapy,Stem.Cell
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID24106323_20201005_0.5,,,Effect of oral hygiene and 0.12% chlorhexidine gluconate oral rinse in preventing ventilator-associated pneumonia after cardiovascular surgery.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID24106323_20201005_0.5,,,cardiovascular surgery|chlorhexidine|prevention|ventilator-associated pneumonia,author_keywords,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID24106323_20201005_0.5,,,"Anti-Infective Agents, Local|Cardiovascular Surgical Procedures|Chlorhexidine|Female|Historically Controlled Study|Humans|Incidence|Length of Stay|Male|Middle Aged|Mouthwashes|Pneumonia, Ventilator-Associated|Postoperative Complications|Toothbrushing",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID12594876_20201005_0.5,chlorhexidine oral rinse,drug_umls_atom,Prophylactic chlorhexidine oral rinse decreases ventilator-associated pneumonia in surgical ICU patients.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID12594876_20201005_0.5,,,"Aged|Anti-Infective Agents, Local|Chlorhexidine|Combined Modality Therapy|Critical Care|Cross Infection|Female|Humans|Male|Middle Aged|Mouthwashes|Postoperative Complications|Prospective Studies|Time Factors|Treatment Outcome|Ventilator Weaning|Ventilators, Mechanical",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID22726656_20201214_0.5,chlorhexidine oral rinse,drug_umls_atom,"Interventions that might reduce mortality include chlorhexidine oral rinse, clonidine, insulin, intra-aortic balloon pump, leukodepletion, levosimendan, neuraxial anesthesia, noninvasive respiratory support, hemodynamic optimization, oxygen, selective decontamination of the digestive tract, and volatile anesthetics.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMC6814100_20201005_0.5,,,"Protocol for a multi-centered, stepped wedge, cluster randomized controlled trial of the de-adoption of oral chlorhexidine prophylaxis and implementation of an oral care bundle for mechanically ventilated critically ill patients: the CHORAL study",title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMC6814100_20201005_0.5,,,Chlorhexidine|Critical care|Ventilator-associated pneumonia|Oral care|Stepped-wedge cluster randomized controlled trial|Process evaluation|Mechanical ventilation,author_keywords,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMC6814100_20201005_0.5,,,"Anti-Infective Agents, Local|Chlorhexidine|Critical Illness|Cross-Over Studies|Drainage|Humans|Mouthwashes|Multicenter Studies as Topic|Ontario|Oral Hygiene|Patient Care Bundles|Pneumonia, Ventilator-Associated|Randomized Controlled Trials as Topic|Respiration, Artificial|Time Factors|Toothbrushing|Treatment Outcome",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMC6814100_20201005_0.5,chlorhexidine oral rinse,drug_umls_atom,Background Routine application of chlorhexidine oral rinse is recommended to reduce risk of ventilator-associated pneumonia (VAP) in mechanically ventilated patients.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID15187525_20201005_0.5,,,Prevention of hospital-associated pneumonia and ventilator-associated pneumonia.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID15187525_20201005_0.5,,,"Cross Infection|Equipment Contamination|Humans|Pneumonia|Ventilators, Mechanical",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID15187525_20201005_0.5,chlorhexidine oral rinse,drug_umls_atom,"The evidence-based interventions focus on the prevention of aerodigestive tract colonization (avoidance of unnecessary antibiotics and stress ulcer prophylaxis, use of sucralfate for stress ulcer prophylaxis, chlorhexidine oral rinse, selective digestive decontamination, short-course parenteral prophylactic antibiotics in high-risk patients) and the prevention of aspiration of contaminated secretions (preferred oral intubation, appropriate intensive care unit staffing, avoidance of tracheal intubation with the use of mask ventilation, application of weaning protocols and optimal use of sedation to shorten the duration of mechanical ventilation, semirecumbent positioning, minimization of gastric distension, subglottic suctioning, avoidance of ventilator circuit changes/manipulation, routine drainage of ventilator circuit condensate).",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID12060421_20201005_0.5,,,"Adult|Analysis of Variance|Anti-Infective Agents, Local|Bacteria|Biguanides|Chlorhexidine|Colony Count, Microbial|Cross-Over Studies|Dental Plaque|Double-Blind Method|Drug Combinations|Female|Humans|Male|Mouth Mucosa|Mouthwashes|Normal Distribution|Oils, Volatile|Placebos|Reproducibility of Results|Salicylates|Statistics as Topic|Terpenes|Tooth",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID8195448_20201005_0.5,,,Comparison of 2 chlorhexidine mouthwashes on plaque regrowth in vivo and dietary staining in vitro.,title,Gene Therapy,In Vivo,In Vivo
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID22874549_20201005_0.5,,,An evidence-based oral care protocol to decrease ventilator-associated pneumonia.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID22874549_20201005_0.5,,,"Chlorhexidine|Cross Infection|Humans|Infection Control|Intensive Care Units|Nursing Audit|Oral Hygiene|Pneumonia, Ventilator-Associated|Respiration, Artificial",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
acclean chlorhexidine rinse,Z0000023109,,,chlorhexidine rinse|chlorhexidine gluconate 0.12% oral rinse|dash chlorhexidine gluconate 0.12% oral rinse|chlorhexidine gluconate oral rinse|fms chlorhexidine rinse|qs chlorhexidine rinse|dash chlorhexidine rinse|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine oral rinse|0.12% chlorhexidine rinse|acclean chlorhexidine gluconate 0.12% oral rinse,inn,PubMed,PMID22874549_20201005_0.5,0.12% chlorhexidine rinse,drug_umls_atom,No section The purpose of this study was to examine the impact of 0.12% chlorhexidine rinses and an oral care protocol on ventilator-associated pneumonia rates.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
18f-fluoroestradiol,Z0000017145,,,fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol,inn,PubMed,PMID21903739_20201005_0.5,18f-fluoroestradiol,drug_name,"Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.",title,Gene Therapy,In Vivo,In Vivo
18f-fluoroestradiol,Z0000017145,,,fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol,inn,PubMed,PMID27872957_20210311_0.5,18f-fluoroestradiol,drug_name,Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
18f-fluoroestradiol,Z0000017145,,,fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol,inn,PubMed,PMID30850489_20201005_0.5,18f-fluoroestradiol,drug_name,No section The purpose of this study was to determine the effect of estrogen receptor-α gene (ESR1) mutations at the tyrosine (Y) 537 amino acid residue within the ligand binding domain on 18F-fluoroestradiol (18F-FES) binding and in vivo tumor uptake compared with wild-type (WT)-estrogen receptor α (ER).,abstract,Gene Therapy,In Vivo,In Vivo
18f-fluoroestradiol,Z0000017145,,,fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol,inn,PubMed,PMID30850489_20201005_0.5,fluoroestradiol,drug_umls_atom,No section The purpose of this study was to determine the effect of estrogen receptor-α gene (ESR1) mutations at the tyrosine (Y) 537 amino acid residue within the ligand binding domain on 18F-fluoroestradiol (18F-FES) binding and in vivo tumor uptake compared with wild-type (WT)-estrogen receptor α (ER).,abstract,Gene Therapy,In Vivo,In Vivo
18f-fluoroestradiol,Z0000017145,,,fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol,inn,PubMed,PMID27491481_20201005_0.5,,,"Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.",title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
18f-fluoroestradiol,Z0000017145,,,fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol,inn,PubMed,PMID27491481_20201005_0.5,,,Breast cancer|FES-PET|Lapatinib|Letrozole|Neoadjuvant|Postmenopausal|TILs,author_keywords,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
18f-fluoroestradiol,Z0000017145,,,fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol,inn,PubMed,PMID27872957_20210311_0.5,fluoroestradiol,drug_umls_atom,Utility of 18F-fluoroestradiol (18F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
18f-fluoroestradiol,Z0000017145,,,fluoroestradiol f 18|18f fluoroestradiol (fes)|f-18 fluoroestradiol|fluoroestradiol f|f-18 alpha-fluoroestradiol|[18f]fluoroestradiol (fes) pet/ct|[18f]fluoroestradiol|fluoroestradiol (18f)|[18f]fluoroestradiol (fes)|f fluoroestradiol|18-f fluoroestradiol|fluoroestradiol|f-18 16 alpha-fluoroestradiol,inn,PubMed,PMID27307345_20201005_0.5,fluoroestradiol,drug_umls_atom,"However, recent advances have allowed in vivo evaluation of ER expression with (18)F-fluoroestradiol ((18)F-FES) PET.",abstract,Gene Therapy,In Vivo,In Vivo
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID29300107_20201005_0.5,dextrose monohydrate,drug_name,This study clearly demonstrated the utility of dextrose monohydrate as a non-animal sourced diluent in a HSWG tablet formulation.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID9829362_20201005_0.5,dextrose monohydrate,drug_name,"The rats were made hyperglycemic with an intravenous instillation of a solution containing 40% dextrose monohydrate at a rate of 1.5 ml/h for 24 h. RESULTS The blood glucose level was 387+/-45 mg/dl and 382+/-35 mg/dl (mean +/- standard deviation) in diabetic and hyperglycemic rats, respectively.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID23630052_20201005_0.5,,,The effect of beta-alanine supplementation on isokinetic force and cycling performance in highly trained cyclists.,title,Other Therapies,Vitamin and Mineral Supplement,Supplement
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID23630052_20201005_0.5,,,"Administration, Oral|Adolescent|Adult|Athletes|Athletic Performance|Bicycling|Dietary Supplements|Double-Blind Method|Humans|Hydrogen-Ion Concentration|Lactic Acid|Male|Muscle Strength|Oxygen Consumption|Physical Endurance|Sports Nutritional Physiological Phenomena|Young Adult|beta-Alanine",mesh_terms,Other Therapies,Vitamin and Mineral Supplement,Supplement
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID23630052_20201005_0.5,dextrose monohydrate,drug_name,"Sixteen highly trained cyclists (mean ± SD; age = 24 ± 7 yr; mass = 70 ± 7 kg; VO2max = 67 ± 4 ml · kg(-1) · min(-1)) supplemented with either beta-alanine (n = 8, 65 mg · kg - 1BM) or a placebo (n = 8; dextrose monohydrate) over 4 weeks.",abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID3190967_20201005_0.5,,,"Adult|Anesthesia, Obstetrical|Anesthesia, Spinal|Aorta, Thoracic|Blood Flow Velocity|Blood Pressure|Cesarean Section|Female|Fetus|Heart Rate|Humans|Pregnancy|Pulsatile Flow|Regional Blood Flow|Umbilical Arteries",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID6585801_20201005_0.5,,,Complex carbohydrate diets are not capable of maintaining normal plasma calcium and phosphorus levels in vitamin D-deficient rats.,title,Other Therapies,Vitamin and Mineral Supplement,Vitamin
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID6585801_20201005_0.5,,,Animals|Calcium|Dietary Carbohydrates|Flour|Glucose|Phosphates|Rats|Vitamin D Deficiency,mesh_terms,Other Therapies,Vitamin and Mineral Supplement,Vitamin
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID6585801_20201005_0.5,glucose monohydrate,drug_umls_atom,"No section Substitution of Cerelose (glucose monohydrate) for complex carbohydrate (whole wheat flour) does not alter plasma calcium levels in vitamin D-deficient rats, contrary to a previous report.",abstract,Other Therapies,Vitamin and Mineral Supplement,Vitamin
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID1156929_20201005_0.5,,,The utilisation of various fats by turkeys of different ages.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID1156929_20201005_0.5,glucose monohydrate,drug_umls_atom,"The utilisation of fat and fatty acids supplied as maize oil, tallow or lard in the diet of 2-, 4- and 8-week old turkeys has been investigated: a mixture of 10% fat and 15% cellulose replaced glucose monohydrate in a low-fat basal diet.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID3447140_20201005_0.5,glucose monohydrate,drug_umls_atom,"A 22% protein basal diet composed of 43.3% glucose monohydrate, 45.4% dehulled soybean meal, .5% DL-methionine, 6% stabilized fat, and added minerals and vitamins served as the negative control.",abstract,Other Therapies,Vitamin and Mineral Supplement,Vitamin
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID6669505_20201005_0.5,,,Supplementary inorganic sulfate and methionine for young turkeys.,title,Other Therapies,Vitamin and Mineral Supplement,Supplement
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID6669505_20201005_0.5,glucose monohydrate,drug_umls_atom,"Experimental diets, in which a corn-soybean meal basal diet was supplemented with inorganic sulfate either in the form of sodium sulfate (0, .0952, and .1904%) or potassium sulfate (0, .1180, and .2360%), and with methionine (0, .05, .10 and .15%) in the place of glucose monohydrate, were fed in a 3 X 2 X 4 experimental design.",abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID32051744_20201005_0.5,,,Use of modified Custodiol-N as perfusion solution in ex vivo lung perfusion.,title,Gene Therapy,Ex vivo,Ex Vivo
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMC5457009_20201005_0.5,glucose monohydrate,drug_umls_atom,"The absorption tests were done in accordance with the SR ISI 1817:2015 using distilled water, acetic acid (10%), sodium hydroxide (1%), ethylic alcohol (96%), physiological serum (sodium chloride 0.9%) and glucose (glucose monohydrate 10%).",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID11055856_20201005_0.5,,,Influence of dietary protein level on the broiler chicken's response to methionine and betaine supplements.,title,Other Therapies,Vitamin and Mineral Supplement,Supplement
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID11055856_20201005_0.5,,,"Adipose Tissue|Animals|Betaine|Body Composition|Chickens|Diet|Dietary Proteins|Dietary Supplements|Energy Intake|Energy Metabolism|Lipids|Liver|Male|Methionine|Muscle Proteins|Muscle, Skeletal|Proteins|Tibia|Weight Gain",mesh_terms,Other Therapies,Vitamin and Mineral Supplement,Supplement
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID17679559_20201005_0.5,,,Promising ternary dry powder inhaler formulations of cromolyn sodium: formulation and in vitro-in vivo evaluation.,title,Gene Therapy,In Vivo,In Vivo
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID25280410_20201005_0.5,,,Short-term dietary supplementation with fructose accelerates gastric emptying of a fructose but not a glucose solution.,title,Other Therapies,Vitamin and Mineral Supplement,Supplement
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID25280410_20201005_0.5,,,Appetite|Diet|Fructose supplementation|Gastrointestinal adaptation|Monosaccharide solutions,author_keywords,Other Therapies,Vitamin and Mineral Supplement,Supplement
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID25280410_20201005_0.5,,,Adult|Appetite|Cross-Over Studies|Dietary Carbohydrates|Dietary Supplements|Fructose|Gastric Emptying|Glucose|Humans|Male|Prospective Studies|Young Adult,mesh_terms,Other Therapies,Vitamin and Mineral Supplement,Supplement
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID25280410_20201005_0.5,glucose monohydrate,drug_umls_atom, METHODS The gastric emptying rate of a fructose solution containing 36 g of fructose and an equicaloric glucose solution containing 39.6 g glucose monohydrate were measured in 10 healthy non-smoking men with and without prior fructose supplementation (water control) using a randomized crossover design.,abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID3737508_20201005_0.5,,,The lack of effect of a pyridoxine deficiency on the utilization of the hydroxyl analogue of methionine by the chick.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
dextrose monohydrate,C0017734,,,glucose monohydrate,inn,PubMed,PMID3737508_20201005_0.5,,,Animals|Aspartate Aminotransferases|Chickens|Diet|Methionine|Pyridoxine|Vitamin B 6 Deficiency,mesh_terms,Other Therapies,Vitamin and Mineral Supplement,Vitamin
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33793172_20210411_0.5,,,"Antibodies, Monoclonal, Humanized|COVID-19|Drug Approval|Humans|Nurse Clinicians|Practice Patterns, Nurses'|Severity of Illness Index|United States|United States Food and Drug Administration",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8144687_20210611_0.5,,,"The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization",title,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8144687_20210611_0.5,bamlanivimab,drug_name,COVID-19|bamlanivimab|casirivimab|etesevimab|imdevimab|monoclonal antibodies|pragmatic trial|protocol|randomised controlled trial,author_keywords,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8013486_20210411_0.5,,,A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID‐19 in skilled care facilities,title,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8013486_20210411_0.5,bamlanivimab,drug_name,COVID-19|SARS-CoV-2|bamlanivimab|casirivimab|monoclonal antibodies,author_keywords,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8013486_20210411_0.5,,,"Aged|Antibodies, Monoclonal, Humanized|COVID-19|Drug Combinations|Female|Humans|Male|Minnesota|Mobile Health Units|Patients|Referral and Consultation|Retrospective Studies|Skilled Nursing Facilities",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8109198_20210611_0.5,bamlanivimab,drug_name,Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study,title,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8109198_20210611_0.5,bamlanivimab,drug_name,bamlanivimab|covid-19|covid-19 treatment|long-term care facility|ly-cov555|monoclonal antibody|non-hospital setting|nursing home|sars-cov-2,author_keywords,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8109198_20210611_0.5,,,"Humans|Male|Female|Aged, 80 and over|Aged|Retrospective Studies|Antibodies, Monoclonal|Case-Control Studies|COVID-19|SARS-CoV-2|Nursing Homes|Hospitalization|Skilled Nursing Facilities|Antineoplastic Agents, Immunological|Patients|Hospital Mortality|Risk Factors|Hospitals|New York",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8096193_20210511_0.5,,,COVID-19|monoclonal antibody therapy|skilled nursing facility,author_keywords,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8155772_20210611_0.5,,,Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19,title,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8155772_20210611_0.5,bamlanivimab,drug_name,bamlanivimab|casirivimab|covid_19|imdevimab|monoclonal antibodies|patient outcomes|sars_cov-2,author_keywords,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8155772_20210611_0.5,,,"Humans|Male|Middle Aged|Adult|Female|Antibodies, Monoclonal|COVID-19|Retrospective Studies|COVID-19 Testing|SARS-CoV-2|Antineoplastic Agents, Immunological|Immunotherapy|Social Support|Ethnic Groups|European Continental Ancestry Group|Informed Consent",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8155772_20210611_0.5,bamlanivimab,drug_name," Methods This retrospective cohort study enrolled 2820 adult patients who were offered monoclonal antibody therapies, bamlanivimab and casirivimab-imdevimab, for COVID-19 at Mayo Clinic in the Midwest between 11/19/2020 and 12/31/2020.",abstract,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID34074219_20210611_0.5,,,"Angiotensin-Converting Enzyme 2|Antibodies, Monoclonal, Humanized|Antiviral Agents|Binding Sites|COVID-19|Host-Pathogen Interactions|Humans|Molecular Docking Simulation|Mutation|Protein Binding|Protein Interaction Domains and Motifs|Receptors, Virus|SARS-CoV-2",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID34074219_20210611_0.5,bamlanivimab,drug_name,"The mutated version of RBD also completely abolishes the binding of bamlanivimab, a therapeutic antibody, in vitro.",abstract,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33724631_20210411_0.5,,,Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.,title,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33724631_20210411_0.5,bamlanivimab,drug_name,B.1.1.7|B.1.351|BNT162b2|COVID-19|LY-CoV555|LyCoV016|P.1|P.2|REGN10933|REGN10987|SARS-CoV-2|bamlanivimab|casirivimab|convalescent plasma|etesevimab|imdevimab|immune escape|mRNA-1273|mutations|neutralising antibody|polyclonal immunoglobulins,author_keywords,"Antibodies, Gene Therapy","None, RNA, Messenger","antibod, mRNA"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33724631_20210411_0.5,,,"Humans|spike protein, SARS-CoV-2|Spike Glycoprotein, Coronavirus|Antibodies, Neutralizing|COVID-19|SARS-CoV-2|Phylogeny|Vaccines|Viral Envelope Proteins|Antibodies, Viral|Membrane Glycoproteins|Risk Assessment|Brazil",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33619479_20210611_0.5,,,"Humans|SARS-CoV-2|COVID-19|Antibodies, Neutralizing|Antibodies, Viral|Spike Glycoprotein, Coronavirus|Protein Binding|Antibodies, Monoclonal|Mutation|Biophysical Phenomena|South Africa|Brazil",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33619479_20210611_0.5,bamlanivimab,drug_name,"This mutated version of RBD also completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro .",abstract,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID34081073_20210611_0.5,,,"Humans|Male|Female|United States|COVID-19|Assisted Living Facilities|Incidence|Double-Blind Method|SARS-CoV-2|Antibodies, Neutralizing",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID34081073_20210611_0.5,bamlanivimab,drug_name,"Bamlanivimab, a neutralizing monoclonal antibody against SARS-CoV-2, may confer rapid protection from SARS-CoV-2 infection and COVID-19.",abstract,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8002405_20210411_0.5,,,Fc-fusion protein|immune complex|immunoglobulin G|monoclonal antibody|neonatal Fc receptor|pharmacokinetics|physiologically-based pharmacokinetic modeling,author_keywords,"Antibodies, Peptide or Protein Therapeutics","None, Monoclonal Antibodies, Fusion proteins","antibod, Monoclonal Antibod, Fusion Protein"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8002405_20210411_0.5,,,"Animals|Antibodies, Monoclonal|COVID-19|Histocompatibility Antigens Class I|Humans|Immunoglobulin G|Receptors, Fc|Tissue Distribution",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8002405_20210411_0.5,bamlanivimab,drug_name,"We further comment on therapeutic antibodies authorized for treating SARS-CoV-2 (bamlanivimab, casirivimab, and imdevimab) and evaluate their potential to saturate FcRn-mediated recycling.",abstract,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33820835_20210611_0.5,,,"The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.",title,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33820835_20210611_0.5,,,"Animals|Humans|Antibodies, Neutralizing|COVID-19|SARS-CoV-2|Macaca mulatta|Spike Glycoprotein, Coronavirus|Antibodies, Viral|Antibodies, Monoclonal|Virus Replication|Protein Binding",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33820835_20210611_0.5,bamlanivimab,drug_name,"Here, we report that high-throughput microfluidic screening of antigen-specific B cells led to the identification of LY-CoV555 (also known as bamlanivimab), a potent anti-spike neutralizing antibody from a hospitalized, convalescent patient with coronavirus disease 2019 (COVID-19).",abstract,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID34081820_20210611_0.5,,,COVID-19|monoclonal antibody|transplant|viral infection,author_keywords,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33459118_20210511_0.5,,,Antibodies to watch in 2021.,title,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33459118_20210511_0.5,,,Antibody therapeutics|COVID-19|European Medicines Agency|Food and Drug Administration|Sars-CoV-2|cancer|immune-mediated disorders,author_keywords,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33459118_20210511_0.5,,,Animals|Antibodies|Antiviral Agents|COVID-19|Diffusion of Innovation|Drug Approval|Drug Development|Drug Discovery|Drug Repositioning|Forecasting|Host-Pathogen Interactions|Humans|SARS-CoV-2,mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33459118_20210511_0.5,bamlanivimab,drug_name,"Remarkably, by late November 2020, two anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 in Russia and India, respectively.",abstract,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7694556_20210411_0.5,,,Antiviral Agents|COVID-19|COVID-19 Vaccines|Compassionate Use Trials|Drug Approval|Humans|SARS-CoV-2|United States,mesh_terms,Other Therapies,Vaccines,Vaccine
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33177042_20201214_0.5,bamlanivimab,drug_name,Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients.,title,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7980144_20210411_0.5,,,SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies,title,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7980144_20210411_0.5,,,B.1.1.7|B.1.351|COVID-19|P.1|SARS-CoV-2|VOC|antibodies|escape|host cell entry|neutralization|spike protein|variants|variants of concern,author_keywords,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7980144_20210411_0.5,,,"Animals|Antibodies, Neutralizing|Antibodies, Viral|COVID-19|Cell Line|Drug Resistance, Viral|Humans|Immunization, Passive|Kinetics|Membrane Fusion|Models, Molecular|Neutralization Tests|SARS-CoV-2|Serine Endopeptidases|Solubility|Spike Glycoprotein, Coronavirus|Vaccination|Virus Internalization",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7980144_20210411_0.5,bamlanivimab,drug_name,"In contrast, entry of the B.1.351 and P.1 variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment.",abstract,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8083260_20210511_0.5,bamlanivimab,drug_name,COVID-19|SARS-CoV-2|bamlanivimab|monoclonal antibody,author_keywords,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8083260_20210511_0.5,bamlanivimab,drug_name,"Anti-spike monoclonal antibodies, including bamlanivimab, have demonstrated reduction in hospitalization rates in clinical trials, yet real-world evidence is lacking.",abstract,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8071770_20210511_0.5,,,Development and application of therapeutic antibodies against COVID-19,title,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8071770_20210511_0.5,,,COVID-19|SARS-CoV-2|antibody cocktail|convalescent plasma|monoclonal antibody|therapeutic antibody,author_keywords,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8071770_20210511_0.5,,,"Antibodies, Monoclonal|Antibodies, Neutralizing|COVID-19|Humans|Immunization, Passive|SARS-CoV-2",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8092710_20210511_0.5,,,"Chlorocebus aethiops|Animals|Humans|SARS-CoV-2|Pandemics|Genes, Reporter|COVID-19|Virus Replication|Antibodies, Neutralizing|Vero Cells|Antiviral Agents|Antibodies, Viral|Genome, Viral|Luciferases|Antibodies, Monoclonal|Family Characteristics",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8092710_20210511_0.5,bamlanivimab,drug_name,"To date, only one Food and Drug Administration (FDA)-approved therapeutic drug (remdesivir) and a monoclonal antibody (MAb), bamlanivimab, are available for the treatment of SARS-CoV-2.",abstract,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7799019_20210211_0.5,,,Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of COVID-19 in Children and Adolescents,title,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7799019_20210211_0.5,,,"Adolescent|Antibodies, Monoclonal|Antibodies, Monoclonal, Humanized|Antiviral Agents|COVID-19|Child|Drug Approval|Female|Humans|Male|Pandemics|Pneumonia, Viral|SARS-CoV-2|United States|United States Food and Drug Administration",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7799019_20210211_0.5,bamlanivimab,drug_name,"Background In November 2020, the US Food and Drug Administration (FDA) provided Emergency Use Authorizations (EUA) for two novel virus-neutralizing monoclonal antibody therapies, bamlanivimab, and REGN-COV2 (casirivimab plus imdevimab), for the treatment of mild to moderate COVID-19 in adolescents and adults in specified high-risk groups.",abstract,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7799019_20210211_0.5,bamlanivimab,drug_name," Conclusions Based on evidence available as of December 20, 2020, the panel suggests against routine administration of monoclonal antibody therapy (bamlanivimab, or casirivimab and imdevimab), for treatment of COVID-19 in children or adolescents, including those designated by the FDA as at high risk of progression to hospitalization or severe disease.",abstract,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID34088863_20210611_0.5,bamlanivimab,drug_name,COVID-19|SARS-Cov-2|bamlanivimab|dexamethasone|hydroxychloroquine/chloroquine|ivermectin|lopinavir/ritonavir|remdesivir|vaccines,author_keywords,Other Therapies,Vaccines,Vaccine
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8135369_20210611_0.5,,,Pharmacist outreach Program for COVID-19 monoclonal antibody distribution,title,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8135369_20210611_0.5,bamlanivimab,drug_name,COVID-19 drug treatment|Federally Qualified Health Center partnership|bamlanivimab|monoclonal antibody therapy|pharmacist outreach|pharmacy services,author_keywords,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8135369_20210611_0.5,,,"Humans|Pandemics|COVID-19|SARS-CoV-2|Pharmacists|Antibodies, Monoclonal|Peer Review, Research",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33830966_20210511_0.5,,,"Antibodies, Monoclonal, Humanized|Antiviral Agents|COVID-19|Drug Approval|Humans|SARS-CoV-2|Treatment Outcome|United States|United States Food and Drug Administration",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8020059_20210411_0.5,,,Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016,title,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8020059_20210411_0.5,bamlanivimab,drug_name,SARS-CoV-2|antibody escape|bamlanivimab|deep mutational scanning,author_keywords,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8020059_20210411_0.5,,,"Humans|Antibodies, Monoclonal|SARS-CoV-2|SARS-CoV-2 variants|COVID-19|Spike Glycoprotein, Coronavirus|Neutralization Tests|Epitopes|Antibodies, Viral|Viral Envelope Proteins|Antineoplastic Agents, Immunological|Mutation|Membrane Glycoproteins",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8020059_20210411_0.5,bamlanivimab,drug_name,report a complete map of all of the SARS-CoV-2 mutations that escape binding by the LY-CoV555 (bamlanivimab) antibody and its cocktail with LY-CoV016.,abstract,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33443490_20210311_0.5,bamlanivimab,drug_name,An EUA for bamlanivimab - a monoclonal antibody for COVID-19.,title,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33443490_20210311_0.5,,,"Aged|Aged, 80 and over|Antibodies, Monoclonal, Humanized|Antiviral Agents|Clinical Trials, Phase II as Topic|Drug Approval|Female|Hospitalization|Humans|Male|Middle Aged|United States|United States Food and Drug Administration",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7759095_20210111_0.5,,,COVID-19 vaccines: The status and perspectives in delivery points of view,title,Other Therapies,Vaccines,Vaccine
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7759095_20210111_0.5,,,Coronavirus disease 2019 (COVID-19)|Immune response|Neutralizing antibodies|Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)|Vaccine delivery,author_keywords,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7759095_20210111_0.5,,,Animals|Antiviral Agents|COVID-19|COVID-19 Vaccines|Drug Development|Humans|Immunization Programs|SARS-CoV-2,mesh_terms,Other Therapies,Vaccines,Vaccine
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7759095_20210111_0.5,bamlanivimab,drug_name,"Even with the recent approval of the anti-viral drug, remdesivir, and Emergency Use Authorization of monoclonal antibodies against S protein, bamlanivimab and casirimab/imdevimab, efficient and safe COVID-19 vaccines are still desperately demanded not only to prevent its spread but also to restore social and economic activities via generating mass immunization.",abstract,"Antibodies, Cellular Immunotherapy, Other Therapies","None, Monoclonal Antibodies, Therapeutic Tumor Infiltrating Lymphocytes, Vaccines","antibod, Monoclonal Antibod, TIL, Vaccine"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33993281_20210611_0.5,,,"Humans|Male|Adult|Middle Aged|Female|Cohort Studies|Retrospective Studies|Military Personnel|COVID-19|SARS-CoV-2|Hospitalization|Ambulatory Care|Double-Blind Method|Antibodies, Monoclonal|China",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33993281_20210611_0.5,bamlanivimab,drug_name,"In November 2020, the monoclonal antibody bamlanivimab was approved by the FDA for non-hospitalized patients with SARS-CoV-2 (COVID-19) who possessed risk factors for progression to severe COVID-19.",abstract,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33993281_20210611_0.5,bamlanivimab,drug_name," METHODS Patients who regularly received ambulatory care at a military treatment facility and who were diagnosed with mild-to-moderate COVID-19 and possessed risk factors for progression to severe COVID-19 were treated with a single, intravenous infusion (700 mg) of the virus-neutralizing monoclonal antibody bamlanivimab.",abstract,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33475701_20210411_0.5,,,"Adult|Aged|Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|Antiviral Agents|COVID-19|Dose-Response Relationship, Drug|Double-Blind Method|Drug Therapy, Combination|Female|Hospitalization|Humans|Infusions, Intravenous|Male|Middle Aged|SARS-CoV-2|Severity of Illness Index|Viral Load",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7717131_20210111_0.5,,,Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic,title,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7717131_20210111_0.5,,,SARS-CoV-2|spike or S protein|human antibody|cocktail therapy|single domain antibody or nanobody,author_keywords,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7717131_20210111_0.5,,,"Animals|Humans|spike protein, SARS-CoV-2|SARS-CoV-2|Pandemics|COVID-19|Spike Glycoprotein, Coronavirus|Neutralization Tests|Antibodies, Neutralizing|Viral Envelope Proteins|Antibodies, Viral|Antibodies, Monoclonal|Epitopes|Membrane Glycoproteins|Antigens, Viral|COVID-19 drug treatment|Coronavirus Infections|Immunization|Amino Acid Sequence",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMID33564771_20210611_0.5,bamlanivimab,drug_name,"Nevertheless, a therapeutic antibody, Bamlanivimab, still binds to the Y501-RBD as efficiently as its binds to N501-RBD.",abstract,"Antibodies, Cellular Immunotherapy","None, Therapeutic Tumor Infiltrating Lymphocytes","antibod, TIL"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8067572_20210511_0.5,,,Neutralizing Antibody Therapeutics for COVID-19,title,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8067572_20210511_0.5,bamlanivimab,drug_name,COVID-19|SARS-CoV-2|bamlanivimab|casirivimab|etesevimab|imdevimab|neutralizing antibody|resistance,author_keywords,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8067572_20210511_0.5,,,"Antibodies, Monoclonal, Humanized|Antibodies, Neutralizing|Antiviral Agents|COVID-19|Humans|SARS-CoV-2|Spike Glycoprotein, Coronavirus|United States|United States Food and Drug Administration",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC8067572_20210511_0.5,bamlanivimab,drug_name,"Two nAb cocktails (casirivimab/imdevimab and bamlanivimab/etesevimab) and one nAb monotherapy (bamlanivimab) have been granted Emergency Use Authorization by the US Food and Drug Administration for the treatment of ambulatory patients who have a high risk of progressing to severe disease, and the European Medicines Agency has similarly recommended both cocktails and bamlanivimab monotherapy for use in COVID-19 patients who do not require supplemental oxygen and who are at high risk of progressing to severe COVID-19.",abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7755170_20210211_0.5,,,Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline,title,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7755170_20210211_0.5,bamlanivimab,drug_name,BGB-DXP593|COVID-19|CT-P59|GSK4182136|LY-CoV016|LY-CoV555|REGN-COV2|SARS-CoV-2|VIR-7831|bamlanivimab|monoclonal antibody,author_keywords,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7755170_20210211_0.5,,,"Antibodies, Monoclonal|Antibodies, Neutralizing|Antibodies, Viral|COVID-19|Clinical Trials, Phase II as Topic|Clinical Trials, Phase III as Topic|Humans|Immunization, Passive|SARS-CoV-2",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7717131_20210111_0.5,,,Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic,title,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7717131_20210111_0.5,,,SARS-CoV-2|spike or S protein|human antibody|cocktail therapy|single domain antibody or nanobody,author_keywords,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7717131_20210111_0.5,,,"Animals|Humans|spike protein, SARS-CoV-2|SARS-CoV-2|Pandemics|COVID-19|Spike Glycoprotein, Coronavirus|Neutralization Tests|Antibodies, Neutralizing|Viral Envelope Proteins|Antibodies, Viral|Antibodies, Monoclonal|Epitopes|Membrane Glycoproteins|Antigens, Viral|COVID-19 drug treatment|Coronavirus Infections|Immunization|Amino Acid Sequence",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7717131_20210111_0.5,ly3819253,drug_name_variant,"As of October 11, 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike protein have entered clinical trials with three (REGN-COV2, LY3819253/LY-CoV555, and VIR-7831/VIR-7832) in phase 3.",abstract,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7799234_20210211_0.5,,,"Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective",title,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7799234_20210211_0.5,,,SARS-CoV-2|COVID-19|spike protein|neutralizing antibodies|hACE2,author_keywords,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7799234_20210211_0.5,,,"United States|Humans|Antibodies, Neutralizing|SARS-CoV-2|COVID-19|Neutralization Tests|Spike Glycoprotein, Coronavirus|Antibodies, Viral|Viral Envelope Proteins|Cross Reactions|Membrane Glycoproteins|Cell Line|COVID-19 drug treatment|Coronavirus Infections",mesh_terms,Antibodies,None,antibod
bamlanivimab,C5421805,ly-3819253,ly 3819253|ly3819253,,inn,PubMed,PMC7799234_20210211_0.5,ly3819253,drug_name_variant,"NAbs-based therapeutics against SARS-CoV-2 are being expedited to preclinical and clinical studies with two antibody drugs, LY3819253 (LY-CoV555) and REGN-COV2 (REGN10933 and REGN10987), approved by the US Food and Drug Administration for emergency use authorization for treating COVID-19.",abstract,Antibodies,None,antibod
Ammonia measurement,C0201879,,,ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13,trade_name,PubMed,PMID15839409_20201005_0.5,ammonia measurement,drug_name,The ammonia measurement trends inside of the facilities were affected by the temperature-dependent ventilation systems.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Ammonia measurement,C0201879,,,ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13,trade_name,PubMed,PMID31855649_20201005_0.5,,,Ammonia|Fertiliser Application|Livestock production|Nitrogen losses|Sensors,author_keywords,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Ammonia measurement,C0201879,,,ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13,trade_name,PubMed,PMID27913270_20201005_0.5,ammonia measurement,drug_name,The study also demonstrates that samples for ammonia measurement can be transported over great distances and still correlate well.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Ammonia measurement,C0201879,,,ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13,trade_name,PubMed,PMID10791209_20201005_0.5,,,"Adult|Aged|Ammonia|Antibodies, Bacterial|Breath Tests|Disease Progression|Female|Helicobacter Infections|Helicobacter pylori|Hepatic Encephalopathy|Hepatitis C, Chronic|Humans|Liver Cirrhosis|Male|Middle Aged|Predictive Value of Tests|Reference Values",mesh_terms,Antibodies,None,antibod
Ammonia measurement,C0201879,,,ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13,trade_name,PubMed,PMID26658550_20201005_0.5,,,Clinical utility of breath ammonia for evaluation of ammonia physiology in healthy and cirrhotic adults.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Ammonia measurement,C0201879,,,ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13,trade_name,PubMed,PMID24299143_20201005_0.5,ammonia measurement,drug_name,Point of care monitoring of hemodialysis patients with a breath ammonia measurement device based on printed polyaniline nanoparticle sensors.,title,Nanoparticles,None,Nanoparticle
Ammonia measurement,C0201879,,,ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13,trade_name,PubMed,PMID24299143_20201005_0.5,,,Ammonia|Aniline Compounds|Breath Tests|Calibration|Humans|Nanoparticles|Point-of-Care Systems|Printing|Renal Dialysis,mesh_terms,Nanoparticles,None,Nanoparticle
Ammonia measurement,C0201879,,,ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13,trade_name,PubMed,PMID16624991_20201005_0.5,ammonia measurement,drug_name,"A series of in vivo studies were done in mice, including 1) serum ammonia measurements before and after ammonia infusion, 2) renal ammonia clearance, 3) colonic ammonia absorption, and 4) liver ammonia accumulation and renal ammonia excretion after acute and chronic ammonia loading.",abstract,Gene Therapy,In Vivo,In Vivo
Ammonia measurement,C0201879,,,ammonian|ammoia|ammonia inhalants|ammonian 13|ammonia n 13,trade_name,PubMed,PMID12452390_20201005_0.5,ammonia measurement,drug_name,No section Our aim was to define the utility of breath ammonia measurement in assessing Helicobacter pylori infection.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
benzylpenicilloyl polylysine,C0053327,,,,trade_name,PubMed,PMC5691303_20201005_0.5,,,Utility of basophil activation testing to assess perioperative anaphylactic reactions in real‐world practice,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
benzylpenicilloyl polylysine,C0053327,,,,trade_name,PubMed,PMID7436456_20201005_0.5,,,Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin.,title,Antibodies,None,antibod
benzylpenicilloyl polylysine,C0053327,,,,trade_name,PubMed,PMID28743423_20201005_0.5,,,Utility of minor determinants for skin testing in inpatient penicillin allergy evaluation.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
intersol,Z0000098200,,,,trade_name,PubMed,PMID20497516_20201005_0.5,,,In vitro and in vivo evaluation of apheresis platelets stored for 5 days in 65% platelet additive solution/35% plasma.,title,Gene Therapy,In Vivo,In Vivo
intersol,Z0000098200,,,,trade_name,PubMed,PMID29473178_20201005_0.5,,,"PAS-C platelets contain less plasma protein, lower anti-A and anti-B titers, and decreased HLA antibody specificities compared to plasma platelets.",title,Antibodies,None,antibod
intersol,Z0000098200,,,,trade_name,PubMed,PMID29473178_20201005_0.5,,,ABO Blood-Group System|Antibody Affinity|Antibody Specificity|Blood Group Incompatibility|Blood Platelets|Blood Preservation|Blood Proteins|Epitopes|Female|HLA Antigens|Hemagglutinins|Histocompatibility Testing|Humans|Isoantibodies|Male|Organ Preservation Solutions|Plasma|Plateletpheresis|Transfusion-Related Acute Lung Injury,mesh_terms,Antibodies,None,antibod
intersol,Z0000098200,,,,trade_name,PubMed,PMID18034788_20201005_0.5,,,In vitro and in vivo effects of potassium and magnesium on storage up to 7 days of apheresis platelet concentrates in platelet additive solution.,title,Gene Therapy,In Vivo,In Vivo
intersol,Z0000098200,,,,trade_name,PubMed,PMID30203458_20201005_0.5,,,In vivo viability of extended 4°C-stored autologous apheresis platelets.,title,Gene Therapy,In Vivo,In Vivo
intersol,Z0000098200,,,,trade_name,PubMed,PMID30203458_20201005_0.5,intersol,drug_name," No section While the in vitro variables suggest largely comparable results between plasma and PASs, in vivo recoveries were higher with plasma compared with both Intersol and Isoplate (p = 0.057 and p = 0.002, respectively).",abstract,Gene Therapy,In Vivo,In Vivo
intersol,Z0000098200,,,,trade_name,PubMed,PMID27887865_20201005_0.5,,,Overcoming the bottleneck of platelet lysate supply in large-scale clinical expansion of adipose-derived stem cells: A comparison of fresh versus three types of platelet lysates from outdated buffy coat-derived platelet concentrates.,title,Other Therapies,Stem cell therapy,Stem.Cell
intersol,Z0000098200,,,,trade_name,PubMed,PMID27887865_20201005_0.5,,,adipose-derived stem cells|cell proliferation|cell therapy|gene expression|growth factors|platelet lysate,author_keywords,Other Therapies,Stem cell therapy,Stem.Cell
intersol,Z0000098200,,,,trade_name,PubMed,PMID27887865_20201005_0.5,,,Adipose Tissue|Adult|Adult Stem Cells|Blood Buffy Coat|Blood Platelets|Blood Preservation|Blood Specimen Collection|Cell Culture Techniques|Cell Extracts|Cell Proliferation|Cell Separation|Culture Media|Female|Freezing|Humans|Plasma|Platelet Transfusion|Platelet-Rich Plasma|Refrigeration|Time Factors,mesh_terms,Other Therapies,Stem cell therapy,Stem.Cell
intersol,Z0000098200,,,,trade_name,PubMed,PMID27887865_20201005_0.5,intersol,drug_name,"Three types of PLs were prepared from outdated PCs with platelets suspended in either (1) InterSol (not manipulated), (2) InterSol + supplemented with plasma or (3) plasma alone (InterSol removed).",abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
urea,C0041942,utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k,,carbamide,inn,PubMed,PMC4327555_20201005_0.5,,,Ophthalmic Manifestations of Vitamin A and D Deficiency in Two Autistic Teenagers: Case Reports and a Review of the Literature,title,Other Therapies,Vitamin and Mineral Supplement,Vitamin
urea,C0041942,utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k,,carbamide,inn,PubMed,PMC4327555_20201005_0.5,rynoderm,drug_synonym,Vitamin A|Autism|Phrynoderma|Bitot's spots|Xerophthalmia,author_keywords,Other Therapies,Vitamin and Mineral Supplement,Vitamin
urea,C0041942,utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k,,carbamide,inn,PubMed,PMC4327555_20201005_0.5,,,Child|Adolescent|Male|Humans|Vitamin A|Autistic Disorder|Vitamin A Deficiency|Xerophthalmia|Feeding Behavior|Eye,mesh_terms,Other Therapies,Vitamin and Mineral Supplement,Vitamin
urea,C0041942,utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k,,carbamide,inn,PubMed,PMID24596740_20201005_0.5,rynoderm,drug_synonym,"Therapeutic Response of Vitamin A, Vitamin B Complex, Essential Fatty Acids (EFA) and Vitamin E in the Treatment of Phrynoderma: A Randomized Controlled Study.",title,Other Therapies,Vitamin and Mineral Supplement,Vitamin
urea,C0041942,utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k,,carbamide,inn,PubMed,PMID24596740_20201005_0.5,rynoderm,drug_synonym,Essential fatty acids|Follicular hyperkeratosis|Nutritional deficiency disorders|Phrynoderma|Vitamin A|Vitamin B complex|Vitamin E ligament,author_keywords,Other Therapies,Vitamin and Mineral Supplement,Vitamin
urea,C0041942,utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k,,carbamide,inn,PubMed,PMID24596740_20201005_0.5,,,"Adult|Male|Humans|Middle Aged|Female|Aged|Vitamin B Complex|Vitamin A|Vitamin E|Folic Acid|Keratosis|Fatty Acids, Essential|Hair Diseases|Injections, Intramuscular",mesh_terms,Other Therapies,Vitamin and Mineral Supplement,Vitamin
urea,C0041942,utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k,,carbamide,inn,PubMed,PMID24596740_20201005_0.5,rynoderm,drug_synonym, CONCLUSIONS Intramuscular injections of Vitamin A or Vitamin B are effective in the treatment of phrynoderma.,abstract,Other Therapies,Vitamin and Mineral Supplement,Vitamin
urea,C0041942,utopic|rynoderm|cem-urea|keralac|mousse|xurea|ure-k,,carbamide,inn,PubMed,PMID33428701_20210211_0.5,xurea,drug_synonym,Here we present the first static structural and in situ studies of the formation of iron oxide (hematite) nanoparticles in a DES of choline chloride : urea where xurea = 0.67 (aka.,abstract,Nanoparticles,None,Nanoparticle
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID27183825_20201005_0.5,,,Cation Exchange Resins|Drug Monitoring|Drug Utilization|Humans|Hyperkalemia|Massachusetts|Medical Order Entry Systems|Patient Safety|Polystyrenes|Quality Improvement|Tertiary Care Centers,mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID24815941_20201005_0.5,kayexalate,drug_synonym,Colchicine|Kayexalate|Mycophenolate mofetil|Olmesartan|Paclitaxel|Tetracycline,author_keywords,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID34024647_20210611_0.5,,,"Humans|Male|polystyrene sulfonic acid|Neoplasm Recurrence, Local|Polystyrenes|Melanoma|Ipilimumab|Immunotherapy|Nivolumab|Skin Neoplasms|pembrolizumab|Antibodies, Monoclonal, Humanized|Antineoplastic Agents, Immunological|Sarcoidosis|Granuloma|Biopsy|Neoplasms, Second Primary|Tomography, X-Ray Computed|Lung Diseases|Dyspnea",mesh_terms,Antibodies,None,antibod
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID10624095_20201005_0.5,,,[Induction of protective immunity for Bordetella pertussis by nasal inoculation of pertussis vaccine in mice].,title,Other Therapies,Vaccines,Vaccine
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID10624095_20201005_0.5,,,"Animals|Bordetella pertussis|Female|Immunity, Cellular|Immunoglobulin G|Mice|Mice, Inbred BALB C|Nasal Mucosa|Pertussis Vaccine|Vaccination",mesh_terms,Other Therapies,Vaccines,Vaccine
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID10624095_20201005_0.5,kayexalate,drug_synonym,"In the present study, we inoculated purified Pertussis Toxin (PT) and Filamentous Haemagglutinin (FHA) with or without adjuvant (kayexalate), or Diphtheria acellular Pertussis Tetanus (DaPT) combined vaccine to mice intranasally three times every four weeks to investigate the references of the immunoresponses between nasal and intramuscular vaccination.",abstract,Other Therapies,Vaccines,Vaccine
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID16740839_20201005_0.5,,,"Drug Utilization|Female|Humans|Infant, Newborn|Intensive Care Units, Neonatal|Male|Retrospective Studies",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMC5055282_20201005_0.5,kayexalate,drug_synonym,We present a case of a critically ill patient who underwent total colectomy for colonic necrosis secondary to oral kayexalate administration that was not recognized until late in the pathologic process.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID16878438_20201005_0.5,,,Hyperkalemia after acute metabolic decompensation in two children with vitamin B12-unresponsive methylmalonic acidemia and normal renal function.,title,Other Therapies,Vitamin and Mineral Supplement,Vitamin
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID16878438_20201005_0.5,,,"Child, Preschool|Female|Fumarates|Humans|Hyperkalemia|Hypoaldosteronism|Infant|Kidney|Male|Maleates|Metabolism, Inborn Errors|Vitamin B 12",mesh_terms,Other Therapies,Vitamin and Mineral Supplement,Vitamin
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID27183825_20201005_0.5,,,Cation Exchange Resins|Drug Monitoring|Drug Utilization|Humans|Hyperkalemia|Massachusetts|Medical Order Entry Systems|Patient Safety|Polystyrenes|Quality Improvement|Tertiary Care Centers,mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID26159448_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,"Acute treatments that cause the intracellular translocation of potassium can be effective in the short-term but they simply buy time until definitive removal by dialysis or binding agents (e.g., sodium polystyrene sulfonate) can occur.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMC5367739_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,"Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review",title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMC6946143_20201005_0.5,,,Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMC6946143_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,"We described the association between use of K binders (Patiromer and sodium polystyrene sulfonate [SPS]) and renin-angiotensin-aldosterone system inhibitor (RAASi), on healthcare resource utilization (HRU).",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID27725623_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,"Until recently, options for treating hyperkalemia were limited to the use of thiazide and loop diuretics and sodium polystyrene sulfonate.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMC8010635_20210411_0.5,,,"Humans|Polyelectrolytes|Mesenchymal Stem Cells|Bone Marrow|polyallylamine|Polyamines|polystyrene sulfonic acid|Polystyrenes|Cell Proliferation|Polymers|Cell Adhesion|Surface Properties|Cells, Cultured|Biological Phenomena|Cell Survival|Polyethyleneimine",mesh_terms,Other Therapies,Stem cell therapy,Stem.Cell
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID24656316_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,Cost-utility analysis of sodium polystyrene sulfonate vs. potential alternatives for chronic hyperkalemia.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID24656316_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom," METHODS We performed a cost-utility analysis of outpatients ≥ 18 years of age receiving chronic RAAS-I, with a history of hyperkalemia or chronic kidney disease, prescribed either sodium polystyrene sulfonate or a theoretical ""drug X"" binding resin for chronic hyperkalemia.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID17269822_20201005_0.5,,,Multilayered films fabricated from an oligoarginine-conjugated protein promote efficient surface-mediated protein transduction.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID17269822_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,We demonstrate that it is possible to fabricate multilayered assemblies 80 nm thick using sodium polystyrene sulfonate (SPS) and bovine pancreatic ribonuclease (RNase A) conjugated to the cationic protein transduction domain nonaarginine (R(9)) using an entirely aqueous layer-by-layer process.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID32394928_20210411_0.5,sodium polystyrene sulfonate,drug_umls_atom,"Patient was treated with 10% calcium gluconate, insulin and dextrose, salbutamol nebulization, and sodium polystyrene sulfonate till hemodialysis was initiated.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID19306191_20201005_0.5,,,"Antibodies, Blocking|Antidotes|Antiemetics|Arrhythmias, Cardiac|Blood Pressure|Charcoal|Digoxin|Electrocardiography|Emetics|Fluid Therapy|Humans|Nerium|Ondansetron|Plant Poisoning|Potassium|Resuscitation|Therapeutic Irrigation|Water-Electrolyte Imbalance",mesh_terms,Antibodies,None,antibod
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID19306191_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,Oral or rectal administration of sodium polystyrene sulfonate resin may result in hypokalemia when used together with digoxin-specific antibody fragments.,abstract,Antibodies,"None, Antibody Fragments","antibod, Antibod[a-z]* Fragments"
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMC7465118_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,"Until recently, the only therapeutic option for increasing fecal K excretion was represented by the cation-exchanging resin sodium polystyrene sulfonate.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID28985189_20201005_0.5,,,Charge carrier transport in defective reduced graphene oxide as quantum dots and nanoplatelets in multilayer films.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMC6398969_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,"Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review [Erratum]",title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID24762462_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,"Traditional management steps have included reducing dietary potassium and discontinuing potassium supplements; withdrawal of exacerbating drugs; acute treatment with intravenous calcium gluconate, insulin, and glucose; nebulized albuterol; correction of acidosis with sodium bicarbonate for short-term shifts out of the plasma pool; and, finally, gastrointestinal ion exchange with oral sodium polystyrene sulfonate in sorbitol, which is mainly used in the hospital and is poorly tolerated due to gastrointestinal adverse effects.",abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID13129823_20201005_0.5,,,A physico-chemical approach of polyanion-polycation interactions aimed at better understanding the in vivo behaviour of polyelectrolyte-based drug delivery and gene transfection.,title,Gene Therapy,In Vivo,In Vivo
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID8909271_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom, CONCLUSIONS Sodium polystyrene sulfonate may be a useful therapy in acute iron poisoning once safety and efficacy are determined with the use of in vivo models.,abstract,Gene Therapy,In Vivo,In Vivo
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMC5243974_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,Objective(s): Comparative in vivo studies were carried out to determine the adsorption characteristics of amitriptyline (AMT) on activated charcoal (AC) and sodium polystyrene sulfonate (SPS).,abstract,Gene Therapy,In Vivo,In Vivo
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID28934609_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,Quantitative measurement of sodium polystyrene sulfonate adsorption onto CTAB capped gold nanoparticles reveals hard and soft coronas.,title,Nanoparticles,None,Nanoparticle
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID28934609_20201005_0.5,,,Gold nanoparticles|Layer by layer|Polyelectrolytes,author_keywords,Nanoparticles,None,Nanoparticle
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID28934609_20201005_0.5,,,Gold|Adsorption|polystyrene sulfonic acid|Cetrimonium|Metal Nanoparticles|Polystyrenes|Polymers|Surface Properties|Hardness,mesh_terms,Nanoparticles,None,Nanoparticle
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID28934609_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,"In this work CTAB capped gold nanoparticles, synthesized in a flow reactor, are coated with sodium polystyrene sulfonate and purified through a series of equilibrium dialysis steps.",abstract,Nanoparticles,None,Nanoparticle
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID32678607_20201005_0.5,,,Local Confinement Controls Diffusive Nanoparticle Dynamics in Semidilute Polyelectrolyte Solutions.,title,Nanoparticles,None,Nanoparticle
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID32678607_20201005_0.5,,,"Polyelectrolytes|Diffusion|Nanoparticles|Polymers|polystyrene sulfonic acid|Polystyrenes|Solutions|Viscosity|Osmolar Concentration|Molecular Conformation|Microscopy, Fluorescence",mesh_terms,Nanoparticles,None,Nanoparticle
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID28008346_20201005_0.5,,,Polyelectrolyte multilayer electrostatic gating of graphene field-effect transistors.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID28008346_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,No section We apply polyelectrolyte multilayer films by consecutive alternate adsorption of positively charged polyallylamine hydrochloride and negatively charged sodium polystyrene sulfonate to the surface of graphene field effect transistors.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID16740839_20201005_0.5,,,"Drug Utilization|Female|Humans|Infant, Newborn|Intensive Care Units, Neonatal|Male|Retrospective Studies",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMC6523181_20201005_0.5,,,Bioelectrochemical Properties of Enzyme-Containing Multilayer Polyelectrolyte Microcapsules Modified with Multiwalled Carbon Nanotubes,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMC6523181_20201005_0.5,,,multilayer membrane structures|polyelectrolyte microcapsules (PMCs)|glucose oxidase|modification with multiwalled carbon nanotubes|PMC impedance decrease,author_keywords,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID20073518_20201005_0.5,,,Small angle neutron scattering study of polyelectrolyte brushes grafted to well-defined gold nanoparticle interfaces.,title,Nanoparticles,None,Nanoparticle
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID20073518_20201005_0.5,,,"Electrolytes|Gold|Metal Nanoparticles|Neutron Diffraction|Polystyrenes|Scattering, Small Angle|Surface Properties",mesh_terms,Nanoparticles,None,Nanoparticle
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID20073518_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,The polyelectrolyte layer is prepared at a constant coverage by grafting thiol-functionalized polystyrene (M(w) = 53k) to gold nanoparticles of well-defined interfacial curvature (R(c) = 26.5 nm) followed by a soft-sulfonation of 38% of the segments to sodium polystyrene sulfonate (NaPSS).,abstract,Nanoparticles,None,Nanoparticle
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID1951347_20201005_0.5,,,Cation Exchange Resins|Drug Utilization|Humans|Hyperkalemia|Polystyrenes|Sorbitol|United States,mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID27427666_20201214_0.5,,,Preparation of Chitosan/Polystyrene Sulfonate Multilayered Composite Metal Nanoparticles and Its Application.,title,"Cellular Immunotherapy, Nanoparticles","Therapeutic Tumor Infiltrating Lymphocytes, None","TIL, Nanoparticle"
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID27427666_20201214_0.5,,,Catalysis|Chitosan|Electrochemistry|Metal Nanoparticles|Nanocomposites|Polystyrenes|Surface Properties,mesh_terms,Nanoparticles,None,Nanoparticle
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID27427666_20201214_0.5,sodium polystyrene sulfonate,drug_umls_atom,"The formed composite was alternately deposited on the base with sodium polystyrene sulfonate (PSS) through a layer-by-layer self-assembling technique, followed by an in situ reduction by sodium borohydride to produce a polyelectrolyte nanocomposite thin film containing metal nanoparticles.",abstract,Nanoparticles,None,Nanoparticle
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID9562695_20201005_0.5,,,Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin.,title,Other Therapies,Vaccines,Vaccine
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID9562695_20201005_0.5,,,"Administration, Intranasal|Animals|Antibodies, Viral|Cytokines|Female|Hemagglutinin Glycoproteins, Influenza Virus|Immunoglobulin A|Influenza Vaccines|Ion Exchange Resins|Mice|Nasal Cavity|Particle Size|Polystyrenes",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID9562695_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,"Female Balb/c mice were intranasally immunized with inactivated influenza HA vaccine with one of four kinds of resin microparticles: sodium polystyrene sulfonate, calcium polystyrene sulfonate, polystyrene benzyltrimetylammonium chloride, or polystyrene divinylbenzene.",abstract,Other Therapies,Vaccines,Vaccine
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID9562695_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,"The results demonstrated that intranasal administration of influenza HA vaccine in combination with the 20-45 microns sized particles of sodium polystyrene sulfonate resin induced the highest levels of mucosal IgA, and enhanced systemic haemagglutinin-inhibiting antibodies.",abstract,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID9562695_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,"While the Th2-type cytokine IL-4 was detected in the sera after intranasal immunization with HA vaccine and sodium polystyrene sulfonate, neither IFN-gamma nor IL-2 could be detected.",abstract,Other Therapies,Vaccines,Vaccine
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID9562695_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,"Furthermore, mice intranasally immunized with HA vaccine together with sodium polystyrene sulfonate resin showed higher protection against viral challenge than those that received HA vaccine alone.",abstract,Other Therapies,Vaccines,Vaccine
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID9562695_20201005_0.5,sodium polystyrene sulfonate,drug_umls_atom,Intranasal administration of influenza HA vaccine with sodium polystyrene sulfonate resin might be both a safe and an effective means of immunization.,abstract,Other Therapies,Vaccines,Vaccine
Polystyrenes,C0032604,kionex|resonium-a|kayexalate|kalexate,,polystyrene sulfonate|polystyrene|sodium polystyrene sulfonate,inn,PubMed,PMID15846466_20201005_0.5,,,"Animals|Anti-Infective Agents|Cell Line|Cervix Mucus|Chemistry, Pharmaceutical|Contraceptive Agents|Drug Delivery Systems|Excipients|HIV-1|Herpesvirus 2, Human|Humans|Hyaluronoglucosaminidase|Hydrogels|In Vitro Techniques|Plasticizers|Polystyrenes|Polyvinyl Alcohol|Sorbitol|Sperm Motility|Vaginal Creams, Foams, and Jellies",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMC7819167_20210211_0.5,onasemnogene abeparvovec-xioi,drug_name,"Child|Humans|Male|Female|United States|Infant|Child, Preschool|Adolescent|Young Adult|Adult|Middle Aged|Aged|onasemnogene abeparvovec-xioi|Muscular Atrophy, Spinal|nusinersen|Oligonucleotides|Spine|Surveys and Questionnaires",mesh_terms,Gene Therapy,Oligonucleotides,Oligonucleotide
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMC8107939_20210611_0.5,,,"Humans|Infant|Zolgensma|Disabled Persons|Motor Disorders|Muscular Atrophy, Spinal|nusinersen|Oligonucleotides|Oligonucleotides, Antisense|Motor Neurons|Genetic Therapy|Drug Approval|Central Nervous System Agents|Genes, Regulator",mesh_terms,Gene Therapy,Oligonucleotides,Oligonucleotide
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMC8107939_20210611_0.5,onasemnogene abeparvovec-xioi,drug_name,"Recently, 3 disease-modifying therapies have been approved for SMA patients: nusinersen, an intrathecal antisense oligonucleotide enhancing SMN protein production by the SMN2 gene, risdiplam, also influencing the SMN2 gene to stimulate SMN production but administered orally, and onasemnogene abeparvovec-xioi, an SMN1 gene replacement therapy.",abstract,Gene Therapy,"Antisense Oligonucleotides, Oligonucleotides","Antisense Oligonucleotide, Oligonucleotide"
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID32843442_20210411_0.5,,,Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes.,title,Gene Therapy,None,Gene Therap
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID32843442_20210411_0.5,,,"Adenoviruses, Human|Age Factors|Alanine Transaminase|Aspartate Aminotransferases|Biological Products|Genetic Therapy|Genetic Vectors|Glucocorticoids|Humans|Infant|Ohio|Outcome Assessment, Health Care|Prednisolone|Recombinant Fusion Proteins|Spinal Muscular Atrophies of Childhood|Survival of Motor Neuron 1 Protein|gamma-Glutamyltransferase",mesh_terms,Peptide or Protein Therapeutics,Fusion proteins,Fusion Protein
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID32204605_20210411_0.5,onasemnogene abeparvovec-xioi,drug_name,Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy.,title,Gene Therapy,None,Gene Therap
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID32204605_20210411_0.5,,,"Biological Products|Child, Preschool|Drug Approval|Female|Genetic Therapy|Humans|Mutation|Recombinant Fusion Proteins|Spinal Muscular Atrophies of Childhood|Survival of Motor Neuron 1 Protein|United States|United States Food and Drug Administration",mesh_terms,Peptide or Protein Therapeutics,Fusion proteins,Fusion Protein
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID31037425_20201005_0.5,,,Antisense oligonucleotide|Gene therapy|Nusinersen|Spinal muscular atrophy,author_keywords,Gene Therapy,"None, Antisense Oligonucleotides, Oligonucleotides","Gene Therap, Antisense Oligonucleotide, Oligonucleotide"
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID31037425_20201005_0.5,,,"Humans|Muscular Atrophy, Spinal|nusinersen|Oligonucleotides|Oligonucleotides, Antisense|Neurology",mesh_terms,Gene Therapy,Oligonucleotides,Oligonucleotide
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID32886442_20210411_0.5,,,Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy.,title,Gene Therapy,None,Gene Therap
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID32886442_20210411_0.5,,,antisense oligonucleotide|genetic therapy|neuromuscular diseases|review,author_keywords,Gene Therapy,"Antisense Oligonucleotides, Oligonucleotides","Antisense Oligonucleotide, Oligonucleotide"
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID32886442_20210411_0.5,,,"United States|Humans|Female|Muscular Dystrophy, Duchenne|Zolgensma|Muscular Atrophy, Spinal|Oligonucleotides, Antisense|Genetic Therapy|Morpholinos|Exons|RNA Splicing|Motor Neurons",mesh_terms,Gene Therapy,Oligonucleotides,Oligonucleotide
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMC6822795_20201005_0.5,,,"Humans|Infant|Muscular Atrophy, Spinal|Oligonucleotides",mesh_terms,Gene Therapy,Oligonucleotides,Oligonucleotide
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID33003005_20210511_0.5,,,"Infant|Infant, Newborn|United States|Humans|Muscular Atrophy, Spinal|Spinal Muscular Atrophies of Childhood|Genetic Therapy|United States Food and Drug Administration|Oligonucleotides",mesh_terms,Gene Therapy,Oligonucleotides,Oligonucleotide
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID32710634_20210411_0.5,,,SMA|combine|gene therapy|nusinersen|onasemnogene,author_keywords,Gene Therapy,None,Gene Therap
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID32710634_20210411_0.5,,,"Biological Products|Child, Preschool|Drug Therapy, Combination|Female|Humans|Infant|Male|Oligonucleotides|Recombinant Fusion Proteins|Retrospective Studies|Spinal Muscular Atrophies of Childhood|Treatment Outcome",mesh_terms,"Gene Therapy, Peptide or Protein Therapeutics","Oligonucleotides, Fusion proteins","Oligonucleotide, Fusion Protein"
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID32703464_20201214_0.5,,,"Activities of Daily Living|Adolescent|Adult|Female|Gene Transfer Techniques|Humans|Infant|Infant, Newborn|Male|Muscular Atrophy, Spinal|Neonatal Screening|Oligonucleotides",mesh_terms,Gene Therapy,Oligonucleotides,Oligonucleotide
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID31270752_20201005_0.5,onasemnogene abeparvovec-xioi,drug_name,No section Onasemnogene abeparvovec (onasemnogene abeparvovec-xioi; formerly AVXS-101; ZOLGENSMA®) is an adeno-associated viral vector-based gene therapy designed to deliver a functional copy of the human survival motor neuron (SMN) gene to the motor neuron cells of patients with spinal muscular atrophy (SMA).,abstract,Gene Therapy,None,Gene Therap
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID33130193_20210411_0.5,,,"Humans|Male|Middle Aged|Adult|viltolarsen|Muscular Dystrophy, Duchenne|golodirsen|Zolgensma|Muscular Atrophy, Spinal|Oligonucleotides|nusinersen|Spinal Muscular Atrophies of Childhood|eteplirsen|Morpholinos|Oligonucleotides, Antisense|Dystrophin|Genetic Therapy|Phenotype|Gene Deletion",mesh_terms,Gene Therapy,Oligonucleotides,Oligonucleotide
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID31286145_20201005_0.5,,,[Gene therapies for neuromuscular diseases].,title,Gene Therapy,None,Gene Therap
onasemnogene abeparvovec-xioi,C5140521,,,,trade_name,PubMed,PMID31286145_20201005_0.5,,,Duchenne muscular dystrophy|Gene therapy|Neuromuscular diseases|Spinal muscular atrophy,author_keywords,Gene Therapy,None,Gene Therap
"ROTAVIRUS VACCINE, LIVE",C0795661,,,,inn,PubMed,PMID19155881_20201005_0.5,"rotavirus vaccine, live",drug_name,"Drug approvals: '08 in review. Rotavirus vaccine, live, oral (Rotarix).",title,Other Therapies,Vaccines,Vaccine
"ROTAVIRUS VACCINE, LIVE",C0795661,,,,inn,PubMed,PMID19155881_20201005_0.5,,,"Humans|Rotavirus Vaccines|Vaccines, Attenuated",mesh_terms,Other Therapies,Vaccines,Vaccine
"ROTAVIRUS VACCINE, LIVE",C0795661,,,,inn,PubMed,PMID22294581_20201005_0.5,"rotavirus vaccine, live",drug_name,"This testing did not detect any sequences of contaminating viruses in RotaTeq® (rotavirus vaccine, live, oral, pentavalent, RV5, Merck & Co., Inc., Whitehouse Station, NJ).",abstract,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC4883197_20210511_0.5,,,"Can a Compact Pre-Filled Auto-Disable Injection System (cPAD) Save Costs for DTP-HepB-Hib Vaccine as Compared with Single-Dose (SDV) and Multi-Dose Vials (MDV)? Evidence from Cambodia, Ghana, and Peru",title,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC4883197_20210511_0.5,diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,drug_name,"Child|Humans|Haemophilus influenzae type b|Cambodia|Ghana|Peru|diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine|Diphtheria-Tetanus-Pertussis Vaccine|Haemophilus Vaccines|Vaccines, Combined|Vaccination|Immunization Programs|Hepatitis B Vaccines|Vaccines, Conjugate|Costs and Cost Analysis",mesh_terms,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC4751340_20201005_0.5,diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,drug_name,"Child|Male|Infant|Humans|Female|Retrospective Studies|diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine|Diphtheria-Tetanus-Pertussis Vaccine|Haemophilus Vaccines|diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine|Poliovirus Vaccine, Inactivated|Poliovirus Vaccine, Oral|Poliomyelitis|Measles-Mumps-Rubella Vaccine|Vaccines, Combined|Diphtheria-Tetanus-acellular Pertussis Vaccines|Hepatitis B Vaccines|Vaccines, Conjugate|Vaccines, Attenuated|Hospitalization|Vaccines, Inactivated|Vaccination|Denmark",mesh_terms,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID20212950_20201005_0.5,diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,drug_name,"Child, Preschool|Male|Humans|Female|Child|Prospective Studies|diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine|Diphtheria-Tetanus-Pertussis Vaccine|Haemophilus Vaccines|Poliovirus Vaccine, Inactivated|Measles-Mumps-Rubella Vaccine|Immunization Schedule|Vaccination|Immunization, Secondary|Immunization Programs",mesh_terms,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC4312604_20201005_0.5,,,The impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study,title,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC4312604_20201005_0.5,,,Non-specific vaccine effects|Measles|DTP|Nasopharyngeal bacterial carriage,author_keywords,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC4312604_20201005_0.5,diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,drug_name,"Child|Infant|Male|Humans|Female|Longitudinal Studies|Nasopharynx|Haemophilus influenzae type b polysaccharide vaccine|Haemophilus Vaccines|Pneumococcal Infections|Pneumococcal Vaccines|Streptococcus pneumoniae|diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine|Vaccines, Conjugate|Haemophilus influenzae|Haemophilus Infections|Carrier State|Moraxella (Branhamella) catarrhalis|Prevalence|Staphylococcus aureus|Vaccination|Diphtheria-Tetanus-Pertussis Vaccine|Bacterial Capsules|Gambia",mesh_terms,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC6406170_20201005_0.5,,,Clinical study of safety and immunogenicity of pentavalent DTP-HB-Hib vaccine administered by disposable-syringe jet injector in India,title,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC6406170_20201005_0.5,,,DTP-HB-Hib vaccine|Jet injector|DSJI|Vaccine adjuvant|Immunogenicity|Injection site reactions,author_keywords,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC6406170_20201005_0.5,diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,drug_name,United States|Child|Infant|Male|Humans|Adolescent|Female|Haemophilus influenzae type b|Syringes|diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine|Diphtheria-Tetanus-Pertussis Vaccine|Haemophilus Vaccines|Tetanus|Diphtheria|Whooping Cough|Vaccination|Hepatitis B|India,mesh_terms,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC3373025_20201005_0.5,,,Haemophilus influenzae type b|haemophilus vaccines|antibody avidity|diphtheria-tetanus-acellular pertussis vaccines|antibodies|carrier state/epidemiology|research,author_keywords,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC3373025_20201005_0.5,,,"Antibodies, Viral|Antibody Affinity|Bacterial Capsules|Child, Preschool|Diphtheria-Tetanus-acellular Pertussis Vaccines|Haemophilus Infections|Haemophilus Vaccines|Haemophilus influenzae type b|Humans|Immunization|Pharynx|Polysaccharides, Bacterial|Statistics, Nonparametric|United Kingdom|Vaccines, Conjugate",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC3373025_20201005_0.5,dtp-hib,drug_umls_atom,We measured anti-polyribosyl-ribitol phosphate antibody concentration and avidity before and after a Hib booster in 176 children 2-4 years of age who had received 3 doses of DTP-Hib (either DT whole cell pertussis-Hib or DTaP-Hib) combination vaccine in infancy.,abstract,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID7483772_20201005_0.5,,,Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines.,title,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID7483772_20201005_0.5,,,"Animals|Antibodies, Bacterial|Bacterial Capsules|Diphtheria-Tetanus-Pertussis Vaccine|Dose-Response Relationship, Drug|Female|Guinea Pigs|Haemophilus Vaccines|Immunization, Secondary|Polysaccharides, Bacterial|Tetanus Toxoid|Vaccines, Conjugate",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID7483772_20201005_0.5,dtp-hib,drug_umls_atom,We propose that the guinea pig model may be useful to verify the immunogenicity of PRP conjugate vaccines and for pre-clinical evaluations of DTP-Hib combination vaccines containing PRP conjugates.,abstract,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID17289221_20201005_0.5,,,Immunization with the heptavalent pneumococcal conjugate vaccine in Bangladeshi infants and effects of zinc supplementation.,title,Other Therapies,"Vitamin and Mineral Supplement, Vaccines","Supplement, Vaccine"
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID17289221_20201005_0.5,,,"Antibodies, Bacterial|Dietary Supplements|Female|Heptavalent Pneumococcal Conjugate Vaccine|Humans|Immunization|Infant|Male|Meningococcal Vaccines|Pneumococcal Vaccines|Zinc",mesh_terms,"Antibodies, Other Therapies","None, Vitamin and Mineral Supplement, Vaccines","antibod, Supplement, Vaccine"
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC5947506_20201005_0.5,,,"Adult|Brazil|Child, Preschool|Cross-Sectional Studies|Female|Hospitalization|Humans|Immunization Programs|Infant|Male|Pneumococcal Vaccines|Pneumonia|Prevalence|Risk Factors|Severity of Illness Index|Socioeconomic Factors|Vaccination|Young Adult",mesh_terms,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID19838618_20201005_0.5,,,"Effect of probiotic supplementation on immunoglobulins, isoagglutinins and antibody response in children of low socio-economic status.",title,"Antibodies, Other Therapies","None, Vitamin and Mineral Supplement","antibod, Supplement"
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID19838618_20201005_0.5,,,"Agglutinins|Antibody Formation|Child|Child, Preschool|Dietary Supplements|Double-Blind Method|Enzyme-Linked Immunosorbent Assay|Female|Humans|Immunoglobulins|Infant|Lactobacillus acidophilus|Lactobacillus casei|Male|Probiotics|Socioeconomic Factors|Streptococcus thermophilus",mesh_terms,"Antibodies, Other Therapies","None, Vitamin and Mineral Supplement","antibod, Supplement"
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID19838618_20201005_0.5,dtp-hib,drug_umls_atom,"According to their age, children were vaccinated with DTP-Hib vaccine or a 23-valent anti-pneumococcal vaccine.",abstract,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC4312604_20201005_0.5,,,The impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study,title,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC4312604_20201005_0.5,,,Non-specific vaccine effects|Measles|DTP|Nasopharyngeal bacterial carriage,author_keywords,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC4312604_20201005_0.5,,,"Child|Infant|Male|Humans|Female|Longitudinal Studies|Nasopharynx|Haemophilus influenzae type b polysaccharide vaccine|Haemophilus Vaccines|Pneumococcal Infections|Pneumococcal Vaccines|Streptococcus pneumoniae|diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine|Vaccines, Conjugate|Haemophilus influenzae|Haemophilus Infections|Carrier State|Moraxella (Branhamella) catarrhalis|Prevalence|Staphylococcus aureus|Vaccination|Diphtheria-Tetanus-Pertussis Vaccine|Bacterial Capsules|Gambia",mesh_terms,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC4312604_20201005_0.5,dtp-hib,drug_umls_atom,"The presence of bacteria in the nasopharynx (Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus ) was compared before and after the administration of DTP-Hib-HepB and measles-yellow fever vaccines.",abstract,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID23313652_20201005_0.5,,,Uptake of oral rotavirus vaccine and timeliness of routine immunization in Brazil's National Immunization Program.,title,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID23313652_20201005_0.5,,,"Brazil|Child, Preschool|Diphtheria-Tetanus-Pertussis Vaccine|Haemophilus Vaccines|Haemophilus influenzae|Humans|Immunization Programs|Immunization Schedule|Infant|Male|Membrane Glycoproteins|Rotavirus|Rotavirus Vaccines|Vaccination",mesh_terms,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID23313652_20201005_0.5,dtp-hib,drug_umls_atom, METHODS We analyzed data from Brazil's national immunization program on uptake of oral rotavirus vaccine by geographic region and compared administrative coverage estimates for first and second doses of oral rotavirus vaccine (Rota1 and Rota2) with first and second doses of diphtheria-tetanus-pertussis-Haemophilus influenzae type b vaccine (DTP-Hib1 and DTP-Hib2).,abstract,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID23313652_20201005_0.5,dtp-hib,drug_umls_atom,"For 27 Brazilian cities, we compared differences between estimated rotavirus and DTP-Hib coverage in 2010 with delayed receipt of DTP-Hib vaccine among a cohort of children surveyed before rotavirus introduction.",abstract,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID7779362_20201005_0.5,,,Control testing of combined vaccines: a consideration of potential problems and approaches.,title,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID7779362_20201005_0.5,,,"Bacterial Vaccines|Clinical Trials as Topic|Diphtheria Toxin|Diphtheria-Tetanus-Pertussis Vaccine|Haemophilus Vaccines|Humans|Models, Molecular|Neisseria meningitidis|Protein Conformation|Vaccines, Combined",mesh_terms,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID7779362_20201005_0.5,dtp-hib,drug_umls_atom,"No section Vaccines comprising combinations of diphtheria, tetanus and pertussis (DTP) components with Haemophilus influenzae b polysaccharide--protein conjugates (DTP-Hib) are now available.",abstract,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID7779362_20201005_0.5,dtp-hib,drug_umls_atom,"Combinations of DTP-Hib with additional components such as inactivated poliomyelitis vaccine, hepatitis B vaccine, meningococcal and pneumococcal polysaccharide-protein conjugates are under development.",abstract,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC4489587_20201005_0.5,,,Vaccination Coverage and Compliance with Three Recommended Schedules of 10-Valent Pneumococcal Conjugate Vaccine during the First Year of Its Introduction in Brazil: A Cross-Sectional Study,title,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMC4489587_20201005_0.5,,,Brazil|Cross-Sectional Studies|Guideline Adherence|Humans|Immunization Schedule|Infant|Pneumococcal Vaccines,mesh_terms,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID11282204_20201005_0.5,,,"Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age.",title,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID11282204_20201005_0.5,,,"Antibodies, Bacterial|Female|Humans|Immunoglobulin G|Infant|Male|Meningococcal Vaccines|Neisseria meningitidis|Serotyping|Vaccines, Conjugate",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID15779786_20201005_0.5,,,General practitioners' concerns about childhood immunisation and suggestions for improving professional support and vaccine uptake.,title,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID15779786_20201005_0.5,,,"Attitude of Health Personnel|Attitude to Health|Family Practice|Female|Health Care Surveys|Humans|Immunization|Information Dissemination|Male|Measles-Mumps-Rubella Vaccine|Practice Patterns, Physicians'|Scotland",mesh_terms,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID15779786_20201005_0.5,dtp-hib,drug_umls_atom,"Of GPs 98% thought it was 'likely' that the benefits of the DTP-Hib, polio and men C vaccines outweighed the possible risks.",abstract,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID15779786_20201005_0.5,dtp-hib,drug_umls_atom,"Approximately three quarters of GPs described themselves 'very confident' in discussing the DTP-Hib vaccine with parents, compared with 57% for MMR.",abstract,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID22230581_20201005_0.5,,,Humans|Immunization|Immunization Programs|Measles|Measles Vaccine|South Africa,mesh_terms,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID22230581_20201005_0.5,dtp-hib,drug_umls_atom,"The data included routine immunization for 1st and 2nd doses of measles vaccine (MCV1, MCV2), SIAs, 1st dose of Bacille Calmette-Guérin vaccine, 1st and 3rd doses of oral polio vaccine (OPV1, OPV3), 3rd dose of Diphtheria-Tetanus-Pertussis-Haemophilus-influenzae-B vaccine (DTP-Hib3), and the number of under-one-year-olds having completed a primary course of immunization (Imm1).",abstract,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID16670121_20201005_0.5,,,"Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age.",title,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID16670121_20201005_0.5,,,"Diphtheria-Tetanus-Pertussis Vaccine|Diphtheria-Tetanus-acellular Pertussis Vaccines|Dose-Response Relationship, Immunologic|Haemophilus Vaccines|Humans|Infant|Influenza Vaccines|Meningococcal Vaccines|Poliovirus Vaccine, Inactivated|Vaccines, Conjugate",mesh_terms,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID16670121_20201005_0.5,dtp-hib,drug_umls_atom,"Coadministration of MCC vaccine can influence the Hib response, and the MCC response to a tetanus conjugate can be influenced by the nature of the coadministered DTP-Hib vaccine.",abstract,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID12443662_20201005_0.5,,,Occurrence of adverse events following inadvertent administration of childhood vaccines.,title,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID12443662_20201005_0.5,,,"Adolescent|Adverse Drug Reaction Reporting Systems|Child|Child, Preschool|Female|Humans|Infant|Male|Medication Errors|Seizures|Vaccines",mesh_terms,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID12443662_20201005_0.5,dtp-hib,drug_umls_atom,"Five of these six cases involved a DTP-containing vaccine: one case where DTP was given instead of diphtheria and tetanus toxoid (DT) vaccine as a pre-school booster, one case where a fourth dose of DTP-Haemophilus influenzae type b conjugate vaccine (Hib) was given at 20 weeks of age and three cases where DTP was mixed with DTP-Hib.",abstract,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID16621858_20201005_0.5,,,The effect of zinc supplementation during pregnancy on immune response to Hib and BCG vaccines in Bangladesh.,title,Other Therapies,"Vitamin and Mineral Supplement, Vaccines","Supplement, Vaccine"
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID16621858_20201005_0.5,,,"Antibodies, Bacterial|BCG Vaccine|Bangladesh|Dietary Supplements|Female|Haemophilus Infections|Haemophilus Vaccines|Humans|Immunity|Infant, Newborn|Male|Pregnancy|Tuberculosis|Zinc",mesh_terms,"Antibodies, Other Therapies","None, Vitamin and Mineral Supplement, Vaccines","antibod, Supplement, Vaccine"
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID16621858_20201005_0.5,dtp-hib,drug_umls_atom,A subcohort of 203 infants were in addition immunized at 1-month intervals with three doses of DTP-Hib vaccine starting at 9 weeks of age.,abstract,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID17316928_20201005_0.5,,,Rates of contraindications and use of alternative vaccines in routine immunisation of children: a population based study in the Czech Republic.,title,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID17316928_20201005_0.5,dtp-hib,drug_umls_atom,"Contraindications were most commonly reported for the DTP-Hib vaccine (263 children, 5.2%), and the most frequent type were central nervous system disorders (171 cases).",abstract,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID9489191_20201005_0.5,,,Fragmentation of scheduled visits and missed doses among infants receiving multiple injected vaccines.,title,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID9489191_20201005_0.5,,,"Australia|Bacterial Capsules|Cohort Studies|Diphtheria-Tetanus-Pertussis Vaccine|Dose-Response Relationship, Drug|Female|Haemophilus Vaccines|Hepatitis B Vaccines|Humans|Immunization Schedule|Infant|Infant, Newborn|Injections, Intramuscular|Male|Office Visits|Patient Compliance|Patient Dropouts|Polysaccharides, Bacterial|Retrospective Studies|Surveys and Questionnaires|Vaccination",mesh_terms,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID16303216_20201005_0.5,dtp-hib,drug_umls_atom,"Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.",title,Other Therapies,Vaccines,Vaccine
diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine,C0215600,,,dtp-hib,inn,PubMed,PMID16303216_20201005_0.5,,,"Antibodies, Bacterial|Diphtheria-Tetanus-Pertussis Vaccine|Double-Blind Method|Fever|Haemophilus Infections|Haemophilus Vaccines|Haemophilus influenzae type b|Humans|Immunization, Secondary|Indonesia|Infant|Pentosephosphates|Polysaccharides, Bacterial|Tetanus Toxoid|Vaccines, Conjugate",mesh_terms,"Antibodies, Other Therapies","None, Vaccines","antibod, Vaccine"
polyethyleneglycol,Z0000068882,golytely,,,inn,PubMed,PMID11867987_20201005_0.5,golytely,drug_synonym,Gastrointestinal decontamination was accomplished with activated charcoal and whole-bowel irrigation with polyethylene glycol solution (Golytely) for 24 hours until repeat abdominal radiographs no longer demonstrated the substance in the gastrointestinal tract.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
polyethyleneglycol,Z0000068882,golytely,,,inn,PubMed,PMID27871178_20201005_0.5,golytely,drug_synonym," METHODS Search on MEDLINE, EMBASE and Cochrane databases until May 2016 of all publications adjusted to the following terms: constipation AND/OR fecal impaction AND (PEG OR polyethylene glycol OR macrogol OR movicol OR idralax OR miralax OR transipeg OR forlax OR golytely OR isocolan OR mulytely) NOT colonoscopy.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
polyethyleneglycol,Z0000068882,golytely,,,inn,PubMed,PMID3112357_20201005_0.5,golytely,drug_synonym,All children were given 25 mL/kg/h of Golytely until rectal effluent was clear and free of particulate matter.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
polyethyleneglycol,Z0000068882,golytely,,,inn,PubMed,PMID3338367_20201214_0.5,,,Improvement of oral colonic lavage with supplemental simethicone.,title,Other Therapies,Vitamin and Mineral Supplement,Supplement
polyethyleneglycol,Z0000068882,golytely,,,inn,PubMed,PMID3338367_20201214_0.5,golytely,drug_synonym,"Therefore, a randomized, blinded controlled trial was performed to determine the prevalence of Golytely-induced foam and the effect of supplemental simethicone in decreasing the prevalence of foam.",abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
polyethyleneglycol,Z0000068882,golytely,,,inn,PubMed,PMID3338367_20201214_0.5,golytely,drug_synonym,Foam was present in 32% of colons prepared with Golytely alone but in none of the colons prepared with Golytely supplemented with simethicone.,abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
polyethyleneglycol,Z0000068882,golytely,,,inn,PubMed,PMID3338367_20201214_0.5,golytely,drug_synonym,"In addition, only 5% of colons prepared with supplemental simethicone had residual stool noted at the time of colonoscopy, a significant improvement over the 39% prevalence of residual stool in colons prepared with Golytely alone.",abstract,Other Therapies,Vitamin and Mineral Supplement,Supplement
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC7731723_20210111_0.5,treprostinil,drug_name,The recently completed Freedom-EV study will provide further insights into the utility of oral treprostinil ( ).,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC3040815_20201005_0.5,,,"Animals|Antihypertensive Agents|Cell Count|Cell Separation|Child|Colony-Forming Units Assay|Endothelial Cells|Epoprostenol|Familial Primary Pulmonary Hypertension|Hematopoietic Stem Cells|Humans|Hypertension, Pulmonary|Mice|Neovascularization, Physiologic|Stem Cells",mesh_terms,Other Therapies,Stem cell therapy,Stem.Cell
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC3040815_20201005_0.5,treprostinil,drug_name,ECFC grown ex vivo were tested for their angiogenic capacities before and after prostacyclin analog therapy (subcutaneous treprostinil).,abstract,Gene Therapy,Ex vivo,Ex Vivo
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC4885501_20201005_0.5,,,"Animals|Bone Marrow|Bone Marrow Transplantation|Cell Cycle|Cell Differentiation|Cell Survival|Chemokine CXCL12|Cholera Toxin|Colforsin|Cyclic AMP|Drug Repositioning|Epoprostenol|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cells|Humans|Mice, Inbred BALB C|Receptors, CXCR4|Receptors, Epoprostenol|Survival Analysis|Whole-Body Irradiation",mesh_terms,Other Therapies,Stem cell therapy,Stem.Cell
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC4885501_20201005_0.5,treprostinil,drug_name,"We tested the hypothesis that treprostinil, a prostacyclin analog approved for the treatment of pulmonary hypertension, can be repurposed to improve hematopoietic stem cell transplantation.",abstract,Other Therapies,Stem cell therapy,Stem.Cell
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC4885501_20201005_0.5,treprostinil,drug_name,Treprostinil stimulates the engraftment of human and murine hematopoietic stem cells without impairing their capacity for self-renewal.,abstract,Other Therapies,Stem cell therapy,Stem.Cell
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC3194296_20201005_0.5,treprostinil,drug_name,Treprostinil stimulates the engraftment of haematopoetic stem cells,title,Other Therapies,Stem cell therapy,Stem.Cell
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC3194296_20201005_0.5,treprostinil,drug_name,Humans|treprostinil|Epoprostenol|Central Nervous System Stimulants|Hematopoiesis|Stem Cells,mesh_terms,Other Therapies,Stem cell therapy,Stem.Cell
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC8043024_20210511_0.5,treprostinil,drug_name,"Moreover, the postoperative mechanical ventilation time, intensive care unit (ICU) stay, and hospital stay of the treprostinil group were significantly shorter than those of the control group.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC3412595_20201005_0.5,treprostinil,drug_name,Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID32424651_20201214_0.5,treprostinil,drug_name,"Outcomes evaluated included doses of oral treprostinil utilized, adverse effects related to therapy, and measures of clinical and functional status before and after the initiation of oral treprostinil.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID16636723_20201005_0.5,treprostinil,drug_name,"This issue focuses on the following selection of drugs: 131I-labetuzumab; Abacavir sulfate, abatacept, adalimumab, ademetionine, adjuvanted influenza vaccine, alefacept, alemtuzumab, amlodipine, amphotericin B, anakinra, aripiprazole, aspirin, axitinib; Betamethasone dipropionate, bevacizumab, biphasic insulin aspart, bortezomib, bosentan, botulinum toxin type B, BQ-123; Calcium folinate, canertinib dihydrochloride, carboplatin, carmustine, cetirizine hydrochloride, cetuximab, cholecalciferol, ciclesonide, ciclosporin, cinacalcet hydrochloride, cisplatin, clarithromycin, clofazimine, cold-adapted influenza vaccine trivalent, CpG-7909; Darbepoetin alfa, darifenacin hydrobromide, DB-289, desloratadine, Dexamet, dicycloverine hydrochloride, dimethyl fumarate, docetaxel, dolastatin 10, drospirenone, drospirenone/estradiol, duloxetine hydrochloride; Ecogramostim, edotecarin, efaproxiral sodium, enalapril maleate, epoetin beta, epoprostenol sodium, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, estradiol, etanercept; Fluconazole, fludarabine phosphate, fluorouracil; Gefitinib, gemcitabine, Ghrelin (human), glibenclamide, glimepiride, GTI-2040; Haloperidol, human insulin, hydrocortisone probutate; Imatinib mesylate, indisulam, influenza vaccine, inhaled insulin, insulin aspart, insulin glulisine, insulin lispro, irinotecan, ispronicline; Lamivudine, lamivudine/zidovudine/abacavir sulfate, lapatinib, letrozole, levocetirizine, lomustine, lonafarnib, lumiracoxib;Magnesium sulfate, MD-1100, melphalan, metformin hydrochloride, methotrexate, metoclopramide hydrochloride, mitiglinide calcium hydrate, monophosphoryl lipid A, montelukast sodium, motexafin gadolinium, mycophenolate mofetil, mycophenolic acid sodium salt; Nitisinone; Omalizumab, omapatrilat, ONYX-015, oxaliplatin; Paclitaxel, paclitaxel nanoparticles, panitumumab, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pertuzumab, phosphatidylcholine-rich phospholipid mixture, pimecrolimus, pioglitazone hydrochloride, pramlintide acetate, prasterone; QR-333; Ranelic acid distrontium salt, ranolazine, rasagiline mesilate, RFB4(dsFv)-PE38, ribavirin, rifabutin, risperidone, rituximab, rofecoxib, rosiglitazone maleate, rosiglitazone maleate/metformin hydrochloride, rotavirus vaccine; S-236, salmeterol xinafoate, sarizotan hydrochloride, sildenafil, sildenafil citrate, sunitinib malate; Tadalafil, tegaserod maleate, temozolomide, tenofovir disoproxil fumarate, teriparatide, tiotropium bromide, tipifarnib, trabectedin, treprostinil sodium; Vandetanib, vardenafil hydrochloride hydrate, vatalanib succinate, vinflunine, virosome influenza vaccine, voriconazole; Zidovudine.",abstract,"Cellular Immunotherapy, Nanoparticles, Other Therapies","Therapeutic Tumor Infiltrating Lymphocytes, None, Vaccines","TIL, Nanoparticle, Vaccine"
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID19715380_20201005_0.5,,,Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID16894408_20201005_0.5,treprostinil,drug_name,"This issue focuses on the following selection of drugs:(R)-Flurbiprofen, 90Yttrium-DOTA-huJ591; ABT-510, ACP-103, Ad5-FGF4, adalimumab, ademetionine, AG-7352, alemtuzumab, Amb a 1 ISS-DNA, anakinra, apaziquone, aprepitant, aripiprazole, atazanavir sulfate; BAL-8557, bevacizumab, BMS-188797, bortezomib, bosentan, brivudine; Calcipotriol/betamethasone dipropionate, cannabidiol, caspofungin acetate, catumaxomab, CERE-120, cetuximab, ciclesonide, cilomilast, cizolirtine citrate, Cypher, cystemustine; Dalbavancin, darifenacin hydrobromide, dasatinib, deferasirox, denosumab, desmoteplase, dihydrexidine, dimethyl fumarate, dutasteride, DW-166HC; Eculizumab, enfuvirtide, entecavir, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, eszopiclone, etoricoxib, everolimus; Fallypride, febuxostat, fenretinide, fesoterodine, fingolimod hydrochloride; Gabapentin enacarbil, gefitinib; hMaxi-K, human papillomavirus vaccine, HYAL-CT1101; Imatinib mesylate, indiplon, inolimomab, ISAtx-247; J591; Lacosamide, landiolol, lasofoxifene tartrate, lestaurtinib, lidocaine/prilocaine, linezolid, lixivaptan, lonafarnib, lopinavir, lopinavir/ritonavir, lumiracoxib; Natalizumab, nesiritide; OC-108, omalizumab, onercept, OSC; Palifermin, palonosetron hydrochloride, parathyroid hormone (human recombinant), parecoxib sodium, PD-MAGE-3 vaccine, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, pegsunercept, pelitinib, pitavastatin calcium, plerixafor hydrochloride, posaconazole, prasterone sulfate, pregabalin; Ramelteon, ranelic acid distrontium salt, rasburicase, rosuvastatin calcium, rotigotine, RSD-1235, rufinamide, rupatadine fumarate; Sarizotan hydrochloride, SHL-749, sirolimus-eluting stent, solifenacin succinate, sunitinib malate; Tadalafil, talampanel, tasidotin hydrochloride, Taxus, tegaserod maleate, telavancin hydrochloride, tenofovir disoproxil fumarate, tiotropium bromide, tocilizumab, tositumomab, treprostinil sodium, tridolgosir hydrochloride, TTS-CD3; Ularitide; Valdecoxib, Val-Tyr sardine peptidase, vardenafil hydrochloride hydrate, voriconazole; Yttrium (90Y) edotreotide, Yttrium 90 (90Y) ibritumomab tiuxetan; Zileuton, zucapsaicin.",abstract,Other Therapies,Vaccines,Vaccine
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID28904003_20201005_0.5,,,"Administration, Inhalation|Animals|Antihypertensive Agents|Dogs|Dose-Response Relationship, Drug|Drug Compounding|Drug Delivery Systems|Drug Evaluation, Preclinical|Epoprostenol|Excipients|Female|Guinea Pigs|Humans|Hypertension, Pulmonary|Lung|Male|Nanoparticles|Phosphatidylethanolamines|Platelet Aggregation|Polyethylene Glycols|Prodrugs|Rats, Sprague-Dawley|Squalene|Vasodilation|Vasodilator Agents",mesh_terms,Nanoparticles,None,Nanoparticle
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID28904003_20201005_0.5,treprostinil,drug_name,"No section This article describes the preclinical pharmacology and pharmacokinetics (PK) of hexadecyl-treprostinil (C16TR), a prodrug of treprostinil (TRE), formulated in a lipid nanoparticle (LNP) for inhalation as a pulmonary vasodilator.",abstract,Nanoparticles,None,Nanoparticle
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC7007891_20210311_0.5,,,"Animals|Antihypertensive Agents|Cells, Cultured|Dipeptidyl Peptidase 4|Dipeptidyl-Peptidase IV Inhibitors|Drug Antagonism|Drug Synergism|Epoprostenol|Fetal Blood|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cells|Humans|Mice|Vildagliptin",mesh_terms,Other Therapies,Stem cell therapy,Stem.Cell
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC7007891_20210311_0.5,treprostinil,drug_name," Key messages Pretreatment with treprostinil increases surface levels of DPP4/CD26 in HSPCs.. Vildagliptin enhances in vitro migration of pretreated HSPCs.. Vildagliptin enhances in vivo homing and engraftment of pretreated HSPCs.. Unexpected mutual antagonism in vivo by concomitant administration of vildagliptin and treprostinil.. Electronic supplementary material The online version of this article (10.1007/s00109-019-01869-8) contains supplementary material, which is available to authorized users.",abstract,"Gene Therapy, Other Therapies","In Vivo, Vitamin and Mineral Supplement","In Vivo, Supplement"
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID20508873_20201005_0.5,treprostinil,drug_name,"No section O(6)-Benzylguanine; (-)-Gossypol; Abatacept, AC-2592, Adalimumab, AIDSVAX gp120 B/E, Alemtuzumab, Aliskiren fumarate, ALVAC E120TMG, Ambrisentan, Amlodipine, Anakinra, Aripiprazole, Armodafinil, Atomoxetine hydrochloride, Avotermin; Bevacizumab, BIBW-2992, Bortezomib, Bosentan, Botulinum toxin type B; Canakinumab, CAT-354, Ciclesonide, CMV gB vaccine, Corifollitropin alfa, Daptomycin, Darbepoetin alfa, Dasatinib, Denosumab; EndoTAG-1, Eplerenone, Esomeprazole sodium, Eszopiclone, Etoricoxib, Everolimus, Exenatide, Ezetimibe, Ezetimibe/simvastatin; F-50040, Fesoterodine fumavate, Fondaparinux sodium, Fulvestrant; Gabapentin enacarbil, Golimumab; Imatinib mesylate, Inhalable human insulin, Insulin glargine, Ivabradine hydrochloride; Lercanidipine hydrochloride/enalapril maleate, Levosimendan, Liposomal vincristine sulfate, Liraglutide; MDV-3100, Mometasone furoate/formoterol fumavate, Multiepitope CTL peptide vaccine, Mycophenolic acid sodium salt, Nabiximols, Natalizumab, Nesiritide; Obeticholic acid, Olmesartan medoxomil, Omalizumab, Omecamtiv mecarbil; Paclitaxel-eluting stent, Paliperidone, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Peginterferon alfa-2b/ ribavirin, Pemetrexed disodium, Polymyxin B nonapeptide, PORxin-302, Prasugrel, Pregabalin, Pridopidine; Ranelic acid distrontium salt, Rasagiline mesilate, rDEN4delta30-4995, Recombinant human relaxin H2, rhFSH, Rilonacept, Rolofylline, Rosiglitazone maleate/metformin hydrochloride, Rosuvastatin calcium, Rotigotine; Salcaprozic acid sodium salt, Sirolimus-eluting stent, Sitagliptin phosphate monohydrate, Sitaxentan sodium, Sorafenib, Sunitinib malate; Tadalafil, Tapentadol hydrochloride, Temsirolimus, Tenofovir, Tenofovir disoproxil fumarate, Teriparatide, Tiotropium bromide, Tocilizumab, Tolvaptan, Tozasertib, Treprostinil sodium; Ustekinumab; Vardenafil hydrochloride hydrate, Varenicline tartrate, Vatalanib succinate, Voriconazole, Vorinostat; Zotarolimus-eluting stent.",abstract,Other Therapies,Vaccines,Vaccine
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID18518827_20201005_0.5,treprostinil,drug_name,"Strategies for further improvement of inhaled prostanoid therapy include use of prostacyclin analogues with longer half-life (e.g., treprostinil), combinations with oral drugs (e.g., phosphodiesterase inhibitors or endothelin receptor antagonists) and development of aerosolized controlled release formulations such as liposomes and nanoparticles.",abstract,Nanoparticles,"None, Liposomes","Nanoparticle, Liposome"
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID15834459_20201005_0.5,treprostinil,drug_name,"This issue focuses on the following selection of drugs:[188Re]-HDD; A-179578, adalimumab, AK-602, albumin interferon alfa, alfimeprase, amelubant, anakinra, anti-CD2 MAb, APD-356, aripiprazole, atvogen; Bimatoprost, bimosiamose, BLP-25, brivaracetam; Caspofungin acetate, cilansetron, CMV vaccine (bivalent), conivaptan hydrochloride, Cypher; Darbepoetin alfa, darifenacin hydrobromide, D-D4FC, decitabine, dnaJP1, doranidazole, dronedarone hydrochloride; Efalizumab, efaproxiral sodium, emtricitabine, Endeavor, entecavir, erlotinib hydrochloride, escitalopram oxalate, etoricoxib, etravirine, ezetimibe; Fampridine, fenretinide, ferumoxtran-10, forodesine hydrochloride; Gantacurium chloride, gemi-floxacin mesilate, Glyminox, GW-501516; HBV-ISS, hepavir B, human insulin, HuMax-CD20, hyaluronic acid, HyCAMP; Icatibant, IDEA-070, IGN-311, imatinib mesylate, insulin detemir, insulin glargine, insulin glulisine; Lapatinib, lasofoxifene tartrate, LB-80380, liarozole fumarate, liposome encapsulated doxorubicin, lumiracoxib, LY-570310; MC-1, melatonin, merimepodib, metanicotine, midostaurin; Natalizumab, nicotine conjugate vaccine, NYVAC-HIV C; Patupilone, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pelitinib, Peru-15, pexelizumab, PHP, pimecrolimus, prednisolone sodium metasulfobenzoate; Recombinant alfa1-antitrypsin (AAT), retigabine, rHA influenza vaccine, rifalazil, rofecoxib, rosiglitazone maleate/Metformin hydrochloride, rostaporfin, rosuvastatin calcium, rubitecan; Selenite sodium, semilente insulin, SMP-797, sorafenib; Talampanel, tenofovir disoproxil fumarate, TER-199, tiotropium bromide, torcetrapib, treprostinil sodium, TTA; ValboroPro, valdecoxib, val-mCyd, valtorcitabine dihydrochloride: XP-828L.",abstract,"Nanoparticles, Other Therapies","Liposomes, Vaccines","Liposome, Vaccine"
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID16574908_20201005_0.5,treprostinil,drug_name,"These results suggest that (1) TASK-1 is expressed in human PASMC; (2) TASK-1 is hypoxia-sensitive and controls the resting membrane potential, thus implicating an important role for TASK-1 K+ channels in the regulation of pulmonary vascular tone; and (3) treprostinil activates TASK-1 at clinically relevant concentrations via PKA, which might represent an important mechanism underlying the vasorelaxing properties of prostanoids and their beneficial effect in vivo.",abstract,Gene Therapy,In Vivo,In Vivo
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID16082422_20201005_0.5,treprostinil,drug_name,"This issue focuses on the following selection of drugs: Abiraterone acetate, acyline, adalimumab, adenosine triphosphate, AEE-788, AIDSVAX gp120 B/B, AK-602, alefacept, alemtuzumab, alendronic acid sodium salt, alicaforsen sodium, alprazolam, amdoxovir, AMG-162, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, aminophylline hydrate, anakinra, anecortave acetate, anti-CTLA-4 MAb, APC-8015, aripiprazole, aspirin, atazanavir sulfate, atomoxetine hydrochloride, atorvastatin calcium, atrasentan, AVE-5883, AZD-2171; Betamethasone dipropionate, bevacizumab, bimatoprost, biphasic human insulin (prb), bortezomib, BR-A-657, BRL-55730, budesonide, busulfan; Calcipotriol, calcipotriol/betamethasone dipropionate, calcium folinate, capecitabine, capravirine, carmustine, caspofungin acetate, cefdinir, certolizumab pegol, CG-53135, chlorambucil, ciclesonide, ciclosporin, cisplatin, clofarabine, clopidogrel hydrogensulfate, clozapine, co-trimoxazole, CP-122721, creatine, CY-2301, cyclophosphamide, cypher, cytarabine, cytolin; D0401, darbepoetin alfa, darifenacin hydrobromide, DASB, desipramine hydrochloride, desloratadine, desvenlafaxine succinate, dexamethasone, didanosine, diquafosol tetrasodium, docetaxel, doxorubicin hydrochloride, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecallantide, efalizumab, efavirenz, eletriptan, emtricitabine, enfuvirtide, enoxaparin sodium, estramustine phosphate sodium, etanercept, ethinylestradiol, etonogestrel, etonogestrel/ethinylestradiol, etoposide, exenatide; Famciclovir, fampridine, febuxostat, filgrastim, fludarabine phosphate, fluocinolone acetonide, fluorouracil, fluticasone propionate, fluvastatin sodium, fondaparinux sodium; Gaboxadol, gamma-hydroxybutyrate sodium, gefitinib, gelclair, gemcitabine, gemfibrozil, glibenclamide, glyminox; Haloperidol, heparin sodium, HPV 16/HPV 18 vaccine, human insulin, human insulin; Icatibant, imatinib mesylate, indium 111 (111In) ibritumomab tiuxetan, infliximab, INKP-100, iodine (I131) tositumomab, IoGen, ipratropium bromide, ixabepilone; L-870810, lamivudine, lapatinib, laquinimod, latanoprost, levonorgestrel, licochalcone a, liposomal doxorubicin, lopinavir, lopinavir/ritonavir, lorazepam, lovastatin; Maraviroc, maribavir, matuzumab, MDL-100907, melphalan, methotrexate, methylprednisolone, mitomycin, mitoxantrone hydrochloride, MK-0431, MN-001, MRKAd5 HIV-1 gag/pol/nef, MRKAd5gag, MVA.HIVA, MVA-BN Nef, MVA-Muc1-IL-2, mycophenolate mofetil; Nelfinavir mesilate, nesiritide, NSC-330507; Olanzapine, olmesartan medoxomil, omalizumab, oral insulin, osanetant; PA-457, paclitaxel, paroxetine, paroxetine hydrochloride, PCK-3145, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, perillyl alcohol, pexelizumab, pimecrolimus, pitavastatin calcium, porfiromycin, prasterone, prasugrel, pravastatin sodium, prednisone, pregabalin, prinomastat, PRO-2000, propofol, prostate cancer vaccine; Rasagiline mesilate, rhBMP-2/ACS, rhBMP-2/BCP, rhC1, ribavirin, rilpivirine, ritonavir, rituximab, Ro-26-9228, rosuvastatin calcium, rosuvastatin sodium, rubitecan; Selodenoson, simvastatin, sirolimus, sitaxsentan sodium, sorafenib, SS(dsFv)-PE38, St. John's Wort extract, stavudine; Tacrolimus, tadalafil, tafenoquine succinate, talaglumetad, tanomastat, taxus, tegaserod maleate, telithromycin, tempol, tenofovir, tenofovir disoproxil fumarate, testosterone enanthate, TH-9507, thalidomide, tigecycline, timolol maleate, tiotropium bromide, tipifarnib, torcetrapib, trabectedin, travoprost, travoprost/timolol, treprostinil sodium; Valdecoxib, vardenafil hydrochloride hydrate, varenicline, VEGF-2 gene therapy, venlafaxine hydrochloride, vildagliptin, vincristine sulfate, voriconazole, VRX-496, VX-385; Warfarin sodium; Ximelagatran; Yttrium 90 (90Y) ibritumomab tiuxetan; Zanolimumab, zidovudine.",abstract,"Cellular Immunotherapy, Gene Therapy, Other Therapies","Therapeutic Tumor Infiltrating Lymphocytes, None, Vaccines","TIL, Gene Therap, Vaccine"
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID33346142_20210611_0.5,treprostinil,drug_name,"Treprostinil palmitil, an inhaled long-acting pulmonary vasodilator, does not show tachyphylaxis with daily dosing in rats.",title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID33346142_20210611_0.5,treprostinil,drug_name,Inhaled|Pulmonary vasodilation|Tachyphylaxis|Treprostinil palmitil,author_keywords,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID33346142_20210611_0.5,treprostinil,drug_name,"Male|Rats|Animals|treprostinil|Vasodilator Agents|Tachyphylaxis|Rats, Sprague-Dawley|Epoprostenol|Antihypertensive Agents|Lung|Hypertension, Pulmonary|Vasodilation|Administration, Inhalation|Prodrugs|Nebulizers and Vaporizers|Nanoparticles",mesh_terms,Nanoparticles,None,Nanoparticle
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID33346142_20210611_0.5,treprostinil,drug_name,No section Treprostinil palmitil (TP) is an inhaled long-acting pulmonary vasodilator prodrug of treprostinil (TRE) that has been formulated for delivery as a suspension (treprostinil palmitil inhalation suspension; TPIS) and as a dry powder (treprostinil palmitil inhalation powder; TPIP).,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID26220250_20201005_0.5,,,"In Vitro and In Vivo Performance of a Pre-Filled, Electrochemically-Actuated Infusion System.",title,Gene Therapy,In Vivo,In Vivo
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID24618545_20201005_0.5,treprostinil,drug_name,We conducted a 1-year prospective study of patients utilizing SQ treprostinil.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID29558853_20201005_0.5,treprostinil,drug_name,The most common dosing frequency utilized for treprostinil diolamine was 3 times per day.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID17533419_20201005_0.5,treprostinil,drug_name,We investigated whether treprostinil exerts direct contractile effects on cardiomyocytes that may explain partly the beneficial effects of these drugs.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID17533419_20201005_0.5,treprostinil,drug_name, RESULTS Treprostinil (0.15 - 15 ng ml(-1)) slightly increased contractile dynamics of cardiomyocytes at clinically relevant concentrations.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID31672620_20201214_0.5,treprostinil,drug_name,"Of note, while the ETB receptor antagonist (BQ788) increases ET-1 production from PH Group-III patients' preparations (HPA, parenchyma), even under these more proliferative conditions, iloprost and treprostinil are still effective to inhibit hPASMCs proliferation (-22/-24%).",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID17003851_20201005_0.5,treprostinil,drug_name,"The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com This issue focuses on the following selection of drugs: A-007, A6, adalimumab, adenosine triphosphate, alefacept, alemtuzumab, AllerVax Ragweed, amphora, anakinra, angiotensin-(1-7), anidulafungin, apomine, aripiprazole, atomoxetine hydrochloride, avanafil; BAL-8557, becatecarin, bevacizumab, biphasic insulin aspart, BMS-188797, bortezomib, bosentan, botulinum toxin type B, brivudine; Calcipotriol/betamethasone dipropionate, caspofungin acetate, catumaxomab, certolizumab pegol, cetuximab, CG-0070, ciclesonide, cinacalcet hydrochloride, clindamycin phosphate/benzoyl peroxide, cryptophycin 52, Cypher; Dabigatran etexilate, darapladib, darbepoetin alfa, decitabine, deferasirox, desloratadine, dexanabinol, dextromethorphan/quinidine sulfate, DMF, drotrecogin alfa (activated), duloxetine hydrochloride; E-7010, edaravone, efalizumab, emtricitabine, entecavir, eplerenone, erlotinib hydrochloride, escitalopram oxalate, estradiol valerate/dienogest, eszopiclone, exenatide, ezetimibe; Fondaparinux sodium, fulvestrant; Gefitinib, gestodene, GYKI-16084; Hyaluronic acid, hydralazine hydrochloride/isosorbide dinitrate; Imatinib mesylate, indiplon, insulin glargine; Juzen-taiho-to; Lamivudine/zidovudine/abacavir sulfate, L-arginine hydrochloride, lasofoxifene tartrate, L-BLP-25, lenalidomide, levocetirizine, levodopa/carbidopa/entacapone, lexatumumab, lidocaine/prilocaine, lubiprostone, lumiracoxib; MAb-14.18, mitoquidone; Natalizumab, neridronic acid, neuradiab; Olpadronic acid sodium salt, omalizumab; p53-DC vaccine, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, pemetrexed disodium, perifosine, pimecrolimus, prasterone, prasugrel, PRO-2000, Pseudostat; R24, rasburicase, RHAMM R3 peptide, rilonacept, rosuvastatin calcium, rotavirus vaccine, rufinamide; Sabarubicin hydrochloride, SHL-749, sirolimus-eluting stent, SLx-2101, sodium butyrate, sorafenib, SU-6668; TachoSil, tadalafil, taxus, tegaserod maleate, telbivudine, tenofovir disoproxil fumarate, teriparatide, tetramethylpyrazine, teverelix, tiotropium bromide, tipifarnib, tirapazamine, tolvaptan, TransvaxTM hepatitis C vaccine, treprostinil sodium; Valganciclovir hydrochloride, valsartan/amlodipine, vandetanib, vardenafil hydrochloride hydrate, vatalanib succinate, veglin, voriconazole; Yttrium 90 (90Y) ibritumomab tiuxetan; Zileuton, zotarolimus, zotarolimus-eluting stent.",abstract,Other Therapies,Vaccines,Vaccine
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID22452448_20201214_0.5,treprostinil,drug_name," OBJECTIVE This study provides a cost-effectiveness and cost-utility comparison of initiating prostacyclin therapy with three different treatment alternatives (inhaled iloprost [ILO], intravenous epoprostenol [EPO] and subcutaneous treprostinil [TRE]) for patients with PAH.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID22452448_20201214_0.5,treprostinil,drug_name,"Incremental cost-effectiveness ratios (ICER) and cost-utility ratios (ICUR) of epoprostenol versus iloprost and treprostinil were much above the €30,000 per LYG or QALY threshold commonly used in Spain.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID29791923_20201005_0.5,treprostinil,drug_name,Inhaled Treprostinil-Prodrug Lipid Nanoparticle Formulations Provide Long-Acting Pulmonary Vasodilation.,title,Nanoparticles,None,Nanoparticle
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID29791923_20201005_0.5,,,"Administration, Inhalation|Animals|Antihypertensive Agents|Delayed-Action Preparations|Disease Models, Animal|Dogs|Drug Compounding|Drug Evaluation, Preclinical|Epoprostenol|Half-Life|Humans|Hypertension, Pulmonary|Lipids|Lung|Macaca fascicularis|Male|Nanoparticles|Prodrugs|Rats|Rats, Sprague-Dawley|Vasodilation",mesh_terms,Nanoparticles,None,Nanoparticle
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID15319815_20201005_0.5,treprostinil,drug_name,"This issue focuses on the following selection of drugs: 101M; Adalimumab, adefovir dipivoxil, adenosine triphosphate, albumin interferon alfa, alefacept, alemtuzumab, aminolevulinic acid hexyl ester, autologous renal tumor vaccine, azimilide hydrochloride; Bortezomib, bosentan, BR-1; C340, cantuzumab mertansine, caspofungin acetate, CGP-36742, CHAMPION everolimus-eluting coronary stent, cypher; Dalbavancin, darbepoetin alfa, desloratadine, duloxetine hydrochloride, dutasteride; Efalizumab, emtricitabine, enfuvirtide, erlosamide, ertapenem sodium, everolimus, ezetimibe; Flesinoxan hydrochloride, fosamprenavir calcium, FR-901228, frovatriptan; Gadofosveset sodium, gadomer-17, galiximab, gamma-hydroxybutyrate sodium, gefitinib; HuOKT3gamma1(Ala234-Ala235); IDN-6556, imatinib mesylate, iodine (I131) tositumomab, iseganan hydrochloride, ixabepilone; Keratinocyte growth factor; LB-80380, levocetirizine, liposomal doxorubicin, LMB-9, lopinavir, lopinavir/ritonavir, lumiracoxib, lurtotecan; Mecasermin, midostaurin, morphine hydrochloride; Natalizumab, nelfinavir, nesiritide, niacin/lovastatin; Olcegepant, omalizumab, oregovomab; Parecoxib sodium, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ ribavirin, perospirone hydrochloride, pexelizumab, pimecrolimus, prinomastat; Resiquimod, rhIGFBP-3, rhIGF-I/rhIGFBP-3, ritanserin, ro-31-7453, rosuvastatin calcium; SCIO-469, SDZ-SID-791, SU-11248, suberanilohydroxamic acid; Tadalafil, taxus, telithromycin, tenofovir disoproxil fumarate, TER-286, tezosentan disodium, TH-9507, tipifarnib, tipranavir, tolvaptan, tramadol hydrochloride/acetaminophen, travoprost, treprostinil sodium, tucaresol; Valganciclovir hydrochloride, val-mCyd, vardenafil hydrochloride hydrate, vinflunine, voriconazole; Ximelagatran, XTL-002; Yttrium 90 (90Y) ibritumomab tiuxetan.",abstract,Other Therapies,Vaccines,Vaccine
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC8116805_20210611_0.5,,,"Humans|Receptors, Epoprostenol|Fibroblasts|Lung|Signal Transduction|MAP Kinase Signaling System|Cell Nucleus|Idiopathic Pulmonary Fibrosis|Cyclic AMP|Elementary Particles|Fibrosis|Cell Proliferation|Cells, Cultured|Proto-Oncogene Proteins c-sis|Cell Division|8-chloro-cyclic adenosine monophosphate|8-Bromo Cyclic Adenosine Monophosphate",mesh_terms,Other Therapies,Stem cell therapy,Stem.Cell
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC5824913_20201005_0.5,,,Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC5824913_20201005_0.5,treprostinil,drug_name,"Demographics, clinical characteristics, and resource utilization were compared between epoprostenol and treprostinil groups.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC5824913_20201005_0.5,treprostinil,drug_name,Treprostinil initiation has been increasing and is associated with less resource utilization and lower cost compared to epoprostenol initiation.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID26401252_20201005_0.5,treprostinil,drug_name,"Oral treprostinil dose was inversely associated with change in PVR (r = -0.42, P < 0.05), and change in PVR was numerically better among patients in the highest dosing quartile.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC4073912_20201005_0.5,treprostinil,drug_name,Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID26062754_20201005_0.5,treprostinil,drug_name,Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells.,title,Other Therapies,Stem cell therapy,Stem.Cell
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID26062754_20201005_0.5,,,Stem cells|endothelial progenitor cells|prostacyclin analogues|vascular remodelling|vasculogenesis,author_keywords,Other Therapies,Stem cell therapy,Stem.Cell
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID26062754_20201005_0.5,,,"Adolescent|Adult|Angiogenesis Inducing Agents|Animals|Antibodies|Antihypertensive Agents|Biomarkers|Cell Differentiation|Cell Lineage|Cell Proliferation|Cell Survival|Cells, Cultured|Child|Child, Preschool|Dose-Response Relationship, Drug|Endothelial Progenitor Cells|Epoprostenol|Female|Humans|Hypertension, Pulmonary|Infant|Male|Mesenchymal Stem Cells|Mice, Nude|Neovascularization, Physiologic|Paracrine Communication|RNA Interference|Signal Transduction|Transfection|Up-Regulation|Vascular Endothelial Growth Factor A|Young Adult",mesh_terms,"Antibodies, Gene Therapy, Other Therapies","None, RNAi Therapeutics, Stem cell therapy","antibod, RNA interference, Stem.Cell"
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID26062754_20201005_0.5,treprostinil,drug_name,"We examined the effect of treprostinil on ECFC obtained from cord blood in terms of colony numbers, proliferative and clonogenic properties in vitro, as well as in vivo vasculogenic properties.",abstract,Gene Therapy,In Vivo,In Vivo
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID26062754_20201005_0.5,treprostinil,drug_name,"Surprisingly, treprostinil inhibited viability of cultured ECFC but did not modify their clonogenic properties or the endothelial differentiation potential from cord blood stem cells.",abstract,Other Therapies,Stem cell therapy,Stem.Cell
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID26062754_20201005_0.5,treprostinil,drug_name,Treprostinil treatment significantly increased the vessel-forming ability of ECFC combined with mesenchymal stem cells (MSC) in Matrigel implanted in nude mice.,abstract,Other Therapies,Stem cell therapy,Stem.Cell
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID26062754_20201005_0.5,treprostinil,drug_name,"In vitro, ECFC proliferation was stimulated by conditioned media from treprostinil-pretreated MSC, and this effect was inhibited either by the use of VEGF-A blocking antibodies or siRNA VEGF-A in MSC.",abstract,Antibodies,None,antibod
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID26062754_20201005_0.5,treprostinil,drug_name,Silencing VEGF-A gene in MSC also blocked the pro-angiogenic effect of treprostinil in vivo.,abstract,Gene Therapy,In Vivo,In Vivo
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID29408757_20201005_0.5,,,"Administration, Inhalation|Animals|Antihypertensive Agents|Bleomycin|Cells, Cultured|Disease Models, Animal|Dose-Response Relationship, Drug|Epoprostenol|Fibroblasts|Humans|Hydroxyproline|Idiopathic Pulmonary Fibrosis|Lipids|Male|Nanoparticles|Prodrugs|Pyridones|Rats|Rats, Inbred F344|Real-Time Polymerase Chain Reaction",mesh_terms,Nanoparticles,None,Nanoparticle
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID29408757_20201005_0.5,treprostinil,drug_name,"In this study, we evaluated the effect of the inhaled treprostinil prodrug hexadecyl-treprostinil (C16TR) formulated in a lipid nanoparticle (INS1009) administered therapeutically in a fibrotic rat model.",abstract,Nanoparticles,None,Nanoparticle
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID15349141_20201005_0.5,treprostinil,drug_name,"TNF.11D, adefovir dipivoxil, AdPEDF.11, AES-14, albumex, alefacept, alemtuzumab, aliskiren fumarate, alvimopan hydrate, aAminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, anakinra, anti-IL-12 MAb, aprepitant, atazanavir sulfate, atrasentan, avanafil; Banoxantrone, BG-12, bimatoprost, bortezomib, bosentan; Calcipotriol/betamethasone dipropionate, caspofungin acetate, CBT-1, ciclesonide, clofarabine, conivaptan hydrochloride, CpG-7909, C-Vax, Cypher; DA-8159, DAC:GLP-1, darbepoetin alfa, darifenacin, duloxetine hydrochloride; Eculizumab, efalizumab, efaproxiral sodium, EGF vaccine, eletriptan, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, ETC-642, etoricoxib, everolimus, exenatide; Gefitinib, IV gamma-globulin; Human insulin, gamma-hydroxybutyrate sodium; IDN-6556, iguratimod, imatinib mesylate, indiplon, ixabepilone; Laquinimod, LB-80380, lidocaine/prilocaineliraglutide, lopinavir, lopinavir/ritonavir, lucinactant; MAb-14.18, melatonin, MLN-591-DM1; NC-531, neridronic acid, nesiritide, neutrophil-inhibitory factor, niacin/lovastatin; Oblimersen sodium, olcegepant, oral Insulin, ORV-105; Palonosetron hydrochloride, PAmAb, pegaptanib sodium, peginterferon alfa-2a, pegvisomant, perifosine, pexelizumab, phenoxodiol, phenserine tartrate, pimecrolimus, pramlintide acetate, pregabalin, PRO-542, prostate cancer vaccine, PT-141; Ramelteon, rasagiline mesilate, rDNA insulin, reslizumab, rh-Lactoferrin, ribamidine hydrochloride, rosuvastatin calcium; S-8184l, SC-1, sorafenib, St. John's Wort extract, SU-11248; Taxus, telbivudine, tenofovir disoproxil fumarate, teriparatide, testosterone gel, tezosentan disodium, tipifarnib, tolvaptan, trabectedin, travoprost, travoprost/timolol, treprostinil sodium; Vardenafil hydrochloride hydrate; Xcellerated T cells, XR-5944; Yttrium 90 (90Y) ibritumomab tiuxetan; Ziconotide.",abstract,Other Therapies,Vaccines,Vaccine
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID28476928_20201005_0.5,,,Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID28476928_20201005_0.5,,,"Acetamides|Acetates|Animals|CHO Cells|Cell Proliferation|Contractile Proteins|Cricetinae|Cricetulus|Cyclic AMP|Epoprostenol|Extracellular Matrix|Humans|Hypertension, Pulmonary|Iloprost|Male|Muscle Contraction|Muscle Relaxation|Pyrazines|Rats|Rats, Inbred SHR|Rats, Wistar|Receptors, Epoprostenol|beta-Arrestins",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID12616965_20201005_0.5,treprostinil,drug_name,"This issue focuses on the following selection of drugs: Abacavir sulfate, adalimumab, AERx morphine sulphate, alefacept, alemtuzumab, alendronic acid sodium salt, alicaforsen sodium, almotriptan, amprenavir, aripiprazole, atenolol, atorvastatin calcium; BSYX-A110; Cantuzumab mertansine, capravirine, CDP-571, CDP-870, celecoxib; Delavirdine mesilate, docetaxel, dofetilide, donepezil hydrochloride, duloxetine hydrochloride, dutasteride, dydrogesterone; Efavirenz, emtricitabine, enjuvia, enteryx, epristeride, erlotinib hydrochloride, escitalopram oxalate, etanercept, etonogestrel, etoricoxib; Fesoterodine, finasteride, flt3ligand; Galantamine hydrobromide, gemtuzumab ozogamicin, genistein, gepirone hydrochloride; Indinavir sulfate, infliximab; Lamivudine, lamivudine/zidovudine/abacavir sulfate, leteprinim potassium, levetiracetam, liposomal doxorubicin, lopinavir, lopinavir/ritonavir, losartan potassium; MCC-465, MRA; Nebivolol, nesiritide, nevirapine; Olanzapine, OROS(R)-Methylphenidate hydrochloride; Peginterferon alfa-2a, peginterferon alfa-2b, Pimecrolimus, polyethylene glycol 3350, pramlintide acetate, pregabalin, PRO-2000; Risedronate sodium, risperidone, ritonavir, rituximab, rivastigmine tartrate, rofecoxib, rosuvastatin calcium; Saquinavir mesilate, Stavudine; Tacrolimus, tadalafil, tamsulosin hydrochloride, telmisartan, tomoxetine hydrochloride, treprostinil sodium, trimegestone, trimetrexate; Valdecoxib, venlafaxine hydrochloride; Zoledronic acid monohydrate.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC7739096_20210111_0.5,treprostinil,drug_name,"Our objectives were: (1) to investigate the impact of inhaled treprostinil on risk stratification using the French noninvasive approach and REVEAL 2.0, and (2) to analyze the prognostic utility of both risk stratification methods in the predominantly New York Heart Association/World Health Organization functional class III/IV cohorts of TRIUMPH and BEAT.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID19071225_20201005_0.5,treprostinil,drug_name,No impact on ventilation/perfusion matching by treprostinil was demonstrated in 5 patients with pre-existing gas exchange limitations by use of the multiple inert gas elimination technique.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID32468125_20210211_0.5,treprostinil,drug_name,"Although the pulmonary artery pressure in both groups was significantly lower postoperatively than preoperatively, the postoperative pulmonary artery systolic pressure was significantly lower in group T than in group C. The postoperative mechanical ventilation time, ICU stay, and hospital stay in group T were shorter than those in group C. Treprostinil can be used effectively and safely to reduce the perioperative pulmonary artery pressure in infants with non-restrictive VSD and severe PAH undergoing surgical VSD repair.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID21668631_20201005_0.5,treprostinil,drug_name,"IRI significantly increased serum ALT and AST levels, neutrophil infiltration, hepatic necrosis and mRNA levels of proinflammatory cytokines post-OLT, while treatment with treprostinil decreased all the parameters.",abstract,Gene Therapy,"RNA, Messenger",mRNA
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID28441181_20201005_0.5,treprostinil,drug_name,Inhaled Treprostinil Drug Delivery During Mechanical Ventilation and Spontaneous Breathing Using Two Different Nebulizers.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID28441181_20201005_0.5,treprostinil,drug_name,OBJECTIVE To determine the feasibility of delivering inhaled treprostinil during mechanical ventilation and spontaneous unassisted ventilation using the Tyvaso Inhalation System and the vibrating mesh nebulizer.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID28441181_20201005_0.5,treprostinil,drug_name,"We sought to compare differences in fine particle fraction, and absolute inhaled treprostinil mass delivered to neonatal, pediatric, and adult models affixed with a face mask, conventional, and high-frequency ventilation between Tyvaso Inhalation System and with different nebulizer locations between Tyvaso Inhalation System and vibrating mesh nebulizer.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC6831973_20201005_0.5,treprostinil,drug_name,"Background The DelIVery for Pulmonary Arterial Hypertension clinical trial was a multi-center, prospective, single arm, Investigational Device Exemption study utilizing a fully implantable, programmable intravascular delivery system consisting of a pump and a catheter for intravenous treprostinil.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID29610176_20201005_0.5,,,"Antibodies, Monoclonal, Humanized|Anticoagulants|Cerebral Cortex|Cerebral Hemorrhage|Child, Preschool|Enoxaparin|Fatal Outcome|Female|Humans|Malignant Atrophic Papulosis",mesh_terms,Antibodies,None,antibod
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID29610176_20201005_0.5,treprostinil,drug_name,"Nonetheless, because the C5b-9 complex is detected in MAP, some researchers have suggested combined treatment with eculizumab (a humanized monoclonal antibody against C5) and treprostinil (a prostacyclin analog).",abstract,Antibodies,"None, Monoclonal Antibodies","antibod, Monoclonal Antibod"
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC6696021_20201005_0.5,,,Carboxylic Ester Hydrolases|Drug Discovery|Enzyme Activation|Humans|Machine Learning|Molecular Docking Simulation|Molecular Dynamics Simulation|Protease Inhibitors|Quantitative Structure-Activity Relationship|ROC Curve|Reproducibility of Results|Small Molecule Libraries,mesh_terms,Small molecules,None,Small molecule
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID23446048_20201005_0.5,treprostinil,drug_name,"Despite these considerations, safety data on treprostinil are still limited and mainly derived from randomised controlled trials and retrospective studies with relatively small and heterogeneous cohorts of patients with PAH.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID33156922_20210511_0.5,treprostinil,drug_name,"Here we investigate the protective effects of treprostinil, a prostacyclin analog, against renal IRI in vivo.",abstract,Gene Therapy,In Vivo,In Vivo
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID33156922_20210511_0.5,treprostinil,drug_name,"Importantly, these data suggest that treprostinil has the potential to serve as a therapeutic agent to protect the kidney against IRI in vivo.",abstract,Gene Therapy,In Vivo,In Vivo
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID18657627_20201005_0.5,treprostinil,drug_name,Ventilation/perfusion distribution measurement in six patients with pre-existing gas exchange limitations was not changed by sildenafil and treprostinil.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID33095030_20210411_0.5,treprostinil,drug_name,Four patients required positive pressure ventilation in the treprostinil group versus one in the placebo group.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID27717619_20201005_0.5,,,"Abdominal Pain|Anti-Arrhythmia Agents|Antibodies, Monoclonal, Humanized|Atrial Fibrillation|Factor Xa Inhibitors|Female|Humans|Malignant Atrophic Papulosis|Metoprolol|Middle Aged|Paresthesia|Pyrazoles|Pyridones|Tricuspid Valve Insufficiency",mesh_terms,Antibodies,None,antibod
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID32620953_20210511_0.5,treprostinil,drug_name,"The treprostinil dose was increased by 2 ng/kg/min every 3 hours until a target dose of 22 ng/kg/min was achieved, at which point the patient had experienced dyspnea improvement.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID31912412_20210611_0.5,treprostinil,drug_name,"Nine patients were using intravenous treprostinil, two patients were using subcutaneous treprostinil, and five patients were using intravenous epoprostenol at a median dose of 80 (interquartile range, IQR 72-90), 76.5 (68 and 85), and 28 (IQR 26-30) ng/kg/min respectively.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID16258596_20201005_0.5,treprostinil,drug_name,"This issue focuses on the following selection of drugs: AAV-NGFbeta, aprepitant, aripiprazole, atomoxetine hydrochloride; beta-Methyl-6-chloromelatonin, BMS-214662, bortezomib, bosentan; Calcipotriol/betamethasone dipropionate, CEA-TRICOM, cetuximab, ciclesonide, clofarabine, Cypher; Dalbavancin, darbepoetin alfa, darifenacin hydrobromide, desloratadine, Dexamet, drospirenone, drospirenone/ethinylestradiol, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecogramostim, efalizumab, ertapenem sodium, escitalopram oxalate, eszopiclone; Fenretinide; Gefitinib, gestodene, ghrelin (human); hMaxi-K, human papillomavirus vaccine; Imatinib mesylate, indiplon, iodine (i131) tositumomab, irofulven, ISS-1018; Lasofoxifene tartrate, levodopa/carbidopa/entacapone, liposomal doxorubicin; Nemifitide ditriflutate, nesiritide; Omalizumab; Pegfilgrastim, peginterferon alfa-2a, peginterferon alfa-2b, phVEGF-A165, pimecrolimus, pramlintide acetate; Rasburicase, rimonabant hydrochloride; Satraplatin, St. John's Wort extract, sunitinib malate; Tadalafil, tanaproget, Taxus, tiotropium bromide, treprostinil sodium; Valdecoxib, vardenafil hydrochloride hydrate; Ximelagatran; Zileuton.",abstract,Other Therapies,Vaccines,Vaccine
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID26362969_20201005_0.5,,,Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents.,title,"Cellular Immunotherapy, Gene Therapy","Therapeutic Tumor Infiltrating Lymphocytes, Ex vivo","TIL, Ex Vivo"
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID23668545_20201005_0.5,treprostinil,drug_name,In vitro delivery of aerosolized treprostinil via modern mechanical ventilation.,title,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID23668545_20201005_0.5,,,"Administration, Inhalation|Aerosols|Algorithms|Antihypertensive Agents|Drug Delivery Systems|Drug Dosage Calculations|Epoprostenol|Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Inhalation|Models, Anatomic|Nebulizers and Vaporizers|Positive-Pressure Respiration|Respiration, Artificial|Time Factors|Ventilators, Mechanical",mesh_terms,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID23668545_20201005_0.5,treprostinil,drug_name,Our goal was to establish an in vitro method for delivering a standard dose of treprostinil through a ventilator circuit and artificial airway.,abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMID23668545_20201005_0.5,treprostinil,drug_name," CONCLUSIONS Using the algorithm, it was possible to deliver aerosolized treprostinil, at controlled doses, via mechanical ventilation over a wide range of controlled breathing patterns.",abstract,Cellular Immunotherapy,Therapeutic Tumor Infiltrating Lymphocytes,TIL
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC5613235_20201005_0.5,treprostinil,drug_name,Tadalafil|Zaprinast|Treprostinil|Red blood cell|Liposomes|UT-15C,author_keywords,Nanoparticles,Liposomes,Liposome
treprostinil|water,Z0000025801,,,,inn,PubMed,PMC5613235_20201005_0.5,treprostinil,drug_name,"Male|Humans|Female|Phosphodiesterase 5 Inhibitors|treprostinil|Epoprostenol|Erythrocytes|Iloprost|Vasodilator Agents|Adenosine Triphosphate|Cyclic Nucleotide Phosphodiesterases, Type 5|Cyclic AMP|Hypertension, Pulmonary|Signal Transduction|Liposomes",mesh_terms,Nanoparticles,Liposomes,Liposome
